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ABSTRACT
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is responsive
to many exogenous and endogenous ligands. AHR is of particular interest in cancer, and has been shown
to play roles in tumor progression. As such, it has received growing attention as a possible
chemotherapeutic target. Obesity increases the risk of breast cancer, complicates treatment of breast
cancer, and stimulates the growth of larger, more aggressive mammary tumors. Many breast tumors in
obese women are estrogen receptor (ER)-positive and, while targeting hormone receptors like ER is
beneficial, many obese women see a recurrence of their cancer after standard chemotherapy regimens.
Breast tumors also highly express AHR, which has made AHR targeting compounds (both agonists and
antagonists) the subject of intense research in breast cancer models over the last decade. Our laboratory
has uncovered several novel aspects of AHR signaling in response to cytokines, growth factors, and
environmental toxicants, specifically the prototypical AHR agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) which underlie its role in tumorigenesis and tumor progression. We found that silencing AHR
expression in breast tumor cells can block the growth response to adipokines (adipocyte-secreted
factors), which are secreted into the breast tumor microenvironment by adipocytes. We have also shown
AHR recruitment to the cyclin D1 (CCND1) gene promoter to increase the expression of this important
oncogene involved in cell cycle progression upon insulin-like growth factor (IGF)-2 stimulus. AHR was
also found to be necessary for basal and tumor necrosis factor (TNF) induced expression of superoxide
dismutase 2 (SOD2), which encodes manganese superoxide dismutase (MnSOD), a crucial protein in the
oxidative stress pathway. Finally, we have shown AHR is needed for the expression of solute carrier
family 7 (amino acid transporter light chain, L system) member 5 (SLC7A5), which encodes L-type
amino acid transporter 1 (LAT1) in breast tumor cells. The findings presented in this dissertation suggest

xvii

targeting the AHR with antagonists to treat breast cancer would be the most beneficial strategy, as AHR
has been implicated in several aspects of tumor initiation and progression.
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CHAPTER I: THE ARYL HYDROCARBON RECEPTOR (AHR): A MULTI-FACETED
TRANSCRIPTION FACTOR.
1.1. INTRODUCTION AND BRIEF HISTORY OF AHR BIOLOGY.
Over the past 50 years, several advances in understanding the role of the aryl hydrocarbon
receptor (AHR) in cancerous and normal tissues have been made. The goal of this introductory section is
to provide some history of AHR research, before delving further into its complexity. During the
industrial revolution, the twentieth century experienced rapid growth which led to increased risk of
exposure to potentially hazardous environmental pollutants/toxicants. Chemical spills and accidental
exposure to halogenated or polycyclic aromatic hydrocarbons (HAH or PAHs) has unveiled a wide array
of detrimental health effects, which have been studied extensively by researchers [1]. Workers in
chemical factories face a particularly high risk for occupational exposure. One of the earliest PAH/HAH
chemical spills occurred in 1949 in Nitro, WV, not far from Marshall University, where workers were
exposed to toxic levels of the hallmark AHR agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
TCDD is a toxic industrial byproduct found in herbicides like Agent Orange used during the Vietnam
War, as well as a byproduct of the paper bleaching process [2, 3]. Exposure to TCDD resulted in
chloracne, liver disease, leukemia, ischemic heart disease, and even death of some of the workers [4, 5].
However, the exact mechanism by which TCDD causes toxicity in humans is still unclear.
Some of the earliest research with PAHs resulted in the discovery of benzpyrene hydroxylase, an
enzyme named due to its ability to form hydroxylated products of 3,4-benzpyrene, but which would
quickly be renamed aryl hydrocarbon hydroxylase (AHH), as several PAHs induced its activity [6-8].
By the 1970s, numerous studies made it clear there was a direct correlation between induction of AHH
activity and increased cytochrome P450 1A1 (CYP1A1) activity, and that this response varied between
different mouse strains, specifically C57BL/6 and DBA/2 mice [9]. C57BL/6 mice were much more
1

responsive to 3-methylcholanthrene (3-MC)-stimulated increases in AHH activity than DBA/2 mice
[10]. Researchers pondered whether diminished AHH activity in DBA/2 mice in response to 3-MC was
due to these mice having a genetic defect, or whether they express a PAH/HAH receptor with reduced
binding affinity [10]. Utilizing [3H] TCDD, researchers found TCDD accumulated highly in the liver of
C57BL/6 mice where it bound a receptor leading to induction of AHH activity [11]. In DBA/2 mice, the
levels of radio-labeled TCDD in liver extracts were much lower, supporting the previous theory that
they express a receptor with reduced binding affinity [11]. With these radio-labeled TCDD experiments,
the Nebert lab christened this newly identified receptor, AHR [12]. During this time period, it was also
determined that AHH and CYP1A1 were one and the same [13], and CYP1A1 will be used henceforth
to refer to this important enzyme.
The hypothesis that DBA/2 mice expressed an altered AHR, while still speculation in the 1970’s,
was shown to be valid when the AHR was cloned in 1992 by the Bradfield group [14]. These studies
revealed that reduced AHR ligand affinity was due to an altered AHR ligand-binding domain in these
rodents [14]. Other studies found that mutations in the AHR ligand-binding domain were the reason for
reduced AHR affinity for ligands in DBA/2 mice compared with C57BL/6 mice. When AHR coding
sequences from the two strains were compared, two critical alterations were noted: 1) AHR had
undergone a substitution (valine in place of alanine) at position 375 and 2) a T to C mutation in the stop
codon was observed in the DBA/2 mouse strain [15]. The altered stop codon causes a lengthening of the
carboxy-terminus in mature AHR protein in DBA/2 mice resulting in a ligand-binding domain with
lowered ligand affinity [15]. The main advances in AHR biology after these initial findings were made
in the uncovering of the canonical AHR signaling pathway, discussed in the next section.
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1.2. CANONICAL AHR SIGNALING.
When bound by agonists such as TCDD, the AHR becomes an active transcription factor,
moving into the nucleus to regulate expression of target genes. This section will go step by step through
this well characterized process (summarized in Figure 1). In the cytoplasm, AHR is kept in an inactive
state bound with two heat shock protein-90 (HSP90) proteins, which function as chaperone proteins for
steroid hormone receptors as well (Figure 1) [16, 17]. While it was known that there was a third protein
bound to AHR in its inactive state, its identity remained a mystery for some time. Practically
simultaneously, three different research laboratories identified that this third protein that bound AHR in
the cytoplasm was hepatitis B virus X-associated protein 2 (XAP2), however, its function still remains a
mystery [18-20]. Later, p23 was also found to be a part of the cytoplasmic inactive AHR complex, and
helps maintain AHR protein stability [21]. This complex keeps the nuclear localization signal of AHR
concealed, preventing AHR from entering the nucleus in the absence of ligand [22, 23]. Upon TCDD
binding, a conformational change occurs resulting in exposure of the nuclear localization signal and
translocation of the now active complex into the nucleus (Figure 1). Once inside, XAP and p23 are
released, and AHR binds via its basic helix-loop-helix (bHLH) motif to the aryl hydrocarbon nuclear
translocator (ARNT), which is responsible for retaining the AHR in the nucleus (Figure 1) [24, 25].
Binding of ARNT results in the loss of HSP90 proteins [25], and this TCDD-AHR-ARNT complex can
now actively drive transcription of genes.
Classically, the AHR mediates the expression of genes involved in phase I and phase II drug
metabolism. These genes include those encoding monooxygenase enzymes such as the cytochrome
P450s CYP1A1 and CYP1B1 [26]. This enzyme family is important for “first pass” metabolism in the
liver, where a large portion of drugs and xenobiotics (meaning “foreign to the body”) are biotransformed [27]. CYP enzymes hydroxylate xenobiotics to aid in their elimination and excretion [27].
3

Figure 1. The canonical AHR signaling pathway. (A) Binding of agonist results in nuclear
translocation of AHR. (B) Shedding of cytoplasmic chaperones and binding of ARNT occurs. (C)
Active transcriptional complex binds at response elements to increase the expression of primary
TCDD/AHR gene targets including CYP1A1 and CYP1B1. AHR = aryl hydrocarbon receptor, XAP =
hepatitis B virus X-associated protein 2, HSP90 = heat-shock protein 90, ARNT = aryl hydrocarbon
nuclear translocator, DRE/XRE = dioxin/xenobiotic response element, CYP1A1, CYP1B1 =
cytochrome P450s 1A1 and 1B1. This figure created in Microsoft Powerpoint to summarize information
found in references [16- 26].
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Two enzymes in the family, CYP1A1 and CYP1B1, have been highly associated with cancer. CYP1A1
has been shown to regulate breast cancer proliferation and survival [28], in addition to cancer initiation
via conversion of toxicants like benzo(α)pyrene (B(a)P) into genotoxic agents [29]. Silencing of
CYP1A1 resulted in decreased colony formation, decreased proliferation, reductions in cyclin D1, and
cell cycle arrest with increased apoptosis [28]. CYP1B1 has been touted as a “universal tumor marker,”
given its overexpression has been detected in many tumors, including lung, breast, and colorectal tumors
[30]. CYP1B1 has been shown to convert estrogen into genotoxic metabolites like 4-hydroxyestradiol
[31], one way it can initiate tumor formation. Glutathione-S-transferases (GSTs) are phase II enzymes
whose expression is also induced by TCDD via AHR [32]. GSTs catalyze the conjugation of reduced
glutathione (GSH) to xenobiotics to aid in detoxification [33]. Polymorphisms in the GST enzyme
superfamily results in isozymes of various activity, which have been linked to chemotherapy resistance
in tumors [34].
AHR and ARNT bind to specific regions in the DNA of target genes. These regions are termed
AHR response elements (AHR-RE), often referred to in the literature as dioxin-response elements
(DRE) or xenobiotic-response elements (XRE). The specific consensus DNA sequence for TCDD-AHR
complex binding (5’-TGCGTGA-3’) was first found in the CYP1A1 gene promoter [35], and lies
upstream and proximal to the transcriptional start site (TSS) [35]. This site is recognized with high
affinity by AHR-ARNT and confers transcriptional activity to TCDD-AHR target genes. The TCDDAHR-ARNT complex recruits other co-activators of transcription such as the histone acetyltransferase
p300, CREB-binding protein (CBP), and nuclear receptor co-activator 1 (NCOA-1) [36, 37]. CBP,
NCOA-1, and p300 all activate transcription by acetylating histones. CBP and p300 interact, and when
bound together, induce global acetylation of all sites on histones H2A and H2B, but preferentially
acetylate lysines 14 and 18 of histone H3 and lysines 5 and 8 of histone H4 [38]. NCOA-1 preferentially
5

targets histones H3 and H4 for acetylation [39]. These proteins are followed by binding of the
chromatin-modifying protein, brahma-related gene 1 (BRG-1), a member of the ATP-dependent
SWI/SNF (SWItch/Sucrose Non-Fermentable)-like complex family, which utilizes ATP to facilitate
chromatin remodeling and the subsequent recruitment of basal transcriptional machinery to drive
expression of AHR target genes [40].
The discovery of AHR-RE/XRE was a landmark in AHR biology, and allowed for the
identification of other genes regulated by TCDD, such as ATP-binding cassette sub-family G member 2
(ABCG2) [41], which is involved in efflux drug transport in tumor cells, and aldehyde dehydrogenase
1A3 (ALDH1A3) [42], whose expression has been shown to be particularly high in breast cancer stem
cells (CSCs) [43]. Collectively, genes regulated by the canonical AHR pathway are highly associated
with tumors of various types, implicating AHR as an important transcription factor of merit when
studying any cancer, not just breast cancer. We identified and published ~140 TCDD regulated genes in
MCF-7 breast cancer cells (BCCs) using next generation RNA-sequencing (RNA-seq), which included
known TCDD targets CYP1A1, CYP1B1, ABCG2 and ALDH1A3 [44]. Using RNA-seq and comparing
our results with a previously published TCDD-AHR chromatin immunoprecipitation sequencing (ChIPseq) set, we identified and characterized for the first time TCDD/AHR regulation of solute carrier family
7 (amino acid transporter light chain, L system) member 5 (SLC7A5), which encodes L-type amino acid
transporter 1 (LAT1) in MCF-7 and MDA-MB-231 BCCs [44].
1.3. NON-CANONICAL AHR SIGNALING.
The AHR canonical signaling pathway, while very important, is only one way by which AHR
can alter gene expression. AHR can also “cross-talk” with other transcription factors. One of the earliest
reports suggesting AHR could interact with other proteins showed TCDD and epidermal growth factor
(EGF) worked cooperatively to suppress PPARγ activation and modulate focal adhesion complex
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formation during adipogenesis [45]. In AHR-null mice, these effects on PPARγ and adipogenesis were
reversed, revealing that TCDD inhibits triglyceride synthesis and adipocyte differentiation through an
AHR-dependent mechanism [45]. Finding that Vietnam War veterans exhibited defects in thyroid
function suggested that TCDD may also target the thyroid and its associated endocrine signaling [46].
AHR has also been shown to cross-talk with several transcription factors that regulate gene expression
including the estrogen receptor (ER), androgen receptor (AR) and nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) [47-49]. This section will summarize the ways in which AHR
cross-talks with these important transcription factors.
Perhaps the most extensively studied of all is AHR-ER cross-talk (Figure 2). Experiments
looking at long-term TCDD exposure in female Sprague Dawley rats were the first to suggest AHR and
ER cross-talk, as TCDD inhibited the growth of estrogen-responsive mammary and uterine tumors [50].
Other reports established that TCDD inhibited 17β-estradiol (E2)-stimulated increases in the expression
of ER target genes [51], however, the anti-estrogenic effects of AHR activation was not well understood
for some time. The first hypothesis suggested that upon its induction by TCDD, CYP1A1 promoted the
metabolism of E2 [52]. More recent reports have identified that TCDD-activated AHR can also induce
the degradation of ER [53]and secondly, AHR can bind to inhibitory XREs found in ER target genes
that are capable of suppressing gene expression [54]. Finally, TCDD and ER share common
transcriptional coactivators, and TCDD, by stimulating AHR to bind such coactivators, induces a
concomitant reduction in their binding to ER [55]. AHR also interacts with AR, and can play an
important role in prostate development, as TCDD exposure either in utero or via breast milk has been
shown to cause abnormal prostate growth [56].
AHR and NF-κB cross-talk has also been noted. In this regard, the expression of AHR is
stimulated by NF-κB in dendritic cells treated with lipopolysaccharide (LPS) [49]. This study suggests
7

Figure 2. Mechanisms of AHR-ER crosstalk. (A) AHR upregulation of P450 enzymes leads to
metabolism of estrogen, blunting its effects. (B) Agonist-bound AHR-ARNT complexes can bind to
inhibitory response elements in ER target genes to silence expression. (C) Agonist-bound AHR targets
ER for proteasomal degradation. (D) Activation of AHR squelches co-activator proteins preventing
them from binding with ER transcriptional complexes. ERα = estrogen receptor alpha, AHR = aryl
hydrocarbon receptor, ARNT = aryl hydrocarbon nuclear translocator, XRE = xenobiotic response
element, ERE = estrogen response element, iXRE = inhibitory xenobiotic response element, CYP1A1,
1B1 = cytochrome P450s 1A1 and 1B1. This figure created in Microsoft Powerpoint summarizing
information found in references [50-55].
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inflammatory cytokines that activate NF-κB can induce AHR expression during immune cell activation
and differentiation. TCDD and NF-κB interact to promote robust increases in the expression of
interleukin (IL)-6 in MCF-7 breast cancer cells [57]. TCDD, in combination with IL-1β or phorbol 12myristate 13-acetate (PMA) treatment, resulted in synergistic increases in IL-6, which were decreased
by silencing either AHR or NF-κB with short interfering RNAs [57]. In another study, coimmunoprecipitation (co-IP) experiments revealed AHR binds the RELA subunit of NF-κB [58]. TCDD
suppressed the binding of NF-κB to cognate NF-κB response elements in response to tumor necrosis
factor (TNF) and blocked NF-κB translocation to the nucleus in dendritic cells, with these effects
attributed to TCDD-induced AHR degradation (discussed in section 1.4) [58]. Our own data revealed
that AHR and NF-κB interact to regulate both basal and TNF-induced expression of superoxide
dismutase 2 (SOD2), which encodes manganese superoxide dismutase (MnSOD) in MCF-7 BCCs [59].
The importance of MnSOD in cancer is discussed in Chapter II. These results suggest an extensive
relationship between AHR and NF-κB, important for regulating the immune response as well as the
cytotoxic effects of TNF in tumor cells.
1.4. ATTENUATING AHR SIGNALING: TWO MECHANISMS.
This section will discuss the two main ways to “turn off” AHR signaling: 1) degrading AHR
through the ubiquitin-proteasome pathway (Figure 3) or 2) through transcriptional repression via the
AHR repressor (AHRR) (Figure 4). Several reports have demonstrated that TCDD-activated AHR
promotes the degradation of specific proteins, such as ER, by functioning as an E3 ubiquitin ligase [60,
61]. Consistent with its role as a ligand-activated E3 ubiquitin ligase, AHR becomes ubiquitinated [62],
and its levels are decreased in response to agonists like 3-MC and TCDD, via a proteasome-mediated
pathway (Figure 3) [60]. Once inside the nucleus, the ligand-activated AHR-ARNT complex interacts
with the ubiquitin ligase, cullin 4B (CUL4B) [61, 63]. Knockdown of CUL4B revealed that degradation
9

Figure 3. Degradation of agonist-bound AHR by proteasomes. (A) Agonist-bound AHR binds
ARNT and co-activators forming an active transcriptional complex. (B) To shut off AHR signaling,
CUL4B and other ubiquitinating enzymes poly-ubiquitinate AHR targeting it for degradation by
proteasomes. AHR = aryl hydrocarbon receptor, ARNT = aryl hydrocarbon nuclear translocator, RBX1
= ring box-1, DDB1 = damaged DNA binding protein-1, Ub = ubiquitin, and CUL4B = cullin 4B. This
figure created in Microsoft Powerpoint summarizing information found in references [60-65].
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Figure 4. AHRR shuts down AHR signaling. (A) Agonist-bound AHR binds ARNT and co-activators
to regulate expression of target genes such as CYP1A1 and CYP1B1. (B) Agonist-activated AHR also
induces expression of AHRR. (C) AHRR protein competes with ARNT for binding AHR, which
prevents active AHR complex formation and blocks binding at XREs to regulate gene expression. AHR
= aryl hydrocarbon receptor, ARNT = aryl hydrocarbon nuclear translocator, XRE = xenobiotic
response element, CYP1A1, 1B1 = cytochrome P450s 1A1 and 1B1, AHRR = AHR repressor. This
figure created in Microsoft Powerpoint summarizing information found in references [66-69].
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of AHR required expression of this critical enzyme, as it is needed for the recruitment of other enzymes,
such as ring box-1 (RBX1) and damaged DNA binding protein-1 (DDB1), involved in the ubiquitination
process [60]. The collective findings of three reports demonstrated that:1) immunoprecipitated AHR
complex exhibits ubiquitinating activity [53, 64], 2) the binding of TCDD induces AHR to bind ER or
AR, stimulating AHR, ER, and AR degradation (another example of AHR’s anti-estrogenic and antiandrogenic properties) [53, 60], and 3) TCDD-bound AHR becomes ubiquitinated and is then degraded
by proteasomes, as illustrated in Figure 3 [62, 65].
AHRR exhibits homology with AHR in the N-terminal domain, which coincidentally houses the
already described bHLH motif critical for ARNT binding [66, 67]. Yet, the C-terminal domain of AHRR
is quite unique [66, 67]. Two hypotheses were proposed to explain how AHRR inhibits AHR
transcriptional activity. First, AHRR-ARNT heterodimers were speculated to interact with AHR-ARNT
heterodimers to suppress AHR-ARNT transcription at gene promoters, and second, that AHRR
competed for binding at XRE sites to silence AHR target gene expression [68, 69]. One seminal report
by Evans et al. set out to determine which hypothesis was valid.
In this report, overexpression of ARNT failed to reverse AHRR inhibition of AHR signaling,
which suggested squelching of ARNT was not the mechanism of AHRR induced repression [68]. An
AHRR-mutant, which lacked ability to bind DNA, was still able to suppress AHR signaling, suggesting
AHRR-ARNT heterodimers were not competing with AHR-ARNT heterodimers for binding at XRE
sites to block AHR signaling [68]. Other experiments in this report found mutating AHRR C-terminal
domain had no effect on repression either [68]. These results helped solidify the now accepted
hypothesis of AHRR functioning, that AHRR binding to AHR via its N-terminal domain displaces
ARNT from AHR which blunts AHR signaling. Our own RNA-seq data set found that AHR induced
AHRR levels in MCF-7 BCCs [44], lending further credence to this model by which AHRR in response
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to TCDD prevents excessive TCDD-AHR signaling by antagonizing AHR activity. Specifically,
upregulation of AHRR expression results in higher AHRR levels which would then bind AHR protein to
block its signaling via this negative-feedback mechanism (Figure 4).
1.5. TCDD AND AHR ROLES IN DEVELOPMENT, REPRODUCTION, AND IMMUNITY.
In the 1990’s, three separate groups developed AHR-null (Ahr-/-) mice. This was carried out
through deletion of either exon 1 or exon 2 of the AHR gene [70-72]. With these mice, endogenous roles
for the AHR were uncovered, including roles in immunity, proper organ development, and reproduction.
AHR-null mice exhibit decreased accumulation of lymphocytes in the spleen and lymph nodes, but not
in the thymus, compared to wild-type, suggesting a role for the AHR in innate immunity [70]. This
observation was built upon years later by others who uncovered that immune responses are modulated
by AHR and the outcome is dependent on the AHR ligand. As an example, T regulatory cells (Tregs),
which suppress excessive immune responses, are stimulated to differentiate in response to TCDD or
kynurenine (kyn), leading to enhanced immunosuppression [73, 74]. Kyn is an endogenous tumor
promoting ligand and product of tryptophan catabolism [75], as is 6-formylindolo [3,2-b] carbazole
(FICZ) [76]. In contrast to TCDD or Kyn, FICZ enhances the differentiation of naïve T cells into
proinflammatory T helper 17 (Th17) cells [77]. The dietary AHR ligands indolo [3,2-b] carbazole (ICZ)
and 3,3-diidolylmethane (DIM) have been shown to play a role in the immune response as well.
Cruciferous vegetable-derived indole-3-carbinol (I3C) is converted by stomach acid to the products, ICZ
and DIM, which are high-affinity AHR ligands in the gut [78]. ICZ/DIM-activated AHR aids in the
maintenance of gut microbiota, intraepithelial lymphocytes, IL-22 expression, and Th17 activity [78].
These studies helped establish that developmental and functional immunity is AHR-dependent.
The liver expresses higher levels of AHR than all other tissues [79]. Proper liver development
has been shown to be AHR-dependent in rodents [71]. AHR-null mice exhibit smaller liver size as well
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as thickening and fibrosis of the portal vein [71]. These mice also had moderate inflammatory changes
in the bile ducts (cholangitis), which was postulated as a reason for their slowed and diminished growth
compared to wild-type mice [80]. Indeed, in addition to growth, a role for AHR in the developing fetus
has also been established, as AHR mediates the teratogenic effects of TCDD. Female Holtzman rats
exposed to TCDD exhibited dramatic reductions in ovarian follicle number and size, revealing AHR
activation effects follicle maturation [81]. Another report revealed TCDD exposure altered estrous
cycling and blocked ovulation [82, 83]. TCDD has also been shown to induce the atypical release of
follicle stimulating hormone (FSH) and luteinizing hormone (LH) in female Sprague Dawley rats [84].
TCDD exposure to pregnant rodents also induces cleft palate and kidney deficiencies in offspring [85].
When wild-type and AHR-null mice were gavaged with TCDD during pregnancy, only offspring from
wild-type mice developed cleft palate and hydronephrosis [85].
Mouse studies have revealed roles for AHR in mammary development and function also,
including pregnancy associated changes in the mouse mammary gland, and in utero mammary gland
development. In this regard, detectable levels of AHR occur as early as day ten in the gestational period
[86]. In addition to previously mentioned liver deficits, AHR-null mice have improper development of
the mammary gland as well. Deletion of the AHR gene in mice leads to reductions in mammary gland
size and fewer mammary gland terminal end buds, which are the proliferative structures found at the tips
of ducts, compared with wild-type mice [87]. In utero TCDD exposure to normal mice caused defects in
their mammary development, including altered lactogenesis, but this effect was variable and suggested
critical periods of exposure during pregnancy [87, 88]. Mice exposed to TCDD during pregnancy also
had reduced circulating levels of several hormones, including prolactin and E2, when compared to
control mice [89]. Collectively, these reports underline an importance for AHR and its activation in
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proper organ development, proper functioning of the reproductive system, and regulation of the immune
system.
1.6. AHR AND CANCER.
AHR and cancer have been linked by numerous reports. One study found that after exposure to
7,12-dimethylbenz[a]anthracene (DMBA), a potent tumor promoter, AHR levels were dramatically
higher in breast tumors relative to normal breast tissue in rats [90]. Aberrant high AHR expression and
constitutively active AHR is common in many cancers including breast and prostate, even in the absence
of exogenous AHR ligands, and contributes to increased invasiveness and metastasis [91-93]. AHRR
has been shown to be a tumor suppressor in breast models [94], further linking AHR to development and
progression of breast cancer. Endogenous AHR ligands like kyn and kynurenic acid have recently been
established to promote tumor survival of breast tumors and gliomas while also suppressing the immune
response through both autocrine and paracrine mechanisms [75, 95]. The Cancer Cell Line Encyclopedia
has uncovered aberrantly high AHR expression in a number of malignant cell lines, including the
neuroblastoma line CHP-212 and the endometrial cancer line HEC-151 [96]. Overexpressing AHR in a
normal human mammary epithelial line caused these cells to exhibit traits of malignancy such as
increased epithelial-to-mesenchymal transition (EMT), a process where cells lose cell-cell adhesion
proteins and gain migratory properties leading to increased cell migration and invasion [97]. This report
found that overexpressed AHR is sufficient to drive the transition from a normal breast epithelial cell to
a malignant phenotype. The classic AHR gene target, CYP1B1, has also been found to be highly
expressed in many malignant tumors, while the surrounding healthy tissue has minimal to no CYP1B1
expression [30, 98]. High CYP1B1 expression has been noted in cancers of the lung, colon, prostate and
breast [30]. As mentioned previously, CYP1B1 metabolism of E2 to genotoxic metabolites like 4hydroxyestradiol also promote cancer, independent of ER activation [31]. Elevated levels of CYP1B1 in
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tumors is also believed to play a role in chemotherapeutic resistance. For instance, elevated CYP1B1 has
been linked to docetaxel treatment failure, as the enzyme metabolizes the active drug to inactive
metabolites and reduces docetaxel efficacy [99].
AHR promotes cancer via transcriptional mechanisms and by functioning as a scaffold protein
for cell cycle promoting proteins. In regards to transcriptional mechanisms, TCDD-activated AHR
regulates the expression of Slug, an important transcription factor that is one of the main drivers of EMT
[100]. ChIP analysis revealed AHR binds to XRE in the Slug gene promoter to regulate expression
[100]. Slug then regulates the expression of E-cadherin, with loss of E-cadherin a classic mark of EMT,
as cadherin loss results in less cell-cell adhesion and promotes metastasis [101]. In this regard, DMBA
and TCDD have also been shown to suppress the transcription of T-cadherin via AHR [102]. AHR
activation also increases the levels of matrix metalloproteinase (MMP)-9 and MMP-1 which aid in
degradation of extracellular matrix and are crucial enzymes for metastasis to occur [103, 104]. AHR can
also function as a scaffold protein for regulating the phosphorylation of retinoblastoma protein (Rb), a
key player in cell cycle progression in tumor cells [105]. When Rb is hypophosphorylated, it prevents
expression of G1 to S phase target genes regulated by E2F transcription factor 4 (E2F4) by binding and
sequestering E2F4 [106]. AHR was revealed to be needed for the hyperphosphorylation of Rb and
subsequent release of E2F4 to occur in BCCs [105].
Two important papers from the Eltom lab have characterized AHR levels in the increased
aggressiveness of triple-negative breast cancer (TNBC). One report utilizing the TNBC model cell line,
MDA-MB-231, illustrated that knockdown of AHR resulted in reduced expression of many important
genes relevant in cancer, including ABCG2, mucin-1 (MUC1) and IL-8, which are associated with
chemotherapy resistance, tumor survival and poor prognosis in patients [107]. Another report showed
AHR knockdown in TNBC cells reduced anchorage-independent growth, as well as growth of
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xenografts and lung metastasis in mice, again using MDA-MB-231 cells [108]. An important recent
study has linked the kyn-AHR pathway in TNBC cells to play a role in anoikis resistance [109]. Anoikis
is a form of programmed cell death which normal epithelial cells undergo if detached from the basement
membrane [110]. Inhibition or silencing of AHR or tryptophan dioxygenase 2 (TDO2), the enzyme
which produces kyn, decreased anchorage-independent growth and made SUM-159pt cells more
sensitive to anoikis [109]. Recently, we have published that knockdown of AHR and AHR regulation of
SLC7A5 expression was important for MDA-MB-231 BCC growth also [44]. Collectively, researchers
have linked AHR to tumor initiation, tumor invasion, metastasis, and EMT, revealing the complexity by
which AHR functions in tumors (Table 1).
Our laboratory has been focused over the past four years in further uncovering tumor promoting
roles for AHR (Figure 5). We found that AHR is necessary for the proliferative response to adipocytesecreted factors (termed adipokines) in breast tumor cells (Chapter IV) [111]. This growth response is
especially important in the context of obesity, where obese women have a greater incidence for breast
cancer, are more resistant to cancer therapy, and have a higher rate of breast cancer recurrence than lean
women with breast cancer [112, 113]. We also found that induction of cyclin D1 (CCND1) by the
adipokine insulin-like growth factor (IGF)-2 is mediated by AHR (Chapter V) [114]. CCND1 is an
important cell-cycle regulator important for actively dividing tumor cells to move through G1-S phase of
cell division [106]. CCND1 is also an oncogene that is overexpressed in breast tumors compared with
normal breast tissue [115]. Thus, our finding that AHR increases CCND1 expression in BCCs could
have important clinical implications. We then found that regulation of SOD2 by TNF also required AHR
(Chapter VI) [59]. Considering that SOD2 encodes manganese superoxide dismutase (MnSOD), a
mitochondrial protein that reduces reactive oxygen species (ROS) [116], our findings suggest a novel
mechanism by which AHR, by increasing MnSOD, lowers ROS in breast cancer cells stimulated
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Processes
Cell Cycle
Progression
Epithelial to
Mesenchymal
Transition
Metastasis
Anoikis

AHR in Cancer
Specific Role

References

Functions as scaffold protein for
regulating Rb phosphorylation
Regulates transcription of Slug,
Downregulates cadherins

[105]

Regulates expression of matrix
metalloproteinases (MMPs)
Endogenous AHR ligands linked to
resistance to anoikis in triplenegative breast cancer

[103,104]

Table 1. Characterized roles for the AHR in cancer.
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[100-102]

[109]

Figure 5. New roles for AHR in breast cancer. (A) Adipokines, including IGF-2, increase the
proliferation of breast tumor cells, which we found to be AHR-dependent. (B) IGF-2 increases of AHR,
which then binds to the promoter of CCND1 at two sites to induce CCND1 expression. (C) TNF
regulation of SOD2, which encodes MnSOD, requires interactions between AHR and NF-κB. (D)
TCDD and endogenous signaling stimulates AHR regulation of LAT1. AHR = aryl hydrocarbon
receptor, IGF-2 = insulin-like growth factor 2, TNF = tumor necrosis factor, NF-κB = nuclear factor
kappa-light-chain-enhancer of activated B cells, MnSOD = manganese superoxide dismutase, TCDD =
2,3,7,8-tetrachlorodibenzo-p-dioxin, LAT1 = L-type amino acid transporter 1. This figure summarizes
the important findings of my research and was made in Microsoft Powerpoint.
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with TNF. Indeed, we demonstrated that AHR knockdown BCCs are more sensitive to TNF-induced cell
death compared with AHR expressing BCCs [59]. This is an important finding as it is suggests a role for
AHR in reactive oxygen species maintenance and TNF-induced tumor cell death. Finally, we have
shown that AHR is needed for regulation of solute carrier family 7 (amino acid transporter light chain, L
system) member 5 (SLC7A5) which encodes L-type amino acid transporter 1 (LAT1) (Chapter VII)
[44]. LAT1 is an important transporter which brings in amino acids such as leucine and tryptophan to
drive protein synthesis in tumor cells, helping to maintain tumor proliferation [117]. To better
understand these findings, the next chapter summarizes the roles of each of these important genes in
cancer, as well as the effects of various secreted factors by adipose tissue important in obesity-driven
cancers.
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CHAPTER II: OBESITY, ADIPOKINES, AND GENES OF INTEREST IN BREAST CANCER.
2.1. OBESITY AND BREAST CANCER.
Epidemiological data has revealed that the prevalence of obesity has steadily increased over the
past 25 years [118], continuing to be a major health concern in the United States. Adipose tissue is a
potent endocrine gland and larger amounts of adipose tissue contributes to the chronic low grade
inflammation seen in obese patients compared with lean patients [119]. Adipose tissue secretes a variety
of peptide hormones, termed adipokines [120]. This cocktail of factors can influence multiple processes,
including regulation of energy homeostasis (leptin, adiponectin, resistin), insulin sensitivity
(adiponectin), vascular growth (vascular endothelial growth factor (VEGF)), and the immune response
(interleukin (IL)-6 and tumor necrosis factor (TNF)) [120]. In the literature, there is evidence that
obesity is a risk factor for certain cancers, including post-menopausal breast cancer [112, 113]. In premenopausal women, the ovaries are the primary source of circulating estrogen [121]. In contrast,
adipose tissue, not the ovaries, is the major source of estrogen in obese post-menopausal women [122].
Estrogen can cause tumor formation, and supports the growth of established ER-positive breast tumors
[121]. Estrogen production by adipose tissue after menopause, via aromatization of androstenedione in
adipose tissue to estrone and estradiol, is speculated to be a main component of obesity-driven increases
in post-menopausal breast cancer [122]. While estrogen is certainly a dominant factor, it was postulated
that the lower levels of adiponectin coupled with higher levels of leptin seen in obese women could
increase breast cancer incidence and stimulate the growth of larger, more aggressive breast tumors in
obese women compared with lean women [123]. In addition to high levels of leptin, additional
adipokines that stimulate proliferation of ER-positive breast cancer include collagen VI, VEGF, insulinlike growth factor (IGF)-1, and IGF-2 [124-126]. In the following sections, the effects and mechanisms
of these cancer promoting adipokines will be discussed (Figure 6).
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Figure 6. Important secreted adipokines and their roles in the body. Adiponectin, leptin, and resistin
play roles in regulating energy homeostasis. Vascular endothelial growth factor (VEGF) is important in
angiogenesis. Collagen VI is an extracellular matrix protein also important for proper angiogenesis to
occur. Estrogen and insulin-like growth factors (IGFs)-1 and 2 are potent endocrine signaling proteins
important in growth and changing gene expression in target tissues. Tumor necrosis factor (TNF) and
interleukin (IL)-6 are involved in maintaining proper immune system responses.
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2.2. ADIPONECTIN AND CANCER.
Adiponectin plays roles in cancer, vascularization, and maintains insulin sensitivity [127].
Adiponectin, often referred to as ACPR30, exists in serum in three forms: as a trimer, a hexamer, and as
a high molecular weight isoform [128]. Epidemiological studies have revealed that low circulating levels
of adiponectin are associated with increases in breast cancer risk [129]. For instance, low serum
adiponectin concentrations were associated with larger, more aggressive breast tumors [129].
Adiponectin suppresses the growth of MDA-MB-231 and MCF-7 BCCs, an effect mediated by binding
cognate adiponectin receptors AdipoR1 and AdipoR2 [130, 131]. These two receptors exert different
effects upon binding, as determined from in vivo studies. AdipoR1- and AdipoR2-deficient mice were
bred and used to distinguish important aspects of these two receptors [132, 133]. Strikingly, AdipoR1deficient mice exhibited severe metabolic dysfunction and diet-induced weight gain compared to wildtype mice, whereas AdipoR2-deficient mice were protected from perturbations in metabolism,
suggesting AdipoR1 activation suppresses metabolic dysfunction in the context of a high fat diet [132,
133]. AdipoR2 was shown to be more important in mediating revascularization effects of adiponectin
[133]. Adiponectin is anti-angiogenic as well, inducing apoptosis of endothelial cells in vivo [134].
Adiponectin also promotes insulin signaling, through binding its cognate receptors and activating the
adenosine monophosphate dependent kinase (AMPK) pathway [135]. AMPK activation by adiponectin
is the main driver of its insulin sensitizing effects [135]. The diabetes drug, metformin, has also been
shown to activate AMPK which explains its insulin sensitizing properties as well [136]. Low serum
adiponectin levels result in chronic insulin resistance, and subsequent hyperinsulinemia [137]. Breast
tumors express the insulin receptor (IR), and insulin binding to IR on BCCs stimulates their proliferation
and inhibits apoptosis [138, 139]. Thus, hyperinsulinemia in obesity is postulated to promote the growth
of larger, more aggressive breast tumors in obese women compared with lean women. Therefore, there
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are three ways that low adiponectin levels in obesity can contribute to cancer growth: less adiponectin to
bind its cognate receptors to inhibit cancer proliferation [130, 131], hyperinsulinemia which can drive
tumor growth [138], and increases in angiogenesis [134].
2.3. LEPTIN AND CANCER.
The obesity-associated increases in leptin have been attributed to the increased number of
adipocytes and increased leptin expression by adipose tissue in obese women compared with lean
women [140]. Leptin binds its cognate receptor, leptin receptor (LEPR), which activates the Janus
kinase (JAK)/signal transducer and activator of transcription (STAT) pathway to elicit changes in the
expression of genes that are important in cancer including the important cell cycle regulator CCND1,
discussed in depth in section 2.9 [141]. The action of leptin is not limited to breast cancer, as it also
regulates thermogenesis, inhibits appetite, and stimulates the metabolism of fat to maintain a normal
body weight [142]. In obesity, studies suggest high serum leptin enables it to act as a potent breast tumor
signaling hormone, as breast tumor cells express LEPR [143]. Case-control studies have provided
evidence for this, as high serum leptin levels correlated with increased breast cancer incidence in several
reports [144-146]. Dramatic evidence for leptin in breast cancer was provided by studies performed in
obese mice with defects in the leptin receptor isoform B (LEPR-b), considered the major active isoform
of LEPR [147]. Mice with non-functional LEPR-b were crossbred with transforming growth factor alpha
(TGFα) oncogene-expressing mice (MMTV-TGFα mice) [147]. Female offspring with non-functional
LEPR-b did not develop oncogene-driven breast tumors, even with circulating leptin levels 12-20-fold
higher than in lean mice, whereas female offspring with functional LEPR-b had an 80% incidence rate
[147]. Leptin triggers LEPR-positive cancer stem cell (CSC) self-renewal through JAK/STAT pathway
activation [148]. CSCs are cells within a tumor that have a high capacity to initiate tumor formation
[149]. Importantly, silencing LEPR in MDA-MB-231 BCCs inhibited the expression of stem cell self24

renewal transcription factors NANOG, SOX2, and OCT4, due to loss of JAK/STAT activation [150].
LEPR-null MDA-MB-231 cells also lost many of their metastatic properties and underwent a
mesenchymal-to-epithelial transition, with a gain of E-cadherin, an adhesion protein needed for cell-cell
interactions, and loss of vimentin, an intermediate filament protein highly expressed in mesenchymal
cells which helps anchor organelles [150].
2.4. RESISTIN AND CANCER.
Resistin is secreted from monocytes and adipocytes and is known to play roles in
atherosclerosis, stroke, and many cancers [151-153]. These cancers include colorectal, endometrial, and
prostatic cancers, in addition to breast cancer [154-158]. One case-control study found that serum
resistin levels were much higher in women with breast cancer when compared with women without
breast cancer [156]. Another study found that breast tumors express resistin, and that resistin expression
was correlated with a poor prognosis [159]. Resistin expression in breast tumors is likely mediated by
estrogen, as a prior report noted estrogen induced resistin expression in 3T3-L1 adipocytes, which
required ER and extracellular regulated kinase (ERK) activation [160]. Resistin secretion by adipocytes
in the obese state could also be due to higher circulating levels of estrogen noted in obese patients [161].
Resistin also likely contributes to the pro-inflammatory environment noted in obesity, as numerous
reports have linked resistin to inflammatory processes [162-164].
2.5. IGFS, INSULIN, AND CANCER.
We found that adipocytes in cell culture secrete high levels of IGF-1 and IGF-2 [111]. The
insulin and IGF family of proteins have been linked extensively to cancer, and exert their effects through
binding IR-A, IR-B, the IGF-1 receptor (IGF1-R), or the hybrid IGF1-R/IR receptor, resulting in
activation of various signaling cascades (Figure 7) [165, 166]. IGF1-R can be activated by both IGF-1
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Figure 7. The insulin and IGF family signaling pathways. Insulin, insulin-like growth factor (IGF)-1,
and IGF-2 can activate various receptors. IGF-1 can activate its cognate receptor, the IGF-1 receptor
(IGF1-R) or the hybrid IGF1-R/insulin receptor (IR) receptor. Insulin can activate IR-A, IR-B, or the
hybrid IGF-1/IR receptor. IGF-2 can bind its own cognate receptor, the IGF-2 receptor (IGF-2R), IGF1R, IGF1-R/IR, or IR-A. IGF-2R has no kinase activity, yet activation of the other receptors leads to
activation of downstream signaling cascades as noted in the figure. PI3K = phosphatidylinositol-3kinase, AKT = protein kinase B, mTOR = mammalian target of rapamycin, S6K = ribosomal S6 kinase,
MEK = mitogen activated protein kinase kinase, ERK = extracellular regulated kinase. This figure made
in Microsoft Powerpoint to summarize information in references [165, 166].
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and IGF-2, with IGF-1 having higher affinity [166]. IGF1-R/IR preferentially binds IGF-1 and IGF-2,
with lower affinity for insulin [166]. IR exists in two isoforms: IR-B, which are the traditional receptors
which insulin binds, and IR-A, a fetal form of IR expressed on certain tumors, including breast tumors,
which preferentially binds IGF-2 [166]. IGF-2R is a non-signaling receptor with no kinase activity, and
acts to internalize and degrade circulating IGF-2 [166].
Among insulin/IGF receptors, IGF1-R has received the greatest attention in cancer [165]. Some
of the earliest reports linking IGF1-R to cancer found that transformation of mouse embryo fibroblasts
(MEFs) by oncogenes such as SV40 large T antigen and c-Src required an intact, functional IGF1-R
gene [167, 168]. Overexpression of the oncogene K-Ras in mouse mammary glands stimulated
formation and growth of IGF1-R-overexpressing mammary tumors [169]. These tumors resembled
human basal-like breast tumors, which are resistant to current cancer treatment options [169]. K-Ras
overexpressing mammary tumors in these mice were shown to require IGF1-R for growth, as gene
deletion experiments targeting the IGF1-R gene delayed the growth of these tumors [169]. Treatment
with the IGF1-R inhibitor picropodophyllin (PPP) slowed the growth of K-Ras overexpressing
mammary tumors, as well as MDA-MB-231 breast cancer xenografts in mice [169]. Other prior reports
identified that breast tumors grew faster in wild-type mice than in IGF-1-deficient mice [170].
Exogenous IGF-1 administered to mice increased the growth and metastasis of colon cancer [171].
Acromegaly, a condition characterized by growth hormone excess, is associated with higher incidence
of colon cancer, attributed to overproduction of IGF-1 [172]. In contrast, Laron-type dwarfism is
associated with low serum IGF-1 levels and less risk for developing tumors [173]. Collectively, these
reports have revealed that the IGF signaling axis promotes both the transformation and the progression
of many cancers in both rodents and humans.
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As noted, insulin resistance and subsequent hyperinsulinemia occurs frequently in obesity [112,
113]. Breast tumors are responsive to the mitogenic and anti-apoptotic effects of insulin, as breast
tumors express IR [138, 139]. Researchers have worked extensively to uncover the role of insulin and IR
in cancer, with the majority of this work done by the LeRoith group. They developed a transgenic mouse
model which expresses a dominant-negative IGF1-R specifically in skeletal muscle [174]. The
formation of hybrid receptors between the mutant and endogenous IGF1-R and IR occurred, resulting in
ligands failing to bind and activate these receptors [174]. These mice, called MRK mice, therefore
developed insulin resistance and hyperinsulinemia [174]. Breast tumor cells grafted into the mammary
fat pad of MRK mice grew faster than in wild-type mice, attributed to higher circulating insulin in MRK
mice [139]. Breast tumors from MRK mice exhibited higher levels of IR signaling activation than
control mice, including the AKT and mammalian target of rapamycin (mTOR) pathways [175]. The
PI3K/AKT/mTOR pathway is a crucial signaling node in tumor cells, and 70% of breast tumors exhibit
hyperactivation of this pathway [176]. Dosing with the PI3K inhibitor NVP-BKM120 or the dual
PI3K/mTOR inhibitor BEZ235 reduced breast tumor size in MRK mice [175]. High levels of insulin in
these mice specifically activated IR on tumor cells, not IGF1-R [175]. When mice were given the insulin
analog AspB10, which selectively targets IR, they developed larger mammary tumors than mice
administered vehicle control [175]. In all, these reports reveal hyperinsulinemia is sufficient to drive
breast tumor growth.
2.6. TNF, IL-6, AND CANCER.
There is now a sufficient body of evidence that chronic inflammation is conducive to tumor
development and tumor progression [177, 178]. Two important cytokines involved in inflammation and
the immune response, TNF and IL-6, are also secreted by adipocytes and will be reviewed in this section
[179, 180]. TNF is a complex cytokine that regulates cancer and high serum TNF levels have been
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shown in cancer patients [181]. Unlike normal tissue, it has been revealed that tumors of various types,
including those of skin, ovarian, and pancreatic cancers, produce TNF [182]. In ovarian cancer, TNF has
been shown to promote angiogenesis and leukocyte infiltration in the ovarian cancer microenvironment
[183]. In a lung cancer model, TNF produced by malignant cells contributed to increased permeability
of the vasculature leading to malignant pleural effusion (MPE), where fluid buildup occurs between the
thin layers of tissue lining the outer lung and chest cavity [184]. TNF promoted the adhesion and
migration of MDA-MB-231 BCCs through induction of lectin-like oxidized-lowdensity lipoprotein
(oxLDL) receptor-1 (LOX-1) in endothelial cells, which promotes metastasis [185]. Blocking TNF in a
mouse model was shown to reduce the development of colorectal cancer resulting from chronic colitis
[186]. Macrophage-derived TNF in the microenvironment was shown to activate Wnt signaling in
gastric cancer as well [187]. Indeed, given adipocytes secrete TNF into the microenvironment [188];
adipocyte-derived TNF illustrates another way obesity can contribute to cancer growth.
High serum IL-6 levels have been shown to be a good prognostic marker, as patients with
endometrial, ovarian, and hormone-refractory prostate cancers exhibit increased IL-6 levels [189-191].
In breast tumors, IL-6 mRNA levels were found to correlate with the aggressiveness of the cancer, as
highest IL-6 mRNA was noted in the highly aggressive and metastatic basal-like subtype [192]. Another
study linked human epidermal growth factor 2 receptor (HER2) signaling with IL-6 expression in breast
cancer [193]. HER2 is an oncogene upregulated in a subset of breast tumors, and HER2 signaling
through PI3K/AKT/mTOR and ERK pathway activation contributes to tumor proliferation [194]. This
study found that HER2 overexpression was associated with increased IL-6 production and secretion
which then acted on breast tumor cells to activate STAT3 through an autocrine loop, forming a HER2IL-6-STAT3 axis [193]. In pancreatic cancer patients, high IL-6 levels were linked with advanced
cancer stage as well as development of cachexia [195]. Another clinical study found that high IL-6
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levels correlated with a diminished response to chemo and hormone-based cancer therapies in metastatic
breast cancer patients [196]. Lastly, IL-6 was shown to increase expression of VEGF and promote
angiogenesis in gastric tumors, another way it can contribute to cancer growth [197]. Collectively, these
reports reveal a role for TNF and IL-6 in tumor progression, independent of their actions on the immune
system.
2.7. COLLAGEN VI AND CANCER.
Collagen VI is an extracellular matrix protein highly expressed in cancer [198]. Collagen VI is
typically found in the tumor stroma, near blood vessels, and helps facilitate the process of angiogenesis
[198]. Collagen VI, by activating the NG2/chondroitin sulfate proteoglycan (CSP) receptor, activates βcatenin signaling [124]. Upon its activation, β-catenin translocates from the cell membrane to the
nucleus, promoting its binding to T-cell factor (TCF) transcription factors that stimulate the expression
of genes important in cancer, like CCND1 [199]. Collagen VI induced CCND1 expression in MCF-7
BCCs via NG2/CSP receptor binding, stimulating proliferation [124]. Collagen VI also induced
expression of IL-8 and VEG-F in MCF-7 BCCs, further evidence of its tumor promoting effects [124].
Collagen VI production by macrophages facilitates their recruitment and adhesion at the tumor site
resulting in increased inflammation in the tumor microenvironment [200]. While correlated with tumor
invasiveness in breast cancer, high collagen VI expression has also been noted in ovarian cancer,
melanoma, and glioblastomas [198]. Upregulation of metallothioneins by collagen VI has been shown
[124] which could contribute to chemotherapy resistance in tumors, as these small trace metal and free
radical scavenging proteins have been linked to cisplatin treatment failure [201]. One of the lesser
researched adipokines, uncovering the mechanisms of collagen VI in cancer is still a growing area.
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2.8. VEGF AND CANCER.
The role of VEGF in vascular permeability and angiogenesis has been well characterized [202].
Tumor cells also express VEGF receptors (VEGFRs) VEGFR1, VEGFR2, and VEGFR3, and are VEGF
responsive [203]. VEGFRs are receptor tyrosine kinases [202] and belong to the same receptor class as
IR and IGF1-R. Neuropilins (NRPs) are transmembrane proteins which function as co-receptors for
other receptor classes, including VEGFRs [204]. NRPs complex with VEGFRs to increase VEGF
affinity, in addition to functioning as VEGF receptors themselves [203, 204]. VEGF can modulate
various steps in tumorigenesis, including tumor initiation and progression as well as modulating CSC
functioning. VEGFR1 activation has been shown to increase invasion and migration of colorectal cancer
through ERK activation and translocation of the RELA subunit of NF-κB into the nucleus to activate
target gene expression [205]. Other reports have characterized the ability of NRP-mediated VEGF
signaling to promote breast tumor survival via AKT pathway activation [206]. In terms of CSCs, two
reports have shown VEGFR2 and NRPs appear to help sustain stem cell proliferation in both skin and
brain tumors [207, 208]. Targeting VEGF has received continued interest, due to promising work done
with the anti-VEGF antibody, bevacizumab. In patients with advanced stage breast cancer, bevacizumab
treatment increased apoptosis of breast tumor cells [209]. In conclusion, the role of VEGF in cancer is
more complex than initially thought, as not only does it facilitate increased blood supply to the tumor, it
also acts directly on tumor cells to promote their proliferation and survival.
2.9. CCND1 AND CANCER.
The following sections will discuss genes involved in cancer that we have found to be dependent
on AHR regulation. CCND1 was the first gene we identified whose expression was dependent on AHR
[114]. CCND1, one of several D-type cyclins, is an important cell-cycle regulatory protein that promotes
cellular division [115]. CCND1 exerts its effects through binding its partners, cyclin-dependent kinases
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4 and 6 (CDK4/CDK6) [115]. The activation of these CCND1-CDK complexes phosphorylate
retinoblastoma (Rb) protein. Increases in the phosphorylation of Rb inhibits its activity, and decreases in
Rb activity is necessary for cell proliferation (Figure 8) [115]. CCND1 is an oncogene, and is
overexpressed in a variety of tumor types, commonly through alterations in gene copy number [210212]. In breast cancer, 50-70% of all breast tumors overexpress CCND1 [213, 214]. Compounds that
inhibit CCND1/CDK signaling have been investigated as potential anticancer agents. For instance, the
pan-CDK inhibitor flavopiridol showed promising preclinical antitumor activity, however, its efficacy in
clinical trials was poor [215-219]. Flavopiridol treatment failure has been attributed to dosing during the
study which was not optimal and/or poor pharmacokinetics [215, 216]. Second generation CDK
inhibitors, including palbociclib, abemaciclib, and ribociclib, which are specific for CDK4 and CDK6,
have been developed and are currently in phase 3 clinical trials [220]. Other options include inhibiting
CCND1 translation into protein or increasing CCND1 protein degradation. Translation of CCND1
mRNA is dependent on mTOR, thus, mTOR inhibitors are being investigated in CCND1 overexpressing
cancers, including mantle-cell lymphoma (MCL) [221]. Silencing expression of the deubiquitinating
enzyme USP2 increased cyclin D1 degradation and inhibited the growth of tumor cells which
overexpressed cyclin D1, but not control fibroblast cells, suggesting increasing cyclin D1 degradation
could be a novel therapy which targets only tumor cells [222]. Based on our work showing that AHR
induces CCND1 expression in MCF-7 BCCs [114], we postulate that AHR antagonists could be a new
mechanism to reduce CCND1 expression in breast cancer.
2.10. SOD2 AND CANCER.
Superoxide dismutase 2 (SOD2), encodes manganese superoxide dismutase (MnSOD), an
enzyme that neutralizes reactive oxygen species (ROS) [223]. By reducing ROS, MnSOD inhibits cell
death, as high levels of ROS induce oxidative damage to cellular macromolecules in the mitochondria
32

Figure 8. Role of CCND1 in cell cycle progression. CCND1 and CDK4 interact to form a stable
complex. This complex then phosphorylated Rb, removing its inhibitory effects on E2F4. E2F4 can then
move into the nucleus and stimulate gene expression. CCND1 = cyclin D1, CDK4 = cyclin-dependent
kinase 4, Rb = retinoblastoma protein, E2F4 = E2F transcription factor 4. This figure was made in
Microsoft Powerpoint to summarize information from reference [115].
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[223]. While two other genes (SOD1 and SOD3) also encode superoxide dismutases [224], only SOD2
is essential for life, as knockout of SOD2 has been shown to cause embryonic and neonatal lethality in
mouse models [225, 226]. MnSOD inactivates ROS by catalyzing the dismutation of superoxide anion
(O2.-) to hydrogen peroxide (H2O2), which is then further converted to less toxic water and oxygen by
glutathione peroxidase, preventing mitochondrial damage (Figure 9) [223, 227]. The SOD2 gene is
expressed in the nucleus and its product, MnSOD, translocates to the mitochondria via a targeting
sequence [228]. MnSOD is a TNF target gene, and its upregulation by TNF reduces ROS production in
cancer cells [228, 229]. Prior reports have shown that TNF-stimulated increases in SOD2 transcription
are mediated by the transcription factor NF-κB [228]. As detailed in Chapter VI, and in our prior report
[59], we identified that TNF regulation of MnSOD in MCF7 BCCs is mediated by AHR. AHR and NFκB were both recruited to NF-κB-RE in the SOD2 gene upon TNF stimulus, and knockdown of AHR
blocked TNF-stimulated increases in MnSOD [59]. Silencing AHR also sensitized BCCs to TNF
cytotoxicity by preventing upregulation of MnSOD [59]. Considering that our work shows AHR
promotes MnSOD expression, and that MnSOD promotes the survival of breast tumor cells, we
postulate that AHR antagonists may inhibit breast tumor survival by suppressing MnSOD expression.
2.11. LAT1 AND CANCER.
We have most recently published that SLC7A5, which encodes the protein L-Type Amino Acid
Transporter 1 (LAT1), is a primary AHR gene target in MCF-7 and MDA-MB-231 BCCs [44]. LAT1
facilitates the uptake of large neutral amino acids including leucine, arginine, phenylalanine, and
tryptophan [230-232]. LAT1 is overexpressed in a variety of tumor types, including breast, colorectal,
and prostate, compared with surrounding normal tissue [233]. Upregulation of LAT1 is postulated to
promote cancer growth by facilitating the uptake of leucine by tumor cells. Increases in intracellular
leucine is necessary for the activation of mTOR signaling, specifically mTORC1 [234, 235].
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Figure 9. Role of MnSOD in mitochondrial oxidative stress. MnSOD converts superoxide anion
(O2.-) radical into H2O2 + O2. H2O2 is then further converted to H2O by GPX using GSH as electron
donor, forming GSSG in the process. GSSG is then converted back to GSH by GR using NADPH as
electron donor to complete the cycle. MnSOD = manganese superoxide dismutase, GPX = glutathione
peroxidase, GR = glutathione reductase, GSSG = glutathione disulfide, GSH = reduced glutathione,
NADPH = nicotinamide adenine dinucleotide phosphate. This figure made in Microsoft Powerpoint and
summarizes information found in references [223, 224].
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Increases in the activity of mTORC1 promotes the phosphorylation and activation of mTORC1
downstream targets such as ribosomal S6 kinase (p70S6K), eukaryotic initiation factor (eIF), and 4Ebinding proteins (4E-BPs) which promote protein synthesis and cell survival (Figure 10) [234].
Hyperactivation of mTOR and its downstream constituents have been associated with many tumor types,
including melanoma, late-stage head and neck cancers, and ductal cell breast cancers [235, 236].
Importantly, prior reports have demonstrated that breast tumors that express high levels of LAT1 were
more resistant to tamoxifen treatment than breast tumors that expressed low levels of LAT1 [237, 238].
We recently published the first data indicating that LAT1 is a primary AHR gene target in MCF-7 and
MDA-MB-231 BCCs [44]. The finding that AHR promotes LAT1 expression and function, suggests
that AHR antagonists may offer a new way to overcome tamoxifen resistance by downregulating LAT1.
Indeed, my recent work from our laboratory has revealed that CCND1, MnSOD and LAT1 are primary
AHR target genes in human BCCs, suggesting that the inhibition of AHR may be useful in the treatment
of breast tumor growth and survival.
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Figure 10. Role of LAT1 in tumor cell survival. LAT1 facilitates the uptake of amino acids like
leucine through interactions with chaperone CD98. Leucine activates mTOR signaling which activates
downstream targets, such as p70S6K, that are important for increasing protein synthesis and maintaining
tumor survival. LAT1 = L-type amino acid transporter 1, CD98 = 4F2 heavy chain antigen, mTOR =
mammalian target of rapamycin, p70S6K = ribosomal s6 kinase 1. This figure made in Microsoft
Powerpoint to summarize information found in references [230-235].
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CHAPTER III: METHODS TO STUDY AHR SIGNALING.
3.1 MATERIALS
The purpose of this introductory methods sections is to provide a brief overview of the
methods that were used in this dissertation (Table 2). MCF-7, T-47D, and MDA-MB-231 breast cancer
cells and 3T3-L1 fibroblast cells were purchased from ATCC (Manassas, Va). Dulbecco's Modified
Eagle Medium/High glucose (DMEM) with L-glutamine and sodium pyruvate, phenol red-free DMEM,
phosphate buffered saline (PBS), fetal bovine serum (FBS), penicillin, and streptomycin were purchased
from Thermo Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulfate (SDS), 30 % acrylamide/bis
solution, ammonium persulfate, Tween-20, and 2-mercaptoethanol were obtained from Bio-RAD
(Hercules, CA). Trypsin-EDTA was purchased from Thermo Fisher Scientific (Pittsburgh, PA). DMSO,
SU5416, CH-223191, 3-isobutyl-1-methylxanthine (IBMX), insulin, dexamethasone, L-leucine, and all
designed mRNA and ChIP primers were purchased from Sigma Aldrich (St. Louis, MO). TCDD was
purchased from Cambridge Isotopes Laboratory (Andover, MA). Recombinant human IGF-2, IGF-2
blocking antibody, and recombinant human TNF were purchased from R & D Systems (Minneapolis,
MN). All short interfering RNAs (siRNAs) were purchased from GE Dharmacon (Lafayette, CO). The
following antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX): AHR (cat # H-211),
NF-κB RELA (cat # sc-372), ARNT (cat # sc-17812), p300 (cat # sc-584) and control random IgG (cat #
2027). The following antibodies were purchased from Millipore (Temecula, CA): Glyceraldehyde 3phosphate dehydrogenase (GAPDH) (cat # MAB374) and cyclin D1 (cat # 04-1151). The following
antibodies were purchased from Cell Signaling Technology (Santa Cruz, CA): LAT1 (cat # 5347),
acetyl-histone H3 (K9) (cat # 9649), and acetyl-histone H3 (K14) (cat # D4B9). MnSOD antibody
purchased from Abcam (Cambridge, UK) (cat # ab13533).
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ChIP

mRNA

Gene Targets Gene Targets
CCND1
SOD2
LAT1
CYP1A1, 1B1

Western

Function

Proteins

AHR
CCND1
SOD2
LAT1
CYP1A1
GAPDH

AHR
CCND1
MnSOD
LAT1
GAPDH

Table 2. Methods and targets to study AHR signaling.
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Gene Regulation
Cell Proliferation
ROS Reduction
Leucine Uptake
Metabolism
Loading Control

3.2. GENE BINDING: CHROMATIN IMMUNOPRECIPITATION.
Chromatin immunoprecipitation (ChIP) assays were conducted to investigate the binding of
transcription factors, transcriptional coactivators and changes in histone H3 acetylation within chromatin
corresponding to CYP1A1, CYP1B1, CCND1, SOD2 and LAT1 genes. To this end, 500,000 BCCs
were plated into 60 mm culture plates in DMEM supplemented with 10% FBS for twenty four hours
prior to treatment with vehicle, IGF-2 (100 ng/mL, three hr), TNF (10 ng/mL, twleve hr) or TCDD (10
nM, forty five min). Post treatment, formaldehyde (1% final concentration) was added to cell culture
medium for ten min, and then cells were incubated in glycine (final concentration 0.5 M) for five min in
order to quench the crosslinking reaction. Cells were then rinsed with PBS, scraped and collected in
PBS, and pelleted by brief low speed centrifugation (800 RPM). Cell pellets were then lysed in 300 μL
of lysis buffer (1% SDS; 5 mM EDTA; 50 mM Tris–HCl, pH 8) per 60 mm plate plus protease
inhibitors (Thermo Scientific) for 15 min on ice.
Sonication (Fisher Sonic Dismembrator Model 500 at 15% amplitude) was utilized to shear
chromatin to an average length of 500 bp. Cellular extracts containing sheared chromatin were then
diluted 1:10 in dilution buffer (16.7 mM Tris–HCl, pH 8; 167 mM NaCl; 1.2 mM EDTA; 0.01% SDS;
1.1% Triton X-100) and rotated overnight at 4°C with 1 μg of non-specific IgG or antibodies
recognizing specific transcription factors, the transcriptional coactivator p300 or acetylated histone H3
at lysine residues 9 and 14 (Table 3). Antibody-chromatin complexes were collected using 5 μL of
magnetic protein A or G beads (Dynabeads, Invitrogen) with rotation at 4° C for 90 min. Using
magnetic separation (Life Technologies; part # 49-2025), beads were washed sequentially with buffer 1
(20 mM Tris–HCl, pH 8; 150 mM NaCl; 2.0 mM EDTA; 0.1% SDS), buffer 2 (20 mM Tris–HCl, pH 8;
500 mM NaCl; 2.0 mM EDTA; 0.1% SDS), buffer 3 (10 mM Tris–HCl (pH 8); 0.25 M LiCl; 1 mM
EDTA; 1% NP-40; 1% deoxycholate), and then 1× TE buffer for five mins each, and incubated at
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ChIP Antibodies
Protein

Catalog #

Concentration

Company

AHR

H-211

1 μg

Santa Cruz Biotech

ARNT

sc-17812

1 μg

Santa Cruz Biotech

p300

sc-584

1 μg

Santa Cruz Biotech

Acetyl-histone H3 (K9)

9649

1 μg

Cell Signaling

Acetyl-histone H3 (K14)

D4B9

1 μg

Cell Signaling

NF-κB RELA

sc-372

1 μg

Santa Cruz Biotech

Control IgG

2027

1 μg

Santa Cruz Biotech

Table 3. List of antibodies used for ChIP experiments
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65° C for four to six hours in elution buffer (1% SDS, 0.1 M NaHCO3) containing 1 µL proteinase K (10
mg/ml stock) per ChIP reaction to elute off beads and cleave peptide bonds to aid in DNA purification.
DNA was purified (Qiagen; cat # 28204) and analyzed using real time quantitative PCR (detailed in
section 3.4.). Primers spanning AHR-response elements (AHR-RE) in the promoter regions of CYP1A1,
CYP1B1, intron 3 of the LAT1 gene, NF-κB-RE in the SOD2 gene, or the activator protein 1 (AP1)-RE
or T-cell factor (TCF)-RE in CCND1 were used to investigate the binding of AHR, ARNT, NF-κB,
p300 or increases in the acetylation in histone H3 in these gene targets (Table 4). ChIP data was
expressed as % input, in which signals obtained from the ChIP are divided by signals obtained from an
input sample.
3.3. SHORT INTERFERING RNA: GENE KNOCKDOWN EXPERIMENTS.
Gene specific short interfering RNAs (siRNA) were used to knockdown the expression of
specific genes in order to evaluate their function. 200,000 cells in 1 mL of DMEM + 10% FBS were
mixed directly with 100 nM of short interfering RNA (siRNA) that was either non-targeting (control),
AHR targeting (AHR-siRNA), NF-κB RELA targeting, or LAT1 targeting (LAT1-siRNA) and 3 µl of
transfection reagent (Lipofectamine RNAi Max, Life Technologies), and then plated into 35 mm tissue
culture plates. After thirty six hours, cells were treated with vehicle, IGF-2 (100 ng/mL, three hr), TNF
(10 ng/mL, twelve hr) or TCDD (10 nM, six hr, or sixteen hr). Treatments were removed, and total
cellular RNA or protein was extracted with RNA-purification kits (Qiagen RNeasy) or 2× Laemmli
sample lysis buffer, respectively. In some experiments, total RNA was isolated using TRI-reagent in
accordance with protocols provided by the manufacturer (Sigma Aldrich). For cell growth studies,
treatments were prolonged and are described in section 3.7.
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ChIP DNA Primers for PCR
Gene Element

Forward Primer

Reverse Primer

CCND1 AP1-RE

5′-GGCAGAGGGGACTAATATTTCCAGCA-3′

5′-GAATGGAAAGCTGAGAAACAGTGATCTCC-3′

CCND1 TCF-RE

5′-GCTCCCATTCTCTGCCGG-3′

5′-CGGAGCGTGCGGACTCTG-3′

CYP1A1 AHR-RE

5′-ACGCAGACCTAGACCCTTTGC-3′

5′-CGGGTGCGCGATTGAA-3′

CYP1B1 AHR-RE

5′-GTGCGCACGGAGGTGGCGATA-3′

5′-GCTCCTCCCGCGCTTCTCAC-3′

LAT1 AHR-RE

5′-GCACGTACCTGTAGGGGTTG-3′

5′-ATGCTCTCTCCCCGGTGATT-3′

SOD2 NF-κB-RE

5'-GGAAAAGGCCCCGTGATTT-3'

5'-TCCTGGTGTCAGATGTTGCC-3'

Table 4. ChIP primers used to analyze gene regulation by transcription factors.
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3.4. MESSENGER RNA: REAL TIME QUANTITATIVE PCR.
Total cellular RNA was isolated with TRI-Reagent or RNEasy Purification Kits (Qiagen)
and quantitated by Nanodrop spectrophotometry. RNA at 100-300 ng starting concentration was reverse
transcribed to complementary DNA (cDNA) (Verso cDNA kit; Thermo Fisher Scientific; cat # AB1453/B). The resulting cDNAs were subjected to quantitative real-time PCR (RT-qPCR) using gene
specific primers (300 nM per reaction) and 40 cycles of PCR in accordance with Absolute Blue SYBR
Green Rox Mix (Thermo Fisher Scientific; cat # AB-4162/B) protocols (Table 5 contains all mRNA
primer sets). Relative gene expression between control and treated cells was calculated using the
formula 2−ΔΔCT, as described by Livak and Schmittgen [239]. GAPDH mRNA levels served as the
internal control. The Harvard Primer Bank http://pga.mgh.harvard.edu/primerbank/ and NIH primer
blast search engines http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome
were used to design primers. Primer specificity was verified with melt curve analysis during each real
time PCR run.
3.5. PROTEIN: WESTERN BLOTTING.
To assay changes in protein levels, 200,000 cells were plated in 35 mm plates for 24 h prior to
specific treatments. Once treatments were carried out, total cellular extract was isolated in 200 μL of
Laemmli sample buffer and approximately 12.5 μg of protein was subjected to SDS PAGE analysis and
transferred to polyvinylidene difluoride (PVDF) membranes (Bio-RAD; Hercules, CA). Membranes
were blocked in PBS, .01% Tween 20 (PBS-T), 5% (wt/vol) low-fat powdered milk for one hr and
incubated overnight with primary antibody at 4° C with gentle mixing. Primary antibodies used, their
dilutions, and where they were obtained is provided in Table 6. Membranes were rinsed five times (five
minutes each wash) with PBS-T and then incubated with an appropriate HRP-labeled secondary
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mRNA Primer Sets
Gene Targets
AHR
CCND1
SOD2
CYP1A1
CYP1B1
HMGCS2
OAS1
PLA2G2
ABCG2
NRF2
ALOX5
ALDH3A1
PKD1L1
PYDC1
PGR
MGP
SERPIN3A
CREB3L
SERPIN5A
ADORA
GAPDH
LAT1
RELA

Forward Primer

Reverse Primer

5′-ACATCACCTACGCCAGTGG-3′

5′-CTCTATGCCGCTTGGAAGGAT-3′

5′-CCGCAATGACCCCGCACGAT-3′

5′-AGGGCAACGAAGGTCTGCGC-3′

5′-GGAAGCCATCAAACGTGACTT-3′

5′-CCCGTTCCTTATTGAAACCAAGC-3′

5′-CTTCACCCTCATCAGTAATGGTC-3′

5′-AGGCTGGGTCAGAGGCAAT′-3'

5′-CTGCACTCGAGTCTGCACAT-3'

5′-TATCACTGACATCTTCGGCG-3′

5′-CAATGCCTGCTACGGTGGTA-3′

5′-GACGGCAATGTCTCCACAGA-3′

5′-CAGACGATGAGACCGACGAT-3′

5′-CCTGGAGTGTGCTGGGTCTA-3′

5′-ACCAGACGTACCGAGAGGAG-3′

5′-CGCTGGGGATTGGTGACTG-3′

5′-ACGAACGGATTAACAGGGTCA-3′

5′-CTCCAGACACACCACGGAT-3′

5′-TCCAGTCAGAAACCAGTGGAT-3′

5′-GAATGTCTGCGCCAAAAGCTG-3′

5′-CTCAAGCAACACCGACGTAAA-3′

5′-CCTTGTGGCATTTGGCATCG-3′

5′-TGTTCTCCAGCAACGACAAGG-3′

5′-AGGGCAGAGAGTGCAAGGT-3′

5′-CGCCTCTGGATTGTGATAACAG-3′

5′-CGGTCCCAGTAGCACACAG-3′

5′-CACACGTATAGCTACCGGCG-3′

5′-CGCGTAAGACAACAGCAGTG-3′

5′-TTATGGTGTCCTTACCTGTGGG-3′

5′-GCGGATTTTATCAACGATGCAG-3′

5′-TCCGAGAACGCTCTAAGCCT-3′

5′-GCAAAGTCTGTAGTCATCACAGG-3′

5′-TGCCAGCGCACTCTTCATC-3'

5′-TGTCGTTCAGGTTATAGTCCCTC-3′

5′-CCTCCCGAAGCCTCCTATTCT-3′

5′-GGGGTTGATTTCCCAGCCA-3′

5′-ATGCCCTTTTCACCGACCTG-3′

5′-TGCAGAGTCCCTAAAGTTGGTAG-3′

5′-CCACAGACCTACTTCCACACC-3′

5′-TACCGGAGAGGGATCTTGACC-3′

5′-CATGAGAAGTATGACAACAGCCT-3′

5′-AGTCCTTCCACGATACCAAAGT-3′

5′-CCGAGGAGAAGGAAGAGGC-3′

5′-GAAGATGCCCGAGCCGATAA-3′

5′- TCCAGACCAACAACAACCCC-3′

5′-GATCTTGAGCTCGGCAGTGT-3'

Table 5. Primer sets for mRNA studies.
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Protein

Cat #

Western Antibodies
Conc. & Incubation

H-211
1 : 2000, overnight, 4C
AHR
04-1151
1 : 20000, overnight, 4C
CCND1
1 : 10000, 1 h, room temp.
GAPDH MAB374
5347
1 : 2000, overnight, 4C
LAT1
ab13533
1 : 5000, overnight, 4C
MnSOD
Table 6. Antibodies used for western blotting.
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Company
Santa Cruz Biotech
Millipore
Millipore
Cell Signaling
Abcam

antibody (diluted 1:10,000 in PBS, .01% tween-20, 5% milk) (Thermo Scientific, Pierce) for one hr,
followed with rinsing five times (five mins each wash) in PBS-T. Membranes were developed with
enhanced chemiluminescent substrate (Millipore, Immobilon ECL substrate) and exposure to X-ray film
(Midwest Scientific). GAPDH western blots were performed as a loading control for all western blot
experiments herein to confirm equal protein loading. Normalized levels of proteins of interest were
expressed as a ratio relative to GAPDH levels. Densitometry was calculated with ImageJ PC-based
software (National Institute of Health).
3.6. FUNCTION: LEUCINE UPTAKE.
Leucine uptake experiments were performed in MCF-7 cells grown to confluence on 24 well
plates. The cells were first washed twice with Na-free buffer (130 mM TMACl, 4.7 mM KCl, 1 mM
MgSO4, 1.25 mM CaCl2, 20 mM HEPES; pH 7.4) and incubated with the same for ten min at room
temperature. The uptake was then initiated by incubating the cells for thirty sec with Na-HEPES buffer
(130 mM NaCl, 4.7 mM KCl, 1 mM MgSO4, 1.25 mM CaCl2, 20mM HEPES; pH 7.4) with 10 µCi of
3H-L-Leucine (PerkinElmer; Waltham, MA) and 10 µM L-Leucine (Sigma). The reaction was stopped
with ice cold Na-HEPES buffer after which the cells were washed twice with the same ice-cold buffer.
The cells were then lysed in 500 µl of 1 N NaOH followed by incubation for 20 min at 70° C. The lysed
contents of each well was collected in a 7 ml scintillation tube and mixed with 5 ml Ecoscint A
(National Diagnostics; Atlanta, GA). Leucine uptake experiments were conducted using chemicals
obtained from Sigma–Aldrich. The vials were kept in the dark for forty eight hours and the radioactivity
was determined in a Beckman 6500 scintillation counter. Data expressed as leucine uptake pmol/mg
protein.
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3.7. FUNCTION: CANCER PROLIFERATION.
For cellular proliferation studies, two methods were used: manual cell counting via
hemocytometers or commercially available colorimetric proliferation assay kits. For specific treatments,
refer to methods and results sections found in the subsequent chapters of this document. Generally, for
manual cell counting, breast cancer cells were seeded into six well plates at a density of 80,000 cells per
well. Once specific treatments were applied, cells were maintained in culture for three days to observe
discernable changes in cell number. After three days, treated cells were rinsed with PBS solution,
subjected to trypsinization, and then suspended in complete medium (DMEM, 10% FBS, and 1%
penicillin/streptomycin (P/S)) at a final volume of 1mL cell suspension per well. Cells were diluted 1:1
with trypan blue to determine the number of viable cells, as dead cells take up the compound and exhibit
a blue color and can be excluded from counts [240]. 12.5 µL of each cell suspension was loaded onto
hemocytometers and counted. Three replicates were performed per treatment group and these numbers
were averaged. Control untreated cells were assigned a value of 1, and fold change in cell number for
treated cells was determined and expressed graphically.
Proliferation was assayed using commercially available Aqueous One Solution Cell
Proliferation Assay kits (Promega, Madison, WI). Cells were plated into 96 well plates at a density of
1,000 to 2,000 cells per well, depending on the cell line. After three days, cell proliferation was assayed
in accordance with the manufacturer’s protocol.
3.8. STATISTICAL ANALYSIS.
Two-tailed, paired t tests with confidence intervals of 95% were used to determine statistically
significant differences between two groups. The Student Newman–Keuls (SNK) post hoc test was used
to determine statistically significant differences among groups following one-way analysis of variance
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(ANOVA). “*” denotes statistical significance reached at P < 0.05, “**” denotes statistical significance
reached at P < 0.01, and “***” denotes statistical significance reached at P < 0.001.
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ABSTRACT
Obesity increases human cancer risk and the risk for cancer recurrence. Adipocytes secrete paracrine
factors termed adipokines that stimulate signaling in cancer cells that induce proliferation. The aryl
hydrocarbon receptor (AHR) is a ligand-activated transcription factor that plays roles in tumorigenesis,
is regulated by exogenous lipophilic chemicals, and has been explored as a therapeutic target for cancer
therapy. Whether exogenous AHR ligands modulate adipokine stimulated breast cancer cell proliferation
has not been investigated. We provide evidence that adipocytes secrete insulin-like growth factor 2
(IGF-2) at levels that stimulate the proliferation of human estrogen receptor (ER) positive breast cancer
cells. Using highly specific AHR ligands and AHR short interfering RNA (AHR-siRNA), we show that
specific ligand-activated AHR inhibits adipocyte secretome and IGF-2-stimulated breast cancer cell
proliferation. We also report that a highly specific AHR agonist significantly (P < 0.05) inhibits the
expression of E2F1, CCND1 (known as Cyclin D1), MYB, SRC, JAK2, and JUND in breast cancer
cells. Collectively, these data suggest that drugs that target the AHR may be useful for treating cancer in
human obesity.

Keywords: AHR, IGF-2, Adipokines, Obesity, Breast Cancer
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4.1. INTRODUCTION
Human obesity is common and has been linked with increases in breast cancer risk and
breast cancer recurrence [112, 113, 241]. Although the underlying links between obesity and
cancer are not completely clear, adipocytes themselves are postulated to play a role [112, 113,
124, 241-246]. Adipocytes secrete multiple paracrine factors termed adipokines that stimulate
signaling in human cancer cells that stimulate proliferation [124, 242-244, 246]. Specific
adipokines that stimulate the proliferation of human estrogen receptor (ER) positive breast
cancer cells are leptin, collagen VI, and members of the insulin-like growth factor (IGF) family
of proteins [124, 242, 243, 245]. In ER positive breast cancer cells, leptin through its cognate
membrane spanning cytokine leptin receptor activates the JAK/STAT pathway [244, 247].
Collagen VI by activating the NG2/chondroitin sulfate proteoglycan receptor activates AKT and
β-catenin signaling [59, 124, 243]. IGF-1 and IGF-2 signal through specific cell surface tyrosine
kinase receptors, IGF-1 receptor (IGF1-R) and insulin receptor isoform A (IR-A)), that are highly
expressed on human ER expressing breast cancer cells [248, 249]. The critical pathway by which
IGF-1 and IGF-2 stimulate breast cancer cell proliferation is the PI3K pathway that leads to
increases in AKT activity [248, 249]. Leptin, collagen VI, and IGF proteins have all been
reported to stimulate increases in the transcription and expression of CCND1 (also known as
Cyclin D1) in ER expressing breast cancer cells [124, 243, 244, 249]. CCND1 is a regulatory
protein that activates the cell cycle, increases cell proliferation, and has been implicated as a
promoter of breast tumorigenesis [115]. New drugs and drug targets that inhibit adipokine
stimulated breast cancer cell proliferation could be particularly relevant to reducing the higher
rates of breast cancer risk and breast cancer recurrence that are observed in obese women
compared to women of normal weight. However, there are currently no specific therapies for
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reducing breast cancer risk and recurrence in obesity.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that has
been explored as a therapeutic target for cancer [250, 251]. Ligand-activated AHR inhibits the
growth of some human cancer cell lines [250, 251]. The AHR is stimulated by lipophilic
chemicals that function as AHR agonists including the environmental toxicant 2,3,7,8
tetrachlorodibenzo-p-dioxin (TCDD) and the experimental drug 3-(3,5-dimethyl-1H-pyrrol-2-yl
methylene)-1,3-dihydro-indol-2-one (SU5416) [250, 252]. In the absence of an exogenous AHR
agonist, the AHR is located in the cytoplasm bound to p23, HSP90, and XAP2 chaperon proteins
[253]. Upon activation by an agonist, the AHR dissociates from p23, HSP90, and XAP2,
translocates into the nucleus, and stimulates transcription by binding to sequence specific
response elements termed AHR response elements (AHR-RE) in enhancers of genes that are
stimulated by AHR ligands [253]. CYP1A1 is a prototypical AHR regulated gene target that has
been used to study AHR signaling [253]. Whether specific ligand-activated AHR inhibits
adipokine stimulated breast cancer cell proliferation and the potential mechanisms by which this
could occur have not been investigated.
Obese women with ER positive breast tumors have worse clinical outcomes and have a
higher risk for breast cancer recurrence than obese women with ER negative breast tumors [254].
This suggests that ER positive breast cancer cells could be more sensitive to the proliferative
effects of mitogenic adipokines than ER negative breast cancer cells. The human ER positive
MCF-7 breast cancer cell line has been used extensively as a model to investigate mitogenic
adipokine signaling in human breast cancer cells and MCF-7 cells, express leptin, collagen VI,
and IGF receptors [124, 243, 244, 249]. The human T-47D breast cancer cell line expresses ER
and IGF receptors, and fewer reports have used this cell line to investigate adipokine signaling in
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human breast cancer cells [250]. Given these prior reports, the purpose of this study was to
examine the possibility that specific ligand-activated AHR inhibits mitogenic adipokine signaling
in human MCF-7 breast cancer cells and to provide preliminary insights into the mechanism by
which this occurs. Primary findings were also validated in T-47D cells.
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4.2. MATERIALS AND METHODS
4.2.1. Conditioned Media
A previously published standard adipocyte differentiation protocol was used to
differentiate murine 3T3-L1 preadipocyte fibroblasts into fully differentiated adipocytes [243].
Specifically, confluent 3T3-L1 fibroblasts were treated with Dulbecco's Modified Eagle Medium
(DMEM), 10% FBS, 160 nM insulin, 250 nM dexamethasone, and 0.5 mM 3-isobutyl-1methylxanthine (IBMX)) for 3 days, followed by 10% fetal bovine serum (FBS) and 160 nM
insulin for 3 days and then DMEM 10% FBS for an additional 6 days, with a medium change
every three days. In order to examine the effects of adipocyte secreted adipokines in the absence
of confounding factors in FBS, medium was removed from fully differentiated adipocytes,
followed by rinsing twice with phosphate buffered saline (PBS), and adipocytes were then
incubated in phenol red-free, serum-free DMEM for an additional 24 hr. This serum-free
adipocyte conditioned medium (adipo-CM) was centrifuged and stored at −80°C prior to being
applied to breast cancer cells in cell culture. Phenol red-free, serum-free DMEM conditioned by
3T3-L1 fibroblasts for 24 hrs was also isolated. Fibroblast conditioned medium (fibro-CM) was
applied to breast cancer cells as a control media not conditioned by an adipocyte. DMEM, FBS,
P/S, and PBS were purchased from Thermo Fisher Scientific (HyClone Labs, Logan, UT).
IBMX, insulin, and dexamethasone were purchased from Sigma-Aldrich (St. Louis, MO).
4.2.2. Breast Cancer Cell Growth Experiments
Prior to specific growth experiments, MCF-7 and T-47D cells purchased from ATCC
(Manassas, VA) were maintained in DMEM, 10% FBS, and 1% penicillin/streptomycin (P/S). To
explore whether adipo-CM stimulated cancer proliferation more than fibro-CM, phenol red-free,
serum-free DMEM (unconditioned medium), fibro-CM, or adipo-CM was applied to MCF-7 or
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T-47D cells for three days in culture, after which cells were collected and total live cell number
was determined using a hemocytometer and manual cell counting. Preliminary experiments were
conducted to determine the optimal dose of TCDD to use in proliferation experiments. In our
preliminary experiments, we found that MCF-7 cells were more sensitive to the antiproliferative
effects of TCDD than, T-47D cells (data not shown; n= 3). Thus, in all remaining experiments,
MCF-7 cells were treated with 10 nM TCDD and T-47D cells were treated with 100 nM TCDD.
The 100 nM dose of SU5416 was selected based on our preliminary data showing that SU5416 at
this dose is a strong AHR agonist based on its ability to stimulate increases in CYP1A1 gene
expression (data not shown; n= 3). Fibro-CM or adipo-CM supplemented with DMSO vehicle,
TCDD, or SU5416 was applied to overnight serum-starved (phenol red-free DMEM) MCF-7 or
T-47D cells for three days in culture, after which cells were collected and trypan blue and manual
cell counting were used to determine live cell number. In other experiments, overnight serumstarved (phenol red-free DMEM) MCF-7 or T-47D cells were stimulated with PBS vehicle or
IGF-2 (100 ng/mL; R & D Systems) supplemented with DMSO vehicle, TCDD, or SU5416 for
three days in culture, after which cells were collected and live cell was determined with trypan
blue. The IGF-2 dose was based on the work of Worster et al. showing that IGF-1 (100 ng/mL)
induced the proliferation of human breast epithelial cells [255].
4.2.3. SiRNA Experiments
In order to show that TCDD and SU5416 inhibition of IGF-2 requires the AHR, breast
cancer cells were plated in DMEM, 10% FBS, and P/S (80,000 cells per well of a six-well plate)
for 24 hr, then transiently transfected with 50 nM of a single short interfering RNA (siRNA) that
specifically targets the AHR (AHR-siRNA) or with a nontargeting control siRNA (con-siRNA)
with 2 μL of DharmaFECT reagent 1 for 24 hr. Following removal of transient transfection
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reagent, cells were serum-starved overnight in phenol red-free DMEM and then treated with
IGF-2 (100 ng/mL) supplemented with DMSO vehicle or TCDD (MCF-7 (10 nM), T-47D
(100 nM)) or SU5416 (MCF-7 100 nM) for three days in culture, after which cells were collected
and trypan blue was used to determine the number of live cells. Con-siRNA (cat number D001810-01-20), AHR-siRNA (J-004990-05), and DharmaFECT transfection reagent number 1
were purchased from Thermo Scientific, Dharmacon. DMSO and SU5416 were purchased from
Sigma-Aldrich (St. Louis, MO). TCDD was purchased from Cambridge Isotopes Laboratory
(Andover, MA) (cat number ED-901-B).
4.2.4. Western Blot Experiments
To validate AHR-siRNA mediated knockdown of the AHR, breast cancer cells (300,000
cells per 35 mm plate) were transfected with con-siRNA or AHR-siRNA for 36 hr, followed by
isolation of total cellular extract in 250 μL of 2X sample lysis buffer (Bio-RAD; cat number 1610737). Total cellular extract (~12.5 μg of protein) was subjected to SDS PAGE in MiniPROTEAN TGX 4–12% Precast Gels (Bio-Rad; Hercules, CA) and transferred to
polyvinylidene difluoride (PVDF) membranes (Bio-Rad; Hercules, CA). Membranes were
blocked in PBS, 0.05% Tween 20 (PBS-T), and 5% (wt/vol) low-fat powdered milk for one hr,
followed by overnight incubation at 4°C with rocking with an appropriate primary antibody.
Membranes were rinsed five times (five minutes each wash) with PBS-T and then incubated with
an appropriate HRP-labeled secondary antibody (Thermo Scientific, Pierce) for 1 h, followed by
rinsing five times (five minutes each wash) in PBS-T followed by the application of enhanced
chemiluminescent substrate (Thermo Scientific, Millipore) and exposure to X-ray film (Midwest
Scientific). Equal protein loading was confirmed by glyceraldehyde 3-phosphate dehydrogenase
(abbreviated as GAPDH) western blots. AHR antibody was purchased from Santa Cruz
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Biotechnology, cat number: sc-5579, and diluted 1 : 5,000 in PBS, 0.01% tween-20, and 5%
powdered milk. GAPDH was purchased from Millipore, cat #: MAB374, and diluted 1 : 20,000
dilution in PBS, .01% tween-20, and 5% powdered milk.
4.2.5. RT-qPCR Experiments
A RT2 Profiler PCR Array (PAHS-502ZC) (Superarray Bioscience Corporation, Qiagen)
was used to compare gene expression between MCF-7 cells treated with IGF-2 (100 ng/mL) plus
DMSO vehicle and MCF-7 cells treated with IGF-2 (100 ng/mL) plus TCDD (10 nM) for 48 hrs.
The PAHS-502ZC PCR array allows for the integration of 84 genes that are prooncogenes or
tumor suppressors and thus are key genes in tumorigenesis. Treatments were stopped, total RNA
was isolated (RNeasy Mini Kit, Qiagen), and 1 μg of RNA was converted into cDNA (RT2 First
Strand Kit, Qiagen). cDNA was combined with RT2 SYBER Green ROX qPCR Master Mix
(Qiagen), and changes in gene expression were analyzed by RT2 Profiler PCR Array (PAHS502ZC). Statistically significantly differentially expressed genes between groups were calculated
by RT2 Profiler PCR Array Data Analysis software package that calculates ΔΔ CT calculated
fold changes and uses Student's t-test to calculate two-tail, equal variance P values. Experiments
were performed three times (n= 3).
4.2.6. IGF-2 Blocking Antibody Experiments
In order to explore whether adipocytes secreted levels of IGF-2 are sufficient to stimulate
the proliferation of breast cancer cells, a control mouse IgG (5 μg/mL) (R & D systems, cat
number MAB002) or human IGF-2 blocking antibody (5 μg/mL) (R & D Systems, cat number
MAB292) was added to adipo-CM prior to being added to human breast cancer cells for three
days in culture, after which total live cell number was determined using trypan blue. This
particular IGF-II blocking antibody was selected because it has been shown to specifically
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neutralize human IGF-2 in MCF-7 proliferation assays and exhibits 100% cross-reactivity with
mouse IGF-2 (R & D Systems product sheet, cat number MAB292).
4.2.7. Mouse Adipokine Array Kit
Protein adipokine arrays were purchased from R&D systems (Minneapolis, MN, cat
number ARY-013) and conducted in accordance with the manufactured protocols. Normalized
adipokine levels were calculated as the density of a specific adipokine divided by the density of
an internal loading control on each array. Densitometry was calculated with ImageJ PC-based
software (National Institute of Health).
4.2.8. Statistical Analysis
All experiments were performed for a minimum of three times. One way analysis of
variance (ANOVA), followed by Student-Newman-Keuls Post-Hoc Tests, was performed to
determine statistically significant differences between multiple groups. Student's t-test was used
to determine statistically significant differences between two groups. All statistical tests were run
at a 95% confidence interval, and significance was denoted as P < 0.05.
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4.3. RESULTS AND DISCUSSION
4.3.1. Adipocytes Secrete IGF-2 at Levels That Stimulate Breast Cancer Cell Proliferation
The application of adipocyte conditioned medium (adipo-CM) to MCF-7 or T-47D breast
cancer cells for three days in culture significantly (P < 0.0001 and P < 0.005, resp.) increased
proliferation more than the application of fibroblast conditioned medium (fibro-CM) or
unconditioned medium (uncond-M) (Figures 11 (A) and (B)). Adipokine protein arrays revealed
that the levels of several adipokines in adipo-CM were significantly higher than in fibro-CM,
including insulin-like growth factor-2 (IGF-2) (by approximately three-fold; (P < 0.05)) (Figures
11 (C) and (D)). Since the levels of IGF-2 were higher in adipo-CM than in fibro-CM (Figures
11 (C) and (D)), and MCF-7 and T-47D cells overly express IGF1-R and IR-A [248, 249], we
questioned the role of IGF-2 in adipo-CM. The addition of a specific IGF-2 blocking antibody to
adipo-CM significantly reduced MCF-7 (P < 0.0003) and T-47D (P < 0.05) proliferation
compared to control cells incubated in adipo-CM containing a nonspecific control IgG (Figures
11 (E) and (F)). This result suggests that adipocyte secreted IGF-2 contributes to the proliferation
of ER expressing breast cancer cells.
4.3.2. Ligand-Activated AHR Inhibits Adipo-CM and IGF-2 Stimulated Breast Cancer Cell
Proliferation
TCDD is a highly specific AHR agonist [253]. The application of adipo-CM plus TCDD
to MCF-7 and T-47D cells significantly (P < 0.0001 and P < 0.002, resp.) reduced proliferation
compared to that observed in control cells stimulated with adipo-CM in the presence of vehicle
DMSO (Figures 12 (A) and (B)). Conversely, MCF-7 and T-47D proliferation in fibro-CM was
not inhibited by TCDD (Figures 12 (A) and (B)). These data suggest that activation of the AHR
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Figure 11. Adipocytes secrete levels of IGF-2 that contribute to adipo-CM stimulated breast
cancer cell proliferation. (A, B)The total number of live MCF-7 (A) and T-47D (B) cells grown
in unconditioned (uncond-M), fibroblast (fibro-CM), or adipocyte (adipo-CM) conditioned
medium for three days in culture was determined and is shown relative to the number of live
cells in the uncond-M group, which was arbitrarily assigned a value of 1. Data shown are the
means ± S.E. for three replicate experiments, and significant (P < 0.05) induction of cell number
by fibro-CM (∗) compared to the uncond-M group or by adipo-CM (∗∗) compared to the uncondM and fibro-CM groups is shown. (C, D) Adipokine protein arrays were used to determine the
relative levels of adipokines in adipo-CM and fibro-CM. (D) Data shown are the means ± SE for
three experiments, and significantly (P < 0.05) higher levels of an adipokine in adipo-CM (∗)
compared to fibro-CM are shown. Normalized adipokine levels were calculated as the
densitometry of an adipokine normalized to the densitometry of an internal loading control. (E,
F) The total number of live MCF-7 (E) and T-47D (F) cells treated with nonspecific IgG (5
μg/mL) or a specific IGF-2 blocking antibody (5 μg/mL) in adipo-CM for three days in culture
was determined and is displayed relative to the number of live cells in the fibro-CM nonspecific
IgG group, which was arbitrarily assigned a value of 1. Data shown are the means ± S.E. for
three replicate experiments. A significant (P < 0.05) decrease in cell number by IGF-2 antibody
(∗) is shown.
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Figure 12. AHR ligands inhibit
adipo-CM and IGF-2 stimulated
breast cancer cell growth. (A, B)
The total number of live MCF-7
(A) and T-47D (B) cells treated
with DMSO vehicle or TCDD in
fibro-CM or adipo-CM for three
days in culture was determined and
is displayed relative to the number
of live cells in the fibro-CM DMSO
control group, which was arbitrarily
assigned a value of 1. Data shown
are the means ± S.E. for three
experiments, and a significant (P <
0.05) decrease in cell number by
TCDD (*) is indicated. (C, D) The
total number of MCF-7 (C) and
T47D (D) cells treated with DMSO
or TCDD alone or plus IGF-2 (100
ng/mL) for three days in culture
was determined and is displayed
relative to the number of live cells
in the DMSO group, which was
assigned a value of 1. Data shown
are the means ± S.E. for three
experiments, and a significant (P <
0.05) decrease in cell number by
TCDD (*) is indicated. (E, F) The
total number of MCF-7 cells
stimulated with DMSO or SU5416
in fibro-CM or adipo-CM (E) or
with DMSO or SU5416 alone or
plus IGF-2 (100 ng/mL) (F) for
three days in culture was
determined and is displayed
relative to the number of live cells
in the DMSO group, which was
assigned a value of 1. Data shown
are the means ± S.E. for three
experiments, and a significant (P <
0.05) decrease in cell number by
TCDD (*) is indicated.
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with a highly specific AHR ligand specifically inhibits the mitogenic effects of adipokines that
are present in the adipo-CM. Next, we conducted experiments to determine whether TCDD
inhibits IGF-2 stimulated breast cancer cell proliferation. Treating MCF-7 and T-47D cells with
IGF-2 (100 ng/mL) plus TCDD significantly (P < 0.0001 and P < 0.0034, resp.) inhibited
proliferation compared to that observed in control cells stimulated with IGF-2 plus DMSO
vehicle (Figures 12 (C) and (D)). This result indicates that activation of the AHR by a highly
specific AHR agonist blocks IGF-2 stimulated breast cancer cell proliferation.
To provide further evidence that ligand-activated AHR inhibits the proliferation effects of
adipokines, we tested a second AHR agonist, SU5416 [252]. The application of adipo-CM with
SU5416 significantly (P < 0.0001) inhibited MCF-7 cell proliferation compared to that observed
in adipo-CM plus DMSO vehicle group (Figure 12 (E)). SU5416 did not reduce breast cancer
cell number in the presence of fibro-CM (Figure 12 (E)). Further, SU5416 significantly (P <
0.001) blocked IGF-2 stimulated MCF-7 cell proliferation (Figure 12 (F)). Collectively, these
data indicate that exogenous AHR ligands inhibit the proliferative effects of mitogenic
adipokines (including IGF-2) in human ER expressing breast cancer cells.
4.3.3. AHR Ligand-Stimulated Inhibition of IGF-2 Requires the AHR
Next, experiments were conducted to provide evidence that exogenous AHR ligands
inhibit the proliferative effects of adipokines through a mechanism that is dependent on the AHR.
To this end, MCF-7 and T-47D cells were transiently transfected with a short interfering RNA
that specifically targets the AHR (AHR-siRNA) or with a nontargeting control siRNA (consiRNA) prior to treatment with IGF-2 (100 ng/mL) supplemented with DMSO vehicle or TCDD.
The level of AHR protein in AHR-siRNA transfected MCF-7 and T-47D cells was significantly
(P < 0.0002 and P < 0.0001, resp.) lower than in con-siRNA transfected cells (Figures 13 (A) and
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(B)). In the presence of con-siRNA, TCDD significantly (P < 0.001) inhibited IGF-2 stimulated
MCF-7 proliferation (Figure 13 (B)). Reducing the AHR in the presence of IGF-2 significantly
(P < 0.001) inhibited proliferation relative to control cells treated with con-siRNA plus IGF-2
(Figure 13 (B)). This result suggests that in the absence of exogenous AHR ligands, the AHR
itself plays an endogenous role in MCF-7 cells that is required for maximal proliferation in the
presence of IGF-2. Importantly, as shown in Figure 13 (B), reducing AHR prevented TCDD
inhibition of IGF-2 (Figure 13 (B); compare last two right bars). This latter result provides
evidence that TCDD inhibits IGF-2 by activating the AHR, because TCDD does not inhibit IGF2 in cells with reduced expression of the AHR (Figure 13 (B)). The TCDD-stimulated inhibition
of IGF-2 by AHR was further confirmed in T-47D cells, which showed the TCDD
antiproliferative effects towards IGF-2 were reversed upon AHR knockdown (Figures 13 (C) and
(D)). To provide evidence that a different AHR ligand also inhibits IGF-2 by specifically
activating the AHR, AHR-siRNA experiments were repeated with SU5416. As shown in Figure
13 (E), under con-siRNA conditions, SU5416 significantly (P < 0.0001) inhibited IGF-2
stimulated MCF-7 cell proliferation. In accordance with our prior result, reducing the AHR itself
inhibited MCF-7 cell proliferation in the presence of IGF-2 compared to control cells transfected
with con-siRNA and stimulated with IGF-2 (Figure 13 (E)). AHR-siRNA blocked SU5416
inhibition of IGF-2 (Figure 13 (E); compare last two right bars). Collectively, these data provide
mechanistic evidence that upon activation by exogenous AHR agonists TCDD and SU5416, the
AHR inhibits IGF-2 stimulated MCF-7 and T-47D proliferation.
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Figure 13. AHR ligand-stimulated inhibition of IGF-2
requires the AHR. (A, C) MCF-7 (A) or T-47D (C) cells
transiently transfected with con-siRNA or AHR-siRNA for 36
hr, followed by isolation of total cellular extract and western
blot analysis with AHR and GAPDH antibody. GAPDH was
used to normalize between samples. Data shown are the means
± S.E. of three experiments. A significant (P < 0.05) decrease
in AHR by AHR-siRNA (*) is indicated. (B, D) The total
number of MCF-7 (B) or T-47D (D) cells transfected with
nontargeting control short interfering RNA (con-siRNA) or
aryl hydrocarbon receptor siRNA (AHR-siRNA) for 36 hr and
then treated with DMSO, vehicle control (con), IGF-2 (100
ng/mL) plus DMSO or IGF-2 plus TCDD (MCF-7; 10 nM, T47D; 100 nM) for three additional days in culture was
determined and is displayed relative to the number of live cells
in the DMSO con-siRNA group, which was assigned a value
of 1. Data shown are the means ± S.E. of three experiments.
(E) The total number of MCF-7 cells transfected with consiRNA or AHR-siRNA for 36 hr and then treated with DMSO
vehicle control (con), IGF-2 (100 ng/mL) plus DMSO, or IGF2 plus SU5416 (100 nM) for three additional days in culture
was determined and is displayed relative to the number of live
cells in the DMSO con-siRNA group, which was assigned a
value of 1. Data shown are the means ± S.E. of three
experiments.
66

Table 7. Reduced expression of proto-oncogenes in MCF-7 cells stimulated with IGF-2 plus
TCDD compared to cells stimulated with IGF-2 at 48hrs.
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4.3.4. TCDD Stimulates Reductions in E2F1, CCND1, MYB, SRC, JAK2, and JUND Gene
Expression
To begin to investigate the mechanism by which ligand-activated AHR inhibits
proliferation, experiments were conducted to determine whether TCDD reduces the expression
of genes that could be important for breast cancer cell proliferation in the presence of IGF-2. To
this end, we used a commercially available RT2 Profiler PCR Array that is capable of integrating
84 genes that are protooncogenes or tumor suppressors and thus key regulators of tumorigenesis.
We focused on comparison between two groups, MCF-7 cells stimulated with IGF-2 and MCF-7
cells cotreated with IGF-2 plus TCDD for 48 hrs. This analysis revealed that the expression of
E2F1, CCND1, MYB, SRC, JAK2, and JUND was significantly reduced in cells treated with
IGF-2 plus TCDD compared to that observed in cells stimulated with IGF-2 (Table 7; n= 3).
TCDD inhibition of these specific gene targets could be one mechanism by which ligandactivated AHR inhibits mitogenic adipokine signaling, because the observed downregulated
genes in TCDD treated cells play important roles in breast cancer cell proliferation. E2F1 is a
transcription factor that binds retinoblastoma protein, enhances the proliferation of human cancer
cells, and stimulates increases in the transcription and expression of CCND1 [256]. The tyrosine
kinase JAK2 upon activation by cytokine receptor induced signaling to stimulate the
phosphorylation and activation of STAT3 [247]. When activated by JAK2, STAT3 promotes the
transcription and expression of CCND1 [244]. The basic leucine zipper (bZIP) transcription
factor JUND by function as a component of AP-1 enhances the transcription and expression of
CCND1 [257]. MYP is a 17 beta-estradiol regulated transcription factor that has been reported to
be important for the proliferation of ER expressing human breast cancer cells, including T-47D
and MCF-7 cells [257].
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4.4. CONCLUSION
In summary, we provide evidence that adipocyte secreted IGF-2 is sufficient to contribute
to the proliferation of human ER expressing breast cancer cells. This result suggests that
adipocyte secretion of IGF-2 could play a role in promoting breast cancer in the context of
obesity. Adipocytes have also been reported to secrete IGF-1 in the presence of high glucose and
exogenously added fatty acids [245]. Both IGF-1 and IGF-2 enhance the proliferation of human
cancer cells through IGF1-R and IR-A [248, 249]. Using highly specific AHR agonists and
AHR-siRNA, we provide the first evidence suggesting that specific ligand activation of the AHR
inhibits adipo-CM and IGF-2-stimulated proliferation of ER positive human breast cancer cells.
It is important to note that E2F1, SCR, JAK2, and JUND are critical upstream transcriptional
regulators of CCND1 [244, 247, 256, 258]. Thus, their downregulation by TCDD (Table 7)
could be one mechanism by which TCDD downregulates CCND1 expression. CCND1 is also a
critical mediator of the proliferative effects of IGF proteins and other adipokines like leptin [244,
249]. Therefore, TCDD inhibition of CCND1 expression (Table 7) is likely to be one of the
major mechanisms that inhibit mitogenic adipokine signaling in breast cancer cells. The results
of this study provide the impetus for future study investigating the transcriptional mechanisms by
which ligand-activated AHR by regulating the expression of prooncogenes modulates mitogenic
adipokine signaling in human breast cancer cells. Collectively, this report provides evidence that
drugs that target the AHR may reduce breast cancer risk in the context of human obesity.
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ABSTRACT
Insulin like growth factor (IGF)-1 and IGF-2 stimulate normal growth, development and breast
cancer cell proliferation. Cyclin D1 (CCND1) promotes cell cycle by inhibiting retinoblastoma
protein (Rb). The aryl hydrocarbon receptor (AHR) is a major xenobiotic receptor that also
regulates cell cycle. The purpose of this study was to investigate whether IGF-2 promotes MCF7 breast cancer proliferation by inducing AHR. Western blot and quantitative real time PCR (RTqPCR) analysis revealed that IGF-2 induced an approximately two-fold increase (P <.001) in the
expression of AHR and CCND1. Chromatin immunoprecipitation (ChIP), followed by qPCR
indicated that IGF-2 promoted (P < .001) a seven-fold increase in AHR binding on the CCND1
promoter. AHR knockdown significantly (P < .001) inhibited IGF-2 stimulated increases in
CCND1 mRNA and protein. AHR knockdown cells were less (P < .001) responsive to the
proliferative effects of IGF-2 than control cells. Collectively, our findings have revealed a new
regulatory mechanism by which IGF-2 induction of AHR promotes the expression of CCND1
and the proliferation of MCF-7 cells. This previously uncharacterized pathway could be
important for the proliferation of IGF responsive cancer cells that also express AHR.
Keywords: Aryl hydrocarbon Receptor, IGF-2, CCND1, breast cancer cells
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5.1. INTRODUCTION
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor whose
activity is regulated by lipid soluble environmental toxicants [253]. 2,3,7,8 tetrachlorodibenzo-pdioxin (TCDD) is a prototypical AHR agonist which is found in Agent Orange [253]. The
binding of TCDD to AHR stimulates the AHR to translocate into the nucleus and stimulate
transcription through specific xenobiotic response elements (XREs) in enhancers and promoters
of TCDD stimulated genes [253, 259]. TCDD through AHR induces the expression of a
“battery” of phase I and phase II drug metabolizing enzymes including the prototype TCDDAHR gene target cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) [253, 259].
The AHR also regulates cell cycle in part by binding with Cyclin D1 (CCND1) and cyclin
dependent kinase 4 (CDK4) [105, 260]. CDK4 phosphorylates retinoblastoma protein (Rb),
which inhibits Rb-mediated repression of E2F transcription factors [261-263]. The activation of
E2F induces the expression of E2F target genes that are important for DNA synthesis and cell
cycle advance [261-263]. Mitogens promote CDK4 activity by increasing the levels of cyclin
proteins including CCND1 [261-263]. By functioning as a regulatory subunit on CDK
holoenzymes, CCND1 promotes the phosphorylation and inhibition of RB1 to promote cell cycle
advance and proliferation [261-263]. The AHR binds to CDK4 during advance through the cell
cycle in human MCF-7 breast cancer cells [105]. TCDD binding to AHR attenuates AHR
binding with CDK4, which correlated with cell cycle arrest and reductions in RB1
phosphorylation in MCF-7 cells [105]. CCND1 was also present in CDK4-AHR complexes
[105].
Insulin like growth factor (IGF)-1 and IGF-2 stimulate growth, development and the
proliferation of human cancer cells including breast cancer cells [248, 249]. MCF-7 breast cancer
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cells have been reported to express high levels of IGF-1 receptor (IGF1-R) and insulin receptor
subtype A receptor (IR-A) [248, 249]. IGF-R1 and IR-A mediate the proliferative effects of IGFs
on human breast cancer cells by inducing the phosphoinositide 3-kinase (PI3K)/AKT (protein
kinase B) pathway and the mitogen-activated protein kinase (MAPK) pathway [248, 249, 264].
IGF-1 and IGF-2 have also been reported to increase levels of CCND1 to induce proliferation
[248, 249, 262]. CCND1 promoter activity is regulated through multiple enhancers including
activator protein-1 (AP-1) and T-cell factor (TCF)/lymphoid enhancing factor (LEF) sites [265268]. The transcription factors Jun and Fos bind to the AP-1 response elements [265, 266]. The
transcriptional co-activator β-catenin confers transcriptional activity to TCF/LEF transcription
factors bound to TCF/LEF elements in the CCND1 promoter [267, 268].
We have recently shown that adipocytes secrete levels of IGF-2 that are sufficient to
stimulate the proliferation of MCF-7 and T-47D breast cancer cells [111]. We also found that
AHR knockdown MCF-7 cells were less responsive to the proliferative effects of IGF-2 [111].
The purpose of this study was to investigate if: 1) IGF-2 signaling regulates the AHR and 2)
IGF-2 induction of CCND1 requires AHR. We provide evidence that IGF-2 signaling activates
AHR and that AHR is important for inducing the expression of CCND1 and MCF-7
proliferation. This is a new link between IGF-2 signaling and AHR.
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5.2. MATERIALS AND METHODS
5.2.1. Materials and MCF-7 cell culture
Dulbecco's Modified Eagle Medium/High glucose (DMEM) with L-glutamine and
sodium pyruvate, 10% fetal bovine serum, penicillin, and streptomycin (100μg/mL) and
phosphate buffered saline (PBS) were purchased from Fisher Scientific. Non-specific control
RNA (cRNAi) (cat # D-001810-01-20), short interfering RNA against the AHR (AHRi) (J004990-08-0010) and Dharmafect transfection reagent (#1) were purchased from Thermo
Scientific. MCF-7 human breast cancer cells were purchased from ATCC (Manassas) and
maintained in DMEM, 10% FBS, with penicillin (100U/mL) and streptomycin (100 μg/mL) and
.01 μg/mL bovine insulin (Cell Applications, Inc.) Insulin like growth factor 2 (IGF-2) was
purchased from R & D systems and reconstituted in phosphate buffered solution.
5.2.2. Western blot analysis to determine IGF-2 induction of AHR and CCND1
200,000 MCF-7 cells plated in 35 mm plates (50% confluent) were serum starved
overnight in phenol red-free DMEM and then treated with PBS vehicle or IGF-2 (100 ng/mL) for
three hrs. This time point was selected based on our preliminary time course experiments
showing that IGF-2 induction of CCND1 mRNA is maximal at three hr post IGF-2 (data not
shown). Total cellular extract was isolated in 200 μL of 2X sample lysis buffer (Bio-RAD; cat
#161-0737) and approximately 12.5 μg of protein was subjected to SDS PAGE and transferred to
polyvinylidene difluoride (PVDF) membranes (Bio-Rad; Hercules, CA). Membranes were
blocked in PBS, .01% Tween 20 (Bio-Rad; Hercules, CA) (PBS-T), 5% (wt/vol) lowfat
powdered milk for one hr and incubated overnight with primary antibody at 4° C with gentle
mixing. Membranes were rinsed five times (five mins each wash) with PBS-T and then incubated
with an appropriate HRP-labeled secondary antibody (diluted 1:10,000 in PBS, .01% tween-20,
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5% milk) (Thermo Scientific, Pierce) for one hr, followed with rinsing five times (five mins each
wash) in PBS-T. Membranes were developed with enhanced chemiluminescent substrate
(Millipore, Immobilon ECL substrate) and exposure to X-ray film (Midwest Scientific).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was purchased from Millipore
(cat # MAB374), AHR antibody from Santa Cruz (Cat # H-211) and CCND1 antibody from
Millipore (cat # 04-1151). Equal protein loading was confirmed by GAPDH western blots.
Normalized levels of AHR, and CCND1 were expressed as a ratio of AHR/GAPDH and
CCND1/GAPDH. Densitometry was calculated with ImageJ PC-based software (National
Institute of Health).
5.2.3. qPCR analysis to determine IGF-2 induction of AHR, CYP1A1, and CCND1
200,000 MCF-7 cells plated in 35 mm plates were serum starved overnight in phenol redfree DMEM, and then treated with PBS vehicle or IGF-2 (100 ng/mL) for three hrs. Total RNA
was isolated in TRI-Reagent and quantitated by Nanodrop spectrophotometry. RNA was reverse
transcribed to complementary DNA (cDNA) (Verso cDNA kit; Thermo Fisher Scientific; cat #
AB-1453/B). Resulting cDNAs were subjected to quantitative real-time PCR (Q-PCR) using
gene specific primers (300 nM per reaction) and 40 cycles of PCR in accordance with Absolute
Blue SYBR Green Rox Mix (Thermo Fisher Scientific; cat # AB-4162/B) protocols. Relative
gene expression between controls and IGF-2 treated cells was calculated using the formula 2ΔΔCT, as described by Livak and Schmittgen [239]. Glyceraldehyde-3-phosphate (GAPDH)
mRNA levels served as the internal control. Primer sequences for GAPDH, AHR, CCND1 and
CYP1A1 were: GAPDH (forward, 5′-CATGAGAAGTATGACAACAGCCT-3′; reverse, 5′AGTCCTTCCACGATACCAAAGT-3′), AHR (forward, 5′-ACATCACCTACGCCAGTGG-3′;
reverse, 5′-CTCTATGCCGCTTGGAAGGAT-3′), CCND1 (forward, 5′76

CCGCAATGACCCCGCACGAT-3′; reverse, 5′-AGGGCAACGAAGGTCTGCGC-3′) and
CYP1A1 (forward, 5′-CTTCACCCTCATCAGTAATGGTC-3′; reverse, 5′AGGCTGGGTCAGAGGCAAT′-3). The Harvard Primer Bank
http://pga.mgh.harvard.edu/primerbank/was used to design primers. Primer specificity was
verified with melt curve analysis and NIH primer blast search engines
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome.
5.2.4. Chromatin immunoprecipitation
MCF-7 cells (500,000 per 60 mm plate) were serum starved overnight in phenol red-free
DMEM, and then treated with PBS vehicle or IGF-2 (100 ng/mL) for three hr. Formaldehyde
(1%) was then added to medium for ten mins, followed by Glycine (.5M) for five mins. Cells
were rinsed with PBS, collected in PBS, pelleted by centrifugation, and lysed in 300 μL of lysis
buffer (1% SDS; 5 mM EDTA; 50 mM Tris-HCl, pH 8) per 60 mm plate plus protease inhibitors
(Thermo Scientific) for fifteen mins on ice. Cell extracts were sonicated (five times, each time
ten seconds) and diluted 1:10 in dilution buffer (16.7 mM Tris-HCl, pH 8; 167 mM NaCl; 1.2
mM EDTA; 0.01% SDS; 1.1% Triton X-100), rotated overnight at 4C with 1 μg of non-specific
IgG (Santa Cruz; cat # 2027) or anti-AHR antibody (Santa cruz; cat # H-211). Antibodychromatin complexes were collected using 5 μL of magnetic protein A beads (life technologies;
cat # 100.01D) with rotation at 4° C for 90 min. Using magnetic separation (life-technologies;
part # 49-2025), beads were washed sequentially with buffer 1 (20 mM Tris-HCl, pH 8; 150 mM
NaCl; 2.0 mM EDTA; 0.1% SDS), buffer 2 (20 mM Tris-HCl, pH 8; 500 mM NaCl; 2.0 mM
EDTA; 0.1% SDS), buffer 3 (10 mM Tris-HCl (pH 8); 0.25M LiCl; 1mM EDTA; 1% NP-40; 1%
deoxycholate), and then 1X TE buffer for five mins each, and incubated at 65° C for four to six
hrs in elution buffer (1% SDS, 0.1 M NaHCO3) with proteinase K. DNA was purified (Qiagen;
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cat # 28204) and analyzed using real time PCR. Primers spanning AP-1 and TCF/LEF response
elements in the CCND1 promoter and xenobiotic response elements (XREs) in the CYP1A1
promoter were used: AP-1 (forward, 5′-GGCAGAGGGGACTAATATTTCCAGCA-3′; reverse,
5′-GAATGGAAAGCTGAGAAACAGTGATCTCC-3′) [269], TCF/LEF (forward, 5′GCTCCCATTCTCTGCCGG-3′; reverse, 5′-CGGAGCGTGCGGACTCTG-3′) [270] and XRE
(forward, 5′-ACGCAGACCTAGACCCTTTGC-3′, reverse, 5′-CGGGTGCGCGATTGAA-3′)
[271]. ChiP data was expressed as % input, in which signals obtained from the ChIP are divided
by signals obtained from an input sample.
5.2.5. AHR knockdown experiments
MCF-7 cells were reverse transfected using methods we have used previously to
selectively target genes for knockdown [272]. Briefly, 200,000 MCF-7 cells were plated in
phenol red-free DMEM, 5% charcoal treated FBS, 50 nM cRNAi or AHRi, 2 μL of Dharmafect
#1 per well of a six well plate for twelve hr and then new media was applied for twenty four hrs.
Cells were then serum starved overnight in phenol red-free DMEM, followed by treatment with
PBS vehicle or IGF-2 (100 ng/mL) for three hr. Treatments were stopped and cellular protein or
mRNA was isolated for western blot and Q-PCR analysis, respectively, as detailed in sections 2.2
and 2.3.
5.2.6. Cell growth experiments
MCF-7 cells were reverse transfected with 50 nM cRNAi or AHRi as detailed in 2.4 for
36 hr and then serum starved overnight in phenol red-free DMEM. Cells were treated with PBS
vehicle or IGF-2 (100 ng/mL) for three additional days. Cells were collected in trypsin and
manual cell counting using a hemocytometer and trypan blue was used to determine live cell
number.
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5.2.7. Statistics
Two-tailed, paired t tests with confidence intervals of 95% were used to determine
statistically significant differences between two groups (vehicle versus IGF-2 treatment) in
Figure 14. The Newman–Keuls (SNK) post-hoc test was used to determine statistically
significant differences among groups following one-way analysis of variance (ANOVA) in
Figure 15, Figure 16, and Figure 17. Specific P values are indicated in the results sections.
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5.3. RESULTS
5.3.1. IGF-2 increases AHR expression
To investigate whether IGF-2 stimulates AHR expression, overnight serum starved MCF7 cells were treated with vehicle or IGF-2 (100 ng/mL) for three hrs. Western blot analysis
revealed that IGF-2 induced 1.7- and 1.5-fold increases (P < .01) in AHR and CCND1 protein,
respectively, compared with vehicle (Figure 14 (A)). The observed increases in AHR and
CCND1 protein correlated with significant increases (P < .01) in AHR mRNA (1.9-fold) and
CCND1 mRNA (2-fold) in IGF-2 treated cells compared with control cells (Figure 14 (B)). The
levels of CYP1A1 mRNA, which is a TCDD-AHR gene target, were not induced by IGF-2
treatment (Figure 14 (B)). This result suggests that IGF-2 signaling does not induce rapid
increases in the levels of a lipophilic endogenous AHR ligand capable of inducing CYP1A1
expression.
5.3.2. IGF-2 stimulates AHR binding to CYP1A1 and CCND1 gene promoters
To determine if IGF-2 promotes AHR binding to gene promoters, we performed
chromatin immunoprecipitation experiments followed by real-time quantitative PCR (Q-PCR)
(ChIP-qPCR). We first focused on AHR binding XREs in the CYP1A1 promoter [271]. AHRChIP-qPCR experiments revealed that AHR binding to the XREs on the CYP1A1 promoter in
vehicle treated cells was low and not significantly higher than non-specific IgG (Figure 15 (A)).
In contrast, IGF-2 promoted a 5-fold increase (P < .0001) in AHR binding to the XREs on the
CYP1A1 promoter compared to vehicle and this was significantly higher than non-specific IgG
(Figure 15 (A)).
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Figure 14. IGF-2 stimulates AHR. MCF-7 cells were treated with vehicle (Veh) or IGF-2
(100 ng/mL) for 3 h. (A) Total cellular protein was then isolated and subjected to Western blot
analysis. The blot was then probed with the indicated antibodies. Relative level of AHR and
CCND1 protein was expressed as a ratio of AHR/GAPDH and CCND1/GAPDH. Significant
(P < .01) increases in AHR, CCND1 protein by IGF-2 are indicated (*). (B) Quantitative realtime quantitative polymerase chain reaction (Q-PCR) analysis of relative mRNA levels of
CCND1, AHR and CYP1A1, with normalization to GAPDH internal control. The value in
vehicle treated cells was set to 1. Significant (P < .01) increases in AHR and CCND1 mRNA
by IGF-2 are indicated (**). CYP1A1 mRNA was not significantly induced by IGF-2. Data
shown are the means ± S.E. of (A) three and (B) four independent experiments.
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Figure 15. IGF-2 stimulates AHR binding on CYP1A1 and CCND1 gene promoters. MCF7 cells were treated with vehicle (Veh) or IGF-2 (100 ng/mL) for 3 h and chromatin
immunoprecipitation (ChIP) experiments were conducted, followed by Q-PCR. (A) A
significant (P < .0001) increase in AHR binding to the XRE on the CYP1A1 promoter induced
by IGF-2 is indicated (*). (B) A significant (P < .0001) increase in AHR binding to the AP-1 and
TCF/LEF site induced by IGF-2 is indicated as (**). Data shown are the means ± S.E. of three
independent experiments.
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To determine if IGF-2 stimulates the AHR to bind to the promoter of an induced gene, we
examined AHR binding to the AP-1 and TCF/LEF response elements on the CCND1 promoter.
These transcription factor binding sites were selected because AP-1 and TCF/LEF sites promote
CCND1 transcription [265, 267, 268]. The binding of AHR to AP-1 and TCF/LEF sites on the
CCND1 promoter was minimal in vehicle treated cells and not significantly different than nonspecific IgG (Figure 15 (B)). In contrast, the binding of AHR to AP-1 and TCF/LEF response
elements on the CCND1 promoter was substantially increased (approximately seven-fold) by
IGF-2 and this was significantly (P < .0001) greater than non-specific IgG (Figure 15 (B)).
Collectively, these results indicate that IGF-2 promotes AHR binding to CYP1A1 and CCND1
gene promoters.
5.3.3. AHR knockdown inhibits IGF-2 induction of CCND1
Next, experiments were conducted to investigate if IGF-2 induction of CCND1 requires
AHR. Overnight serum starved control and AHR knockdown MCF-7 cells were treated with
vehicle or IGF-2 (100 ng/mL) for three hrs. As shown in Figure 16 (A), AHR protein levels were
lower (P < .0001) in AHR knockdown cells (by ten-fold) than control cells. IGF-2 stimulated (P
< .001) approximately two-fold increases in AHR and CCND1 protein in control cells, which
was completely abrogated in AHR knockdown cells (Figure 16 (A)). Analysis of mRNA revealed
that IGF-2 stimulated a 1.5-fold increase in CCND1 mRNA, which was reduced (P < .01) to 1.3fold in AHR knockdown cells (Figure 16 (B)). These findings indicate that AHR knockdown
cells are less responsive to IGF-2-stimulated increases in CCND1 mRNA and CCND1 protein.
5.3.4. AHR knockdown compromises MCF-7 proliferation
To determine the role of AHR in cell proliferation, MCF-7 control and AHR knockdown
cells were treated with vehicle or IGF-2 (100 ng/mL) for three days. IGF-2 stimulated a 2.3-fold
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Figure 16. IGF-2 induction of CCND1 requires AHR. MCF-7 cells were reverse transfected
(see Section 2 for details) with cRNAi or AHRi prior to treatment with vehicle (Veh) or IGF-2
(100 ng/mL) for 3 h. (A) Total cellular protein was then isolated and subjected to Western blot
analysis. The blot was then probed with the indicated antibodies. Relative level of CCND1 and
AHR protein was expressed as a ratio of AHR/GAPDH and CCND1/GAPDH. A significant (P <
.001) increase in AHR and CCND1 by IGF-2 is indicated by (*). A significant (P < .001)
decrease in AHR and CCND1 by AHRi is indicated by (**). (B) Q-PCR analyses of relative
levels of CCND1 mRNA, expressed normalized to GAPDH. A significant decrease in CCND1
by AHRi is indicated by (P < .01). Data shown are the means ± S.E. of three independent
experiments.
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Figure 17. IGF-2 induction of MCF-7 proliferation requires AHR. (A) MCF-7 cells were
reverse transfected (see Section 2 for details) with cRNAi or AHRi prior to treatment with
vehicle (Veh) or IGF-2 (100 ng/mL). After three days in culture, cells were collected and live cell
number was determined. Cell number (Fold change) was expressed relative to the number of live
cells in the cRNAi plus Veh group, which was arbitrarily assigned a value of 1. (B) Model of
AHR roles in IGF-2 signaling. Dotted lines distinguish our data herein and data from Barhoover
et al. 2010. IGF-2 signaling increases AHR, increases in AHR stimulate increases in CCND1
protein. The increased levels of AHR in IGF-2 treated cells functions as a scaffold that bridges
CCND1 and CDK4, which in turn stimulates the phosphorylation and inhibition of RB1.
Inhibition of RB1 promotes cell cycle and MCF- 7 proliferation

85

increase in the number of live MCF-7 cells, which was reduced (P < .0001) to 1.2-fold by AHR
knockdown (Figure 17 (A)). Reduced proliferation is consistent with observed reductions in
CCND1 levels in AHR knockdown cells compared with control cells (Figure 16 (A)), given that
CCND1 induces cell cycle progression.
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5.4. DISCUSSION
Our data indicates that IGF-2 signaling increases the levels of AHR mRNA and protein
(Figure 14) as well as the binding of AHR to AP-1 and TCF/LEF response elements on the
CCND1 promoter (Figure 15). We propose that the observed increase in AHR binding to the
CCND1 promoter is important for the induction of CCND1 expression. Indeed, we found that
AHR knockdown completely abrogated IGF-2 stimulated increases in CCND1 protein and
significantly inhibited the induction of CCND1 mRNA compared to control cells (Figure 16).
Modeled in Figure 17 (B) are our findings herein and the findings of Barhoover et al
2010. We show that IGF-2 increases AHR, which in turn stimulates increases in CCND1 protein
(Figure 9-11). Based on the results of Barhoover et al 2010 [105], the observed increases in AHR
and CCND1 would bind to CDK4, which would promote the phosphorylation and inhibition of
RB1 to promote cell cycle advance and MCF-7 proliferation (Figure 17 (B)). Our results
showing that AHR knockdown cells are significantly less responsive to the proliferative effects
of IGF-2 (Figure 17 (A)) support a requirement of AHR for the induction of CCND1 and CDK4induced phosphorylation of RB1 in MCF-7 cells [105]. Collectively, our results and the findings
of Barhoover et al 2010 [105], provide two different but complementary mechanisms of action
by which AHR may mediate the proliferative effects of IGF proteins and perhaps other mitogens
that induce CCND1. These new findings suggest that human cancer cells that are highly
responsive to IGF growth factors may require the AHR for maximal proliferation.
Specific transcriptional proteins have been reported to stimulate the expression of AHR.
Nuclear Factor, Erythroid 2-Like 2 (NRF-2) through the activation of an antioxidant response
element (ARE) in the promoter of AHR, induces AHR transcription [273]. Overexpression of
constitutively active β-catenin stimulated increases in AHR mRNA and AHR protein in human
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colon cancer cells [274]. A prior report showed that the application of medium containing 10%
calf serum, platelet-derived growth factor (PDFG) or basic fibroblast growth factor (bFGF) to
overnight serum starved murine 3T3 fibroblasts stimulated increases in the levels of AHR protein
and the activity of a murine AHR promoter reporter construct, which correlated with the onset of
DNA synthesis [275]. Our finding that IGF-2 induced increases in AHR in MCF-7 cells further
links growth factor signaling with endogenous AHR regulation. Our result showing that IGF-2
induction of AHR is important for the induction of CCND1 provides insight as to the mechanism
by which endogenous AHR regulation stimulates proliferation.
In conclusion, we provide evidence that IGF-2 induction of AHR is important for the
induction of CCND1 and MCF-7 proliferation. Barhoover et al 2010 have shown that TCDD
inhibits MCF-7 cell cycle by disrupting interactions between CDK4 and AHR in MCF-7 cells
[105]. We postulate that TCDD and other exogenous AHR ligands may impact cell proliferation
by interfering with AHR-protein interactions on the CCND1 promoter.
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CHAPTER VI: ENDOGENOUS ARYL HYDROCARBON RECEPTOR PROMOTES
BASAL AND INDUCIBLE EXPRESSION OF TUMOR NECROSIS FACTOR TARGET
GENES IN MCF-7 CANCER CELLS.
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ABSTRACT
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that upon
activation by the toxicant 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) stimulates gene
expression and toxicity. AHR is also important for normal mouse physiology and may play a role
in cancer progression in the absence of environmental toxicants. The objective of this report was
to identify AHR-dependent genes (ADGs) whose expression is regulated by AHR in the absence
of toxicants. RNA-Seq analysis revealed that AHR regulated the expression of over 600 genes at
an FDR<10% in MCF-7 breast cancer cells upon knockdown with short interfering RNA.
Pathway analysis revealed that a significant number of ADGs were components of TCDD and
tumor necrosis factor (TNF) pathways. We also demonstrated that siRNA knockdown of AHR
modulated TNF induction of MNSOD and cytotoxicity in MCF-7 cells. Collectively, the major
new findings of this report are: (1) endogenous AHR promotes the expression of xenobiotic
metabolizing enzymes even in the absence of toxicants and drugs, (2) AHR by modulating the
basal expression of a large fraction of TNF target genes may prime them for TNF stimulation and
(3) AHR is required for TNF induction of MNSOD and the cellular response to cytotoxicity in
MCF-7 cells. This latter result provides a potentially new role for AHR in MCF-7 cancer
progression as a mediator of TNF and antioxidant responses.
Keywords: Aryl hydrocarbon receptor (AHR); Gene expression; Breast cancer; Xenobiotics;
Tumor necrosis factor
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6.1. INTRODUCTION
The environmental toxicant TCDD acts through a ligand-activated transcription factor,
the aryl hydrocarbon receptor (AHR), to regulate gene expression and induce toxicity [253]. In
the absence of TCDD, AHR localizes to the cytoplasm and is physically associated with heat
shock protein 90 (HSP90), AHR interacting protein (AIP) and protein p23 in a protein complex
[253]. TCDD stimulates AHR to undergo a conformational change that stimulates its
translocation to the nucleus and dissociation away from HSP90, AIP and p23 [253]. Upon
entering the nucleus, AHR physically interacts with AHR nuclear translocator (ARNT) to
activate canonical TCDD target genes containing dioxin response elements (DREs), including
CYP1A1, CYP1B1, NRF2 and AHR Repressor (AHRR) [253]. Prior pathway analyses have
shown that TCDD regulated gene sets that are associated with metabolism of xenobiotics by
cytochrome P450's, xenobiotic metabolism signaling, and fatty acid and lipid metabolism
pathways; these findings are consistent with induction of phase I and phase II drug metabolizing
enzymes [276, 277].
Several studies have shown that AHR inhibits and stimulates gene expression in the
absence of TCDD [278-281]. For instance, Boutros et al. reported that knockdown of AHR in
liver and kidney of mice disrupted the expression of 417 and 379 genes, respectively [278].
Adenoviral-mediated knockdown of AHR in primary mouse hepatocytes in vitro induced
significant changes in the expression of 97 genes at 12 h and 246 genes at 24 h [279]. Chang et
al. reported that AHR knockdown altered the expression of 1133 genes in mouse embryonic
fibroblasts [280]. Mouse hepatoma cells (Hepa-1) express an AHR that binds DREs, while a
variant line, Hepa-1 C35, harbors a dysfunctional mutant AHR that fails to bind DREs [281].
Consistent with AHR being an endogenous regulator of gene expression, the Hepa-C35
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transcriptome is dramatically disrupted compared to parent Hepa-1 cells [282]. The findings that
AHR knockout mice are less fertile, exhibit higher rates of intestinal cancers, and have
developmental and vascular defects suggests that AHR regulation of gene expression in rodent
models is physiologically important [283-287].
AHR has been reported to play roles in breast tumorigenesis. Knockdown of AHR in
breast cancer cells (BCCs) inhibits mitogen-induced proliferation (MCF-7 cell line),
invasion/migration (MDA-MB-231 cell line) and xenograft tumorigenicity (rodent mammary
fibroblasts) [108, 111, 114, 288]. Further, rat mammary tumors have been shown to express
higher levels of AHR than normal mammary tissue [90]. The mechanism(s) of AHR action in
breast tumorigenesis is not clear. We reasoned that defining AHR-dependent genes (ADGs) in
MCF-7 BCCs would identify pathways downstream of AHR that are important in cancer. To this
end, we performed expression profiling via RNA-Seq on control and AHR knockdown MCF-7
cells in the absence of external stimuli. Pathway analysis of ADGs revealed new roles for AHR.
First, MCF-7 cells maintain expression of xenobiotic metabolizing enzymes in the absence of
toxicants. Second, AHR promotes basal expression of a large fraction of TNF target genes in
MCF-7 cells. Finally, knockdown of AHR inhibited TNF-induced increases in MnSOD and
promoted the cytotoxic response in MCF-7 cells. This latter result provides a potential new role
for AHR in cancer as a mediator of MnSOD induction and the antioxidant cytoprotective
response to TNF.
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6.2. METHODS
6.2.1. Materials and MCF-7 cell culture
Dulbecco's Modified Eagle Medium/High glucose (DMEM) with l-glutamine and sodium
pyruvate, phenol red-free DMEM, phosphate buffered saline (PBS), fetal bovine serum (FBS),
charcoal-treated FBS, penicillin, and streptomycin were purchased from Thermo Fisher
Scientific (Pittsburgh, PA). Sodium dodecyl sulfate (SDS), 30% acrylamide/bis solution,
ammonium persulfate, Tween-20, and 2-mercaptoethanol was obtained from Bio-RAD
(Hercules, CA). Non-specific control RNA (cRNAi) (cat no. D-001810-01-20), short interfering
RNA (siRNA) against AHR (AHR-siRNA, cat no. J-004990-08-0010), RELA (RELA-siRNA,
cat no. J-003533-06-0010) and DharmaFECT 1 Transfection Reagent (no.1) were purchased
from GE Healthcare Life Sciences (Pittsburgh, PA). 2,3,7,8 Tetrachlorodibenzo-p-dioxin
(TCDD) was obtained from Cambridge Isotopes Laboratory (Andover, MA). MCF-7 human
breast cancer cells were purchased from ATCC (Manassas, VA) and maintained in DMEM, 10%
FBS, with penicillin (100 IU/mL) and streptomycin 100 (μg/mL).
6.2.2. AHR knockdown for RNA-Seq
To knockdown AHR for RNA-Seq analysis, 200,000 MCF-7 cells in six-well tissue
culture plates were transfected with 50 nM AHR-siRNA in phenol red-free DMEM, 10%
charcoal-treated FBS and DharmaFECT 1 Transfection Reagent following the manufacturer's
protocols. After 36 h, cells were serum starved overnight in phenol-red free DMEM. Control
cells in 6-well tissue culture plates were transfected with 50 nM control-siRNA using the same
methods used to knockdown AHR.
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6.2.3. Whole transcriptome expression profiling via RNA-Seq
Total RNA was isolated from overnight serum starved control (five replicates) and AHR
knockdown MCF-7 (six replicates) using RNA purification columns (Qiagen, Valencia, CA) with
DNase treatment. DNase was purchased from Qiagen. RNA sample quality was assessed using
Bioanalyzer RNA Nano chips (Agilent); all RNA samples had an RNA Integrity Number greater
than or equal to eight. RNA-Seq libraries were prepared from 1 μg of total RNA using a TruSeq
RNA Prep Kit (Illumina Inc., San Diego, CA).
6.2.4. RNA-Seq analysis
RNA-Seq on AHR knockdown and control MCF-7 cells was performed using an Illumina
HiSeq1000 in a 2 × 100 base paired end design yielding a minimum of 50 million reads per
sample. Demultiplexing of samples was performed using CASAVA 1.8.2 (Illumina). Reads were
aligned to the human reference genome (hg19/GRCh37) using TopHat 2.0.6. [289]. TopHat was
configured to use BowTie 0.12.8 [290] and SAMtools 0.1.18. [291]. Aligned reads were then
mapped to genes from the ensemble database using Bioconductor [292] packages Rsamtools and
biomaRt [293]. Data were then analyzed using the DESeq Bioconductor package [294] as
follows. Counts were normalized to account for differences in sequencing depth between
samples. Samples were clustered using the top 30 expressing genes. One control sample, which
did not cluster with the remaining control samples, was removed from further analysis. In order
to mitigate the loss of statistical power from multiple hypothesis correction, we removed the
lowest 40% of genes by total read count across all samples and performed differential expression
analysis on the remaining 60%. Following standard practice (for example, [294]), genes
statistically significant at a false discovery rate of 10% were reported, irrespective of fold
change. To validate the low-expression filtering step, we repeated the analysis without removing
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the 40% of genes that were low expressers (data not shown). None of the filtered genes were
identified as statistically significant in this analysis, while the loss of statistical power resulted in
126 of the unfiltered genes losing significance. Sequencing data were deposited in the Gene
Expression Omnibus (GEO) database maintained by the National Center for Biotechnology
Information (NCBI) and are accessible with accession number GSE52036s.
6.2.5. Ingenuity pathway analysis (IPA)
Differentially expressed genes (FDR < 10%) were expressed as a ratio of AHR knockdown/control level and loaded into Ingenuity Pathway Analysis software (IPA; Ingenuity
Systems, Redwood City, CA) in order to perform an IPA Core Analysis under default settings. Of
the 634 RNAs, 496 were mapped to known functions and pathways by IPA. In IPA, a biological
function is a process or disease with a pre-defined set of molecules (genes). IPA was used to
compute significant associations between biological functions and our ADG set. Specifically, we
ran a Core Analysis in IPA which used Fisher's Exact Test to assign levels of statistical
significance to associations between biological functions and our gene set. We configured the
core analysis to report Benjamini–Hochberg corrected p-values. We also used the Upstream
Regulator Analysis function to identify candidate regulators of ADG pathways.
6.2.6. Validation of RNA-Seq by qRT-PCR
Real-time reverse-transcription PCR (RT-qPCR) analysis from control and AHR
knockdown MCF-7 cells (five replicates) was carried out to validate RNA-Seq (AHR
knockdown detailed in Section 2.2.). Total RNA was isolated using Qiagen RNA purification
columns and DNase treated. Reverse transcription was performed with 100 ng of total RNA
using Verso cDNA kit (Thermo Fisher Scientific; cat no. AB-1453/B). PCR of cDNA was
conducted with SYBER GREEN and ROX qPCR mix (Qiagen) with a five min denaturing step
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at 95° C, followed by 40 cycles of 15 s at 95° C, 30s at 60° C, 30s at 72° C. Relative gene
expression was calculated using the formula 2ΔΔCT, as described by Livak and Schmittgen
[239]. Glyceraldehyde-3-phosphate (GAPDH) mRNA levels served as the internal control.
Primer sequences GAPDH [forward 5′-catgagaagtatgacaacagcct 3′ and reverse 5′agtccttccacgataccaaagt-3′], OAS1 [forward 5′-cagacgatgagaccgacgat-3′ and reverse 5′cctggagtgtgctgggtcta-3′], PKD1L1 [forward 5′-cgcctctggattgtgataacag-3′ and reverse 5′cggtcccagtagcacacag-3′], PLA2G2 [forward 5′-accagacgtaccgagaggag-3′ and reverse 5′cgctggggattggtgactg-3′], SERPIN5A [forward 5′-atgcccttttcaccgacctg-3′ and reverse 5′tgcagagtccctaaagttggtag-3′], PYDC1 [forward 5′-cacacgtatagctaccggcg-3′ and reverse 5′cgcgtaagacaacagcagtg-3′], HMGCS2 [forward 5′-caatgcctgctacggtggta-3′ and reverse 5′gacggcaatgtctccacaga-3′], SERPIN3A [forward 5′-tgccagcgcactcttcatc and reverse 5′tgtcgttcaggttatagtccctc-3′], CYP1A1 [forward 5′-cttcaccctcatcagtaatggtc-3′ and reverse 5′aggctgggtcagaggcaat-3′], CYP1B1 [forward 5′-ctgcactcgagtctgcacat-3′ and reverse 5′tatcactgacatcttcggcg-3′], NRF2 [forward 5′-tccagtcagaaaccagtggat-3′ and reverse 5′gaatgtctgcgccaaaagctg-3′], PGR [forward 5′-ttatggtgtccttacctgtggg-3′ and reverse 5′gcggattttatcaacgatgcag-3′], MGP [forward 5′-tccgagaacgctctaagcct-3′ and reverse 5′gcaaagtctgtagtcatcacagg-3′], ADORA [forward 5′-ccacagacctacttccacacc-3′ and reverse 5′taccggagagggatcttgacc-3′], CREB3L [forward 5′-cctcccgaagcctcctattct-3′ and reverse 5′ggggttgatttcccagcca-3′], AHR [forward 5′-acatcacctacgccagtgg-3′ and reverse 5′ctctatgccgcttggaaggat-3′], ALOX5 [forward 5′-ctcaagcaacaccgacgtaaa-3′ and reverse 5′ccttgtggcatttggcatcg-3′], ALDH3A1 [forward 5′-tgttctccagcaacgacaagg-3′ and reverse 5′agggcagagagtgcaaggt-3′], RELA [forward 5′- tccagaccaacaacaacccc-3′ and reverse 5′gatcttgagctcggcagtgt] and ABCG2 [forward 5′-acgaacggattaacagggtca-3′ and reverse 5′-
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ctccagacacaccacggat-3′]. The Harvard Primer Bank http://pga.mgh.harvard.edu/primerbank/was
used to design primers above. The primer sequences for the UGTA isoforms have been published
[295]. Primers were purchased from Sigma (St. Louis, MO). Primer specificity was verified with
melt curve analysis and NIH primer blast search engines located at
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome. Two-tailed,
paired t tests with confidence intervals of 95% were used to determine statistically significant
differences between controls and AHR knockdown cells.
6.2.7. Western blot analysis determination of MnSOD
AHR knockdown prior to western blot analysis was carried as detailed in Tomblin and
Salisbury [114]. Briefly, MCF-7 cells (200,000) were mixed directly with siRNA (50 nM control
or AHR-siRNA) and DharmaFECT 1 Transfection reagent (2 μL-per well), added to phenol redfree DMEM, 10% charcoal treated FBS in 6-well tissue culture plates and cultured for twenty
four hrs. Following serum starvation in phenol red-free DMEM for sixteen hrs, cells were treated
with either H2O vehicle or human recombinant TNF (10 ng/mL) (R & D Systems) for twelve hrs.
Treatments were removed, adherent and detached cells were collected and total cellular extract
was isolated in 250 microliter of 2× sample lysis buffer (Bio-RAD; cat no.161-0737) and
approximately 10 microgram of protein was subjected to SDS PAGE and transferred to
polyvinylidene difluoride (PVDF) membranes (Bio-Rad). Membranes were blocked in PBS,
0.01% Tween 20 (PBS-T), 5% (wt/vol) low fat powdered milk for one hr and incubated
overnight with primary antibody at 4° C with gentle mixing. Membranes were rinsed five times
(five min each wash) with PBS-T and then incubated with an appropriate HRP-labeled secondary
antibody (Thermo Fisher Scientific) (diluted 1:10,000 in PBS-T, 5% milk) for one hr, followed
with rinsing five times (five min each wash) in PBS-T. Membranes were developed with
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enhanced chemiluminescent substrate (Millipore Corporation, Billerica, MA) and exposure to Xray film (MidSci, St. Louis, MO). Antibodies were purchased from the following vendors: (1)
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody from Millipore (cat no.
MAB374), (2) AHR antibody from Santa Cruz (Santa Cruz, CA, Cat no. H-211) and (3) MnSOD
antibody from Abcam (Cambridge, MA, cat no.: ab13533). GADPH was diluted 1:10,000, while
AHR and MNSOD were diluted 1:2000 in PBS, 0.01% Tween-20, 5% powdered milk.
Densitometry was calculated with ImageJ PC-based software (National Institute of Health). The
Student–Newman–Keuls (SNK) post-hoc test was used to determine statistically significant
differences among groups following one-way analysis of variance (ANOVA).
6.2.8. qRT-PCR analysis TNF induction of SOD2
MCF-7 cells were reverse transfected in six-well tissue culture plates as detailed in
Section 2.6 and then treated with H2O vehicle or TNF (10 ng/mL) (R&D Systems) for twelve
hrs. Treatments were removed, adherent and detached cells were collected and total RNA was
isolated in TRI-Reagent (Sigma-Aldrich, St. Louis, MO) and quantitated by NanoDrop
spectrophotometry. RNA was reverse transcribed to cDNA (Verso cDNA kit; Thermo Fisher
Scientific; cat no. AB-1453/B). Resulting cDNAs were subjected to qRT-PCR with SYBR Green
Rox Mix (Qiagen) using PCR reaction conditions detailed in Section 2.6. Relative gene
expression among groups was calculated using the formula 2ΔΔCT, as described by Livak and
Schmittgen [239]. Primer sequences for SOD2 mRNA were (forward, 5′GGAAGCCATCAAACGTGACTT-3′; reverse, 5′-CCCGTTCCTTATTGAAACCAAGC-3′). The
SNK post-hoc test was used to determine statistically significant differences among groups
following one-way analysis of variance (ANOVA).
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6.2.9. qRT-PCR analysis of TCDD treated cells
MCF-7 cells plated in 35 mm tissue culture plates (200,000 cells/mL) were serum starved
overnight in phenol red-free DMEM. For TCDD stimulation, either 0.1% (v/v) Dimethyl
sulfoxide (DMSO) (Sigma-Aldrich) or TCDD (10 nM at the final concentration) was added
directly to media along with either H2O vehicle or TNF (10 ng/mL) (R&D Systems) for twelve
hrs. Treatments were stopped and cells were rinsed once with PBS. Total RNA was isolated using
TRI reagent (Sigma-Aldrich) and SOD2 mRNA was measured using real time RT-qPCR
analysis.
6.2.10. Chromatin immunoprecipitation followed by qPCR (ChiP-qPCR)
For ChIP, one 80% confluent 150 mm plate of MCF-7 cells was serum starved in phenol
red-free DMEM and then treated with H2O vehicle or TNF (10 ng/mL) for one h or twelve hrs.
Post treatment, cells were cross-linked with formaldehyde (Sigma-Aldrich) (0.75% v/v) for ten
min at room temp, followed by the application of glycine (0.125 M) (Sigma-Aldrich) for five
min. Cells were rinsed with cold PBS, pelleted by centrifugation, and cell pellets were lysed in 1
mL Lysis Buffer (50 mM Tris–HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
Sodium Deoxycholate, 0.1% SDS plus protease inhibitors (Thermo Scientific no. 78410). After
fifteen min, extracts were sonicated (five times, each time ten s) and diluted 1:10 in dilution
buffer (1% Triton X-100, 2 mM EDTA pH8, 20 mM Tris–HCl pH 8, 150 mM NaCl plus protease
inhibitors), rotated overnight at 4° C with 5 μg of non-specific IgG (Santa Cruz; cat no. sc-2027),
5 μg of anti-AHR antibody (Santa Cruz; cat no. H-211) or 5 μg of anti-p65 NFKB antibody
(Santa Cruz; cat no. sc-372). Antibody-chromatin complexes were collected using ten microliters
of magnetic protein A beads (Invitrogen; cat no. 100.01D) with rotation at 4° C for 90 min.
Using magnetic separation (Life-Technologies; part no. 49-2025), beads were washed three times
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(ten min each wash) with wash buffer (20 mM Tris–HCl, pH 8; 150 mM NaCl; 2.0 mM EDTA;
0.1% SDS) and once with final wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8,
500 mM NaCl) and incubated at 65° C for four to six hrs in elution buffer (1% SDS, 0.1 M
NaHCO3) with proteinase K (20 mg/mL) (Invitrogen Life-Technologies., Carlsbad, CA). DNA
was purified with phenol-chloroform extraction followed by isopropanol precipitation and
analyzed using real time PCR. Phenol, chloroform and isopropanol were purchased from SigmaAldrich. Primers spanning NFκB response elements in intron 2 of SOD2 were: [forward 5′GGAAAAGGCCCCGTGATTT-3′ and reverse 5-TCCTGGTGTCAGATGTTGCC-3′] [296].
ChiP data was expressed as % input, in which signals obtained from the ChIP are divided by
signals obtained from an input sample. Statistical differences among groups were determined by
the SNK post-hoc test following one-way analysis of variance (ANOVA).
6.2.11. Cell viability
MCF-7 cells (200,000/mL) were mixed directly with 50 nM siRNA (either control or
AHR-siRNA) and Dharmafect no. 1 transfection reagent (2 μL/mL), added to phenol red-free
DMEM, 10% charcoal treated FBS and plated into 60 mm tissue culture plates (3 mL per plate)
and cultured for 24 h. Following serum starvation in phenol red-free DMEM for 16 h, cells were
treated with either H2O vehicle or human recombinant TNF (10 ng/mL) (R&D Systems) for 12
h. Cell viability was measured with trypan blue stain (Thermo Fisher Scientific). The percentage
of non-viable cells were calculated as: non-viable cell (%) = (total number of non-viable
cells/total number of cells) multiplied by 100. The SNK post-hoc test was used to determine
statistically significant differences among groups following one-way analysis of variance
(ANOVA).
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6.3. RESULTS
6.3.1. Effect of AHR knockdown on MCF-7 gene expression
Expression profiling on control and AHR knockdown MCF-7 cells was conducted to
identify a set of ADGs in the absence of stimuli. AHR knockdown inhibited the expression of
380 genes and promoted the expression of 254 genes at FDR < 10%, with all reported fold
changes being at least 1.2 fold; we refer to the combined group of 634 genes as the ADG set. A
full list of these genes is included as a supplemental file with NCBI GEO data deposit (accession
number GSE52036). Real-Time qRT-PCR was used to validate RNA-Seq expression in a set of
30 genes. The rational for selecting validation genes listed in Table 8 is that they were among
either the top downregulated (CYP1A1, HMGCS2, OAS1, PLA2G2, ALDH3A1, PKD1L1), the
top upregulated (CREB3L1, PYDC1, MGP, ADORA1, PGR, SERPIN3A, and SERPIN5A)
ADGs or known TCDD gene targets (CYP1A1, CYP1B1, ABCG2, ALDH3A1, NRF2 and UDPglucuronosyltransferases (UGTAs). ALOX5 was selected for validation because it is the rate
limiting gene in leukotriene synthesis [297].
In general, there is a good concordance between the RNA-Seq and qRT-PCR
measurements. Levels of AHR mRNA were lower in knockdown MCF-7 cells than controls as
measured by RNA-Seq (∼four-fold) and qRT-PCR (∼seven-fold) from independent experiments
(Table 8). Expression of known TCDD-target genes (CYP1A1 [298], CYP1B1 [298] and
ALDH3A1 [299]) was lower in AHR knockdown MCF-7 cells by both RNA-Seq and qRT-PCR
measurements (Table 8). Prior reports have shown that TCDD stimulates increased expression of
UGTAs in mouse liver [259]. RNA-Seq and qRT-PCR assays revealed that UGT1A1, UGT1A3,
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Table 8. Fold change expression value from AHR knockdown MCF-7 compared to controls.
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UGT1A4, UGT1A5, UGT1A6, UGT1A7 mRNAs were lower in AHR knockdown cells than
controls (Table 8). UGT1A8, UGT1A9, and UGT1A10 were not differently regulated by qRTPCR, but their levels were lower (∼three-fold) in AHR knockdown cells compared with controls
based on RNA-Seq measurements (Table 8). The drug transporter, ABCG2, has been reported to
be induced by TCDD in human cells (breast, colon and liver), but not in rodent cells [41].
ABCG2 mRNA was ∼three fold lower in AHR knockdown MCF-7 cells than controls in both
RNA-Seq and qRT-PCR data sets (Table 8). NRF2 is a transcription factor that stimulates the
expression of anti-oxidant enzymes [259]. Prior reports have shown that NRF2 is a TCDD gene
target [300, 301]. NRF2 expression was not differentially expressed by RNA-Seq, but its levels
were lower (∼50%) in AHR knockdown cells compared with controls when assayed by qRTPCR (Table 8). The levels of the PLA2G2 and ALOX5 were lower in AHR knockdown MCF-7
cells than controls by RNA-Seq and qRT-PCR (Table 8).
AHR knockdown had modest stimulatory effects on the expression of several genes. As
measured by RNA-Seq, CREB3L was the most upregulated gene (by 2.67290) in AHR
knockdown MCF-7 cells compared with controls (Table 8). The expression of PGR, MGP,
SERPIN3A, CREB3L, SERPIN5A, and ADORA were increased in AHR knockdown cells
compared with controls by RNA-Seq and qRT-PCR (Table 8). Observed expression levels of
IGHG2, IGHA1 and RNF128 were reduced by AHR knockdown by RNA-Seq analysis (GEO
submission GSE52036), but not by qRT-PCR (data not shown). This discrepancy could be
attributed to IGHG2, IGHA1 and RNF128 transcript levels that were below qRT-PCR detection
limits (Ct values higher than 35; data not shown). We note that RNA-Seq fold changes were
greater than qRT-PCR fold changes for several genes including: CYP1A1, HMGCS2, OAS1,
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PLA2G2, ALDH3A1, MGP, CREB3L, UGTAs and ADORA; however the direction of
expression changes were the same (Table 8).
6.3.2. Pathway analysis of AHR-dependent genes
In order to determine functions and pathways regulated by ADGs, we analyzed the ADG
set using the ingenuity pathway analysis (IPA) core analysis tool which finds gene sets that are
over-represented in defined, canonical cellular pathways and molecular functions. Of the 634
genes, 496 were mapped to known functions and pathways by IPA. These ADGs were
significantly associated with cancer-related pathways including: cellular movement, cell cycle,
cellular growth and proliferation, cell death and survival, cellular development and cellular
morphology (Table 9). In addition, significant numbers of ADGs were over-represented in
pathways involved in post-translational modification and in the metabolism of drugs, amino
acids and small molecules (Table 9).
We refined the pathway analysis by applying the IPA Upstream Regulator Analysis tool to
determine if the ADGs are connected through a common upstream regulator. This analysis
revealed that ADGs were enriched among the following IPA canonical regulatory pathways:
beta-estradiol (endogenous hormone), tumor necrosis factor (TNF) (cytokine), tumor protein 53
(TP53) (transcriptional regulator), lipopolysaccharide (chemical drug), decitabine (chemical
drug), calcitriol (chemical ligand), dexamethasone (glucocorticoid receptor), v-erb-b2
erythroblastic leukemia viral oncogene homolog 2 (ERBB2) (kinase), cyclin-dependent kinase
inhibitor 1A (CDKN1A) (kinase), TGF-β (growth factor) and TCDD (toxicant) (Table 10).
Specifically, IPA reveals that 74 of 171 TNF pathway target genes are ADGs (Table 10). Of the
74 ADGs in the TNF pathway, 44 exhibited patterns of expression consistent with inhibition of
TNF activity (Table 10). The finding that IPA revealed 87 of 197 beta-estradiol target genes are
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Table 9. IPA cellular and molecular functions associated with RNA-Seq ADGs.
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ADGs is not surprising, considering that AHR and the estrogen receptor (ER) have been reported
to interact extensively (Table 10) [51, 302]. Finally, ADGs were found to be significantly
enriched within the TCDD pathway (23 of 125 TCDD pathway genes were ADGs) (Table 10).
The IPA-predicted inhibition of TCDD activity (Table 10) was based in part on the observed
inhibition of conical TCDD target genes including: CYP1A1, CYP1B1 and ALDH3A1 in AHR
knockdown cells compared with controls.
6.3.3. Comparison of AHR-dependent gene set with known TCDD and AHR effects
TCDD is a strong exogenous AHR ligand that is resistant to degradation [253]. TCDD
has been reported to regulate the expression of 104 genes in MCF-7 cells [277]. To identify ADG
genes that are induced by TCDD in MCF-7 cells, we overlapped published TCDD microarray
data and AHR knockdown RNA-Seq expression profiles [277]. While the majority of ADGs
(621) did not overlap with reported TCDD-regulated genes, there were 13 genes in both sets
(Figure 18). Common genes included CYP1A1, CYP1B1 and ALDH3A1, which are important in
lipid metabolism, small molecule biochemistry, and drug metabolism (Figure 18).
Lo and Matthews identified TCDD-induced binding sites in MCF-7 cells using ChIP-Seq
technology [277]. Since these should represent AHR binding sites, we compared the TCDDChIP-Seq gene set with ADG set and found that approximately 15% of ADGs have a TCDDAHR binding site. This finding suggests that the remaining 85% could be indirect AHR gene
targets. The 80 specific TCDD-ChIP-Seq genes that overlap with the ADG set are shown in
Figure 19. Common target genes included ABCG2, CYP1A1 and CYP1B1 which are known
TCDD-AHR target genes [41, 277].
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Table 10. IPA upstream regulators associated with RNA-Seq ADGs.
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Figure 18. Genes in common between AHR knockdown RNA-Seq expression profiles and
TCDD-microarray data. Analysis of reported TCDD-microarray data demonstrated that 13 of
634 ADGs were TCDD-regulated genes. The specific 13 ADGs that overlapped with TCDDmicroarray genes in MCF-7 cells are shown in the table.
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Figure 19. Genes in common between AHR knockdown RNA-Seq expression profiles and
TCDD-ChIP-Seq data. Analysis of reported MCF-7 TCDD-ChIP-Seq data revealed that 80 of
the 634 AHR-RNA-Seq genes were TCDD-AHR bound genes. The specific 80 ADGs that
overlapped with TCDD-ChIP-Seq genes in MCF-7 cells are shown in the table.

111

Figure 20. Genes in common between AHR knockdown RNA-Seq expression profiles and
AHR-regulated genes in mouse liver. Analysis of reported AHR gene targets in mouse liver
revealed that 28 of the 634 ADGs were AHR targets in mouse liver. The specific 28 ADGs that
overlapped with AHR-regulated genes in liver are shown in the table.
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Figure 21. Genes in common between AHR knockdown RNA-Seq expression profiles and
AHR-regulated genes in mouse kidney. Analysis of reported AHR gene targets in mouse
kidney revealed that 15 of the 634 ADGs were AHR targets in mouse kidney. The specific 15
ADGs that overlapped with AHR-regulated genes in the kidney are shown in the table.
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Microarray based expression profiles on liver and kidney from AHR null mice has been
reported [278]. Twenty eight genes were shared between the mouse liver gene set and ADG set
(Figure 20). A small number of mouse kidney genes (15) overlapped with ADG set (Figure 21).
The specific ADGs that overlapped with AHR-liver and AHR-kidney are shown in Figure 20 and
Figure 21, respectively. Differences in tissue- and species-specific expression may explain the
limited overlap in these gene sets.
6.3.4. AHR modulates TNF induction of MnSOD and cytotoxicity response
Based on the finding that the ADG set is significantly associated with the TNF pathway,
we sought to determine if TNF induction of SOD2 requires AHR expression. SOD2 is a nuclear
gene that encodes the mitochondrial superoxide dismutase (MnSOD). We focused on MnSOD
regulation because it is inducible [303] and Rico de Souza et al. [304] have reported that
MnSOD levels are lower in AHR knockdown primary mouse lung fibroblasts than control cells
[304]. Serum-starved control and AHR knockdown MCF-7 cells were treated with vehicle or
TNF (10 ng/mL) for 12 h. As expected, AHR protein levels were lower in knockdown cells than
control cells (Figure 22 (A)). While TNF stimulated MnSOD protein levels ∼eight-fold in
control cells, this induction was significantly abrogated in AHR knockdown cells by 60% (Figure
22 (A)). We then asked whether siRNA knockdown of AHR and NF-κB subunit RELA (also
known as p65) inhibited TNF-stimulated induction of MnSOD mRNA expression. The impetus
for including RELA is based on its requirement for TNF induction of the SOD2 gene [305, 306].
RELA mRNA was reduced ∼90% by siRNA treatment (Figure 22 (B)). Knockdown of AHR and
RELA suppressed TNF induction of MnSOD mRNA levels (Figure 22 (B)). We also asked
whether TCDD would modulate TNF regulation of MnSOD. The level of MnSOD induction by
TNF was not affected by TCDD (Figure 22 (B)). Collectively, these data indicate that
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endogenous AHR and RELA promote TNF induction of MnSOD in MCF-7 cells through a
mechanism that is independent of TCDD effects.
TNF-induced RELA stimulates SOD2 expression by binding to NF-kappa-B response
elements (kappa-RE) in intron 2 [305, 306]. Physical interactions between AHR and RELA have
been reported [307]. We therefore tested whether TNF signaling results in recruitment of AHR
and RELA to the SOD2 kappa-RE. ChIP-qPCR experiments revealed that treatment with TNF
(12 h) increased the binding of AHR and RELA on the SOD2 kappa-RE by ∼2.5 fold in each
case (Figure 22 (C)). AHR and RELA association with kappa-RE in vehicle treated cells was not
greater than non-specific IgG (Figure 22 (C)). These results indicate that TNF signaling recruits
AHR and RELA to an active kappa-RE in the SOD2 gene [304, 305].
The finding that AHR modulates TNF induction of MnSOD prompted us to investigate
whether AHR is required in the response to TNF-induced cytotoxicity. To this end, MCF-7 cells
were transiently transfected with non-targeting control or AHR siRNAs prior to treatment with
vehicle or TNF for 12 h, followed by determination of the percentage of non-viable cells. As
shown in Figure 22 (D), TNF-induced cytotoxicity was significantly higher in AHR knockdown
MCF-7 cells compared with controls (Figure 22 (D)). This result suggests that AHR suppresses
TNF-induced cytotoxicity.

115

116

Figure 22. AHR promotes TNF induction of MnSOD. (A) MCF-7 cells were transfected with
control (cRNAi) or AHR (AHRi) siRNAs (please see Section 2 for details regarding transfection)
prior to treatment with vehicle (Veh) or TNF (10 ng/mL) for 12 h. Total cellular protein was then
isolated and subjected to western blot analysis. The blot was then probed with the indicated
antibodies. Relative level of MnSOD protein was expressed as a ratio of MnSOD/GAPDH. A
significant decrease in MnSOD protein by AHRi is indicated by (* P < 0.001). (B) RT-qPCR
analyses of SOD2 and RELA mRNA levels in MCF-7 cells transfected with control (cRNAi), AHR
(AHRi) or RELA (RELAi) siRNAs prior to vehicle (Veh) or TNF (10 ng/mL) treatment for 12 h.
Significant decreases in SOD2 or RELA mRNAs is indicated by ( * P < 0.001). For TCDD
stimulation, MCF-7 cells were stimulated with either dimethyl sulfoxide vehicle (DMSO-veh) or
TCDD (10 nM) in the presence of vehicle or TNF (10 ng/mL) for 12 h, followed by measurement
of SOD2 mRNA with RT-qPCR. No significant difference is indicated by (NS). Gene expression
was normalized against GAPDH. (C) MCF-7 cells were treated with vehicle (Veh) or TNF (10
ng/mL) for 12 h and chromatin immunoprecipitation (ChIP) experiments were conducted,
followed by real-time Q-PCR (ChIP-qPCR). A significant increase in AHR and RELA binding on
an intronic NFKB response element in the SOD2 gene induced by TNF is indicated (* P < 0.03).
(D) MCF-7 cells were transfected with cRNAi or AHRi prior to treatment with vehicle (Veh) or
TNF (10 ng/mL) for 12 h and cell viability was determined as outlined in Section 2. Significant
increases is indicated (* P < 0.05). ((A)–(D)) Data shown are the means -/+ S.E. of at least three
independent experiments.
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6.4. DISCUSSION
In this report, RNA-Seq analysis revealed that the expression of over 600 genes in MCF7 cells is dependent on AHR based on our knockdown experiments. Pathway analysis revealed
that a significant number of ADGs were present in toxicant and TNF pathways (Table 10). TNF
induction of MnSOD required AHR and RELA expression, and this process involved recruitment
of RELA and AHR to a TNF-responsive NF-kappa-B element in the SOD2 gene (Figure 22).
Consistent with AHR/RELA recruitment to MnSOD, the cellular response to TNF was dependent
on AHR expression as demonstrated in knockdown experiments (Figure 22).
There is little current evidence that demonstrates that cancer progression requires the
expression of AHR; however, it is clear that AHR responds to and modulates cancer signals.
From our prior report, we know that insulin like growth factor 2 (IGF-2) signaling rapidly
increases AHR mRNA and protein levels in MCF-7 cells and that upregulated AHR promoted the
activation of the CCND1 gene upon binding to the CCND1 gene promoter [114]. In this report
we demonstrate that AHR modulates MCF-7 responsiveness to TNF. Together these findings
indicate that AHR can modulate MCF-7 cancer progression by interacting with two major cancer
signaling pathways, specifically IGF-2 and TNF.
Even though AHR expression has not been directly associated with cancer, AHR activity
may be aberrant in cancer cells. AHRR is a putative tumor suppressor whose expression is
downregulated in multiple cancers including breast tumors due to hypermethylation of its
promoter [94]. AHRR inhibits AHR activity through a mechanism that could be mediated by
AHRR binding with AHR [308]. Thus, AHR activity could be higher because AHRR expression
is downregulated in human cancers [94].
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There are several lines of evidence that AHR through interactions with RELA regulates
proinflammatory genes; our data suggests this interaction is also important for regulating
MnSOD, a major antioxidant enzyme. DiNatale and colleagues demonstrated that TCDD and
interleukin 1 (IL-1) synergistically induce IL-6 transcription [309]. This was mediated through
DREs in the IL-6 gene promoter [309]. Recently, AHR itself, in the absence of TCDD, has been
reported to activate the IL-6 gene by pairing with RELA at kappa-RE in the IL-6 gene [310].
AHR interaction with NF-kappa-B is not restricted to RELA, considering that AHR binding with
RELB activates the IL-8 gene [311, 312]. TCDD inhibits NF-kappa-B activity when measured
with EMSA and a kappa-B-RE luciferase reporter construct [307]. We found that TNF induction
of MnSOD is refractory to TCDD (Figure 22). So in some cases TCDD interactions with NF-κB
therefore could be gene specific.
AHR-deficient MCF-7 cells were more sensitive to TNF-induced cytotoxicity than
controls (Figure 22 (D)). TNF signaling stimulates opposing cell survival and death pathways
[313]. TNF-induced NF-kappa-B protects cells from TNF-induced cell death by upregulating the
expression of antioxidant and antiapoptotic genes [313]. Upregulation of MnSOD by NF-kappaB inhibits TNF-induced ROS accumulation and cell death [228, 314]. The levels of MnSOD
were lower in AHR knockdown MCF-7 cells in response to TNF compared with controls (Figure
22). Thus, AHR could in part protect MCF-7 cells from TNF-induced cytotoxicity by promoting
upregulation of MnSOD (Figure 22).
Our RNA-Seq data and IPA analyses are consistent with many reports showing that AHR
regulates gene expression in the absence of TCDD. There are potential mechanisms to explain
AHR activity in MCF-7 cells in the absence of TCDD. Chiaro et al. discovered that the 5lipoxygenase (5-LOX) pathway generates 5,6-dihydroxyeicosatetraenoic acid isomers (5,6119

DiHETEs) that induce expression of a DRE-promoter reporter construct, the formation of AHRDNA binding complexes in EMSA assays, and increases in CYP1A1 mRNA in hepatocytes
[315]. DiNatale and colleagues reported that the tryptophan metabolite kynurenic acid induced
CYP1A1 mRNA, DRE-promoter reporter activity and the formation of an AHR-DNA complex,
and competitively displaced labeled AHR ligand from AHR in hepatocytes [95]. Kynurenine has
been reported to be secreted at μM levels from glioma cells and to induce DRE-promoter
reporter activity, CYP1A1 mRNA levels and to competitively displace labeled AHR ligand from
AHR in glioma cells [75]. 5,6-DiHETEs, kynurenic acid and kynurenine therefore may serve as
endogenous AHR ligands that stimulate AHR activity and expression of AHR target genes in
MCF-7 cells in the absence of TCDD. Considering our data showing that TNF-induced AHR
binding at an active NFκB-RE, we postulate that AHR may be recruited to gene promoters by
activated RELA (perhaps in an AHR ligand independent mechanism).
In conclusion, our RNA-Seq data suggest a role for AHR in toxicant and TNF pathways.
Further, AHR and RELA are clearly required for induction of MnSOD and the cytoprotective
response to TNF. In a similar vein, AHR protects lung cells from cigarette induced cytotoxicity
by maintaining MNSOD expression [304]. As a whole, our findings implicate unliganded AHR
expression in a new aspect of cancer progression.
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ABSTRACT
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is regulated
by environmental toxicants that function as AHR agonists such as 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD). L-Type Amino Acid Transporter 1 (LAT1) is a leucine transporter that is
overexpressed in cancer. The regulation of LAT1 by AHR in MCF-7 and MDA-MB-231 breast
cancer cells (BCCs) was investigated in this report. Ingenuity pathway analysis (IPA) revealed a
significant association between TCDD-regulated genes (TRGs) and molecular transport.
Overlapping the TCDD-RNA-Seq dataset obtained in this study with a published TCDD-ChIPseq dataset identified LAT1 as a primary target of AHR-dependent TCDD induction. Short
interfering RNA (siRNA)-directed knockdown of AHR confirmed that TCDD-stimulated
increases in LAT1 mRNA and protein required AHR expression. TCDD-stimulated increases in
LAT1 mRNA were also inhibited by the AHR antagonist CH-223191. Upregulation of LAT1 by
TCDD coincided with increases in leucine uptake by MCF-7 cells in response to TCDD.
Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) assays revealed increases in
AHR, AHR nuclear translocator (ARNT) and p300 binding and histone H3 acetylation at an
AHR binding site in the LAT1 gene in response to TCDD. In MCF-7 and MDA-MB-231 cells,
endogenous levels of LAT1 mRNA and protein were reduced in response to knockdown of AHR
expression. Knockdown experiments demonstrated that proliferation of MCF-7 and MDA-MB231 cells is dependent on both LAT1 and AHR. Collectively, these findings confirm the
dependence of cancer cells on leucine uptake and establish a mechanism for extrinsic and
intrinsic regulation of LAT1 by AHR.
Key Words: Aryl Hydrocarbon Receptor (AHR); L-Type Amino Acid Transporter 1 (LAT1),
TCDD, gene expression; breast cancer
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7.1. INTRODUCTION
Halogenated aromatic hydrocarbons (HAHs) are environmental toxicants that are formed
as byproducts of industry and municipal waste incineration [316, 317]. 2,3,7,8Tetrachlorodibenzo-p-dioxin (TCDD) exhibits the highest affinity for AHR compared with other
HAHs [318]. In the absence of ligand, AHR is associated with chaperone proteins including heat
shock protein 90 (HSP90) [319, 320], Aryl Hydrocarbon Receptor Interacting Protein (also
known as XAP2) [20, 321, 322], and the co-chaperone protein p23 [21]in the cytoplasm. Upon
binding to TCDD, AHR translocates from the cytoplasm into the nucleus and binds AHR nuclear
translocator (ARNT) [36, 253, 323]. TCDD-induced AHR/ARNT dimers confer transcriptional
activity specifically to AHR response elements (AHR-REs) that cluster near the promoter regions
of TCDD target genes [36]. CYP1A1 and CYP1B1 are phase I xenobiotic metabolizing enzymes
that are transcriptionally induced by TCDD via AHR [36]. The induction of CYP1A1 and
CYP1B1 transcription by TCDD also requires several transcriptional coactivators including
steroid receptor coactivator 2 (SRC1), steroid receptor coactivator 2 (SRC2), p300 and BRG-1
[37, 324, 325].
In addition to xenobiotic metabolism, immune responses are modulated by AHR and the
outcome is dependent on the AHR ligand. For instance, T regulatory cells (Tregs) suppress
excessive immune responses and their differentiation is promoted by TCDD or kynurenine
(Kyn), and both of these AHR ligands are immunosuppressive [73, 74]. Th17 cells are
proinflammatory T cells and their expansion and differentiation is enhanced by the endogenous
AHR ligand 6-formylindolo [3,2-b] carbazole (FICZ), but suppressed by TCDD [74, 77].
Developmental and functional immunity is dependent on AHR and the dietary AHR ligands
indolo [3,2-b] carbazole (ICZ) and 3,3-diidolylmethane (DIM) [326, 327]. Finally, cytokine and
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chemokine gene expression in dendritic cells (DC) and macrophages is increased by AHR
ligands, and the transcription of AHR is increased by nuclear factor kappa B in response to
lipopolysaccharide (LPS) in innate immune cells [49, 95, 328].
TCDD-RNA-Seq analysis described herein identified 137 TCDD-regulated genes (TRGs)
in MCF-7 breast cancer cells (BCCs) among which is L-Type Amino Acid Transporter 1 (LAT1).
The uptake of large neutral acids including: leucine, arginine, phenylalanine, tyrosine, and
tryptophan is mediated by LAT1 [230-232]. Breast, colorectal, head and neck, leukemia,
lymphoma, melanoma, prostate and parathyroid cancers express higher levels of LAT1 compared
with corresponding normal tissue [233]. LAT1 promotes proliferation of cancer cells by
stimulating the uptake of amino acids that are important for protein synthesis [233]. In addition,
its ability to promote cellular uptake of leucine would also increase the activity of mTORC1
which has been reported to be important for the growth and survival of some cancers [235].
TCDD has been reported to increase LAT1 mRNA in HEPG2 cells, which are a model of
hepatocellular carcinoma [329]. These observations strongly suggest that LAT1 is critical for
cancer cell growth and survival. However, the mechanism by which TCDD or AHR regulates
LAT1 expression has not been determined.
The objective of this report was to investigate extrinsic regulation of LAT1 by
TCDD/AHR and intrinsic (endogenous) regulation of LAT1 by AHR. Extrinsic regulation of
LAT1 by TCDD/AHR was investigated in MCF-7 cells. Intrinsic regulation of LAT1 by AHR
was investigated in MCF-7 and MDA-MB-231 cells because these BCC lines have been reported
to exhibit endogenous AHR activity [59, 107-109]. Based on our findings, we report a new role
for AHR as an extrinsic and intrinsic regulator of LAT1 expression in BCCs and show that AHR
binds to LAT1 AHR-REs as part of a transcriptional activator complex.
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7.2. METHODS
7.2.1. Materials
Dulbecco’s Modified Eagle Medium/High glucose (DMEM) with l-glutamine and
sodium pyruvate, phenol red-free DMEM, phosphate buffered saline (PBS), fetal bovine serum
(FBS), penicillin, streptomycin, and dimethyl sulfoxide (DMSO) were purchased from Thermo
Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulfate (SDS), 30% acrylamide/bis solution,
ammonium persulfate, Tween-20, 2-mercaptoethanol and polyvinylidene difluoride (PVDF)
membranes were obtained from BIO-RAD (Hercules, CA). Non-targeting short interfering RNA
(siRNA) (cat # D-001810-01-20), ON-TARGET plus human siRNAs against AHR (cat # J004990-08-0010, and cat # J-004990-06-0010) and LAT1 (cat # J-004953-09-0010) were
purchased from GE Dharmacon (Lafayette, CO). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
was obtained from Cambridge Isotopes Laboratory (Andover, MA). The AHR antagonist CH223191 was purchased from Sigma–Aldrich (St. Louis, MO). MCF-7 and MDA-MB-231 BCCs
were purchased from ATCC (Manassas, VA) and maintained in DMEM, 10% FBS, with
penicillin (100 IU/mL) and streptomycin (100 IU/mL).
7.2.2. TCDD RNA-Seq
250,000 MCF-7 cells were seeded in 35 mm plates in DMEM supplemented with 10%
FBS for 24 h, followed by overnight serum-starvation in phenol red-free DMEM, and then
treated with vehicle (DMSO) or 10 nM TCDD for six hr. RNA-Seq analysis was based on four
biological replicates in each experimental group. Total RNA purification kits (Qiagen, Valencia,
CA) were used to extract total RNA. RNA sample quality was assessed using Bioanalyzer RNA
Nano chips (Agilent); all RNA samples had an RNA Integrity Number greater than or equal to
eight. RNA-Seq libraries were prepared from 1 μg of total RNA using a TruSeq RNA Prep Kit
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(Illumina Inc., San Diego, CA). RNA-Seq was performed using an Illumina HiSeq1000 in a 2 ×
100 base paired end design yielding a minimum of 50 million reads per sample. Differentially
expressed genes were identified at a False Discovery Rate (FDR) of 5% as detailed in our prior
report [59]. Raw reads and processed data (unnormalized and normalized read counts by gene)
were deposited in the Gene Expression Omnibus (GEO) at the National Center for
Biotechnology Information and are accessible via accession number GSE76608.
7.2.3. Ingenuity pathway analysis (IPA)
TCDD-regulated genes (TRGs) were expressed as a ratio of TCDD/DMSO and loaded
into IPA software (Ingenuity Systems, Redwood City, CA). Of the 137 TRGs identified by RNASeq, 116 were mapped to known functions and pathways by IPA. The Core Analysis tool and the
Fisher Exact Test in IPA were used to identify statistically significant associations between TRGs
and cellular and molecular pathways. We configured the core analysis to report Benjamini–
Hochberg corrected p-values.
7.2.4. Reverse transcription and real-time polymerase chain reaction (RT-qPCR)
RT-qPCR assays were carried out as described in our prior reports [59, 114]. In brief, total
RNA was extracted using RNA purification columns (Qiagen) and 100–300 ng of extracted RNA
was reverse transcribed to cDNA using High Capacity Reverse Transcription kits (Thermo Fisher
Scientific). Real-time qPCR reactions were performed in triplicate using SYBR Green Master
Mix according to the manufacturer’s instructions (Thermo Fisher Scientific). Relative changes in
gene expression were calculated using the 2−ΔΔCT formula as described by Livak and Schmittgen
[239]. Glyceraldehyde-3-phosphate (GAPDH) mRNA levels served as the internal control. The
sequences of the qPCR primers used to amplify GAPDH and AHR mRNA have been published
[59]. LAT1 mRNA qPCR primers were: forward, 5′-ccgaggagaaggaagaggc-3′; reverse, 5′129

gaagatgcccgagccgataa-3′. The Student–Newman–Keuls (SNK) post hoc test was used to
determine statistically significant differences among groups following one-way analysis of
variance (ANOVA).
7.2.5. Short interfering RNA (siRNA) assays and Western blotting
The siRNA knockdowns were performed as detailed in our prior reports [59, 114].
Briefly, 200,000 cells (MCF-7 or MDA-MB-231) in 1 mL of DMEM supplemented with 10%
FBS were mixed directly with 100 nM of siRNA that was non-targeting, AHR-targeting or
LAT1-targeting and 3 μL of Lipofectamine RNAiMAX transfection reagent (Thermo Fisher
Scientific) and immediately plated in 35 mm tissue culture plates for 48 h. MCF-7 cells were
then treated with vehicle (DMSO) or 10 nM TCDD for 16 h. Treatments were removed and cells
were rinsed once with PBS. For Western blotting, total protein was extracted by scraping cells in
2× Laemmli Sample Buffer containing β-mercaptoethanol (BME). Laemmli sample buffer and
BME were purchased from BIO-RAD. Standard Western blotting techniques were used to
analyze ∼10 μg of protein per sample (please refer to our prior reports for technical details [59,
114]). Western blot analysis of GAPDH was used to confirm equal protein loading. Blots were
probed with anti-GAPDH antibody (diluted 1:10,000), anti-AHR antibody (diluted 1:5,000) or
anti-LAT1 antibody (diluted 1:2,000) overnight at 4° C, followed by incubation with anti-HRP
secondary antibody (1:5000) for one hr at room temperature. The blots were then rinsed with
PBS + 0.1% tween 20, and then developed with enhanced chemiluminescent substrate Millipore
Corp., (Billerica, MA). The anti-GAPDH antibody was purchased from Millipore (Cat
#MAB374). The anti-AHR antibody was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, Cat #H-211) and the anti-LAT1 antibody was purchased from Cell Signaling Technology
(Danvers, MA, Cat #5347). Densitometry was calculated with ImageJ PC-based software
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(National Institute of Health). The Student–Newman–Keuls (SNK) post hoc test was used to
determine statistically significant differences among groups following one-way analysis of
variance (ANOVA).
7.2.6. Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR)
The ChIP-qPCR assays were carried out as described in our previous report [114]. In
brief, nonspecific IgG, and antibodies that were specific for AHR, ARNT or p300 were obtained
from Santa Cruz Biotechnology. The antibodies against acetylated lysine 9 or lysine 14 in histone
H3 were purchased from Cell Signaling Technology. The magnetic protein A beads and
proteinase K were purchased from Life Technologies (Carlsbad, CA). A recent TCDD-ChIP-Seq
report identified an AHR binding site within a 900 bp region in LAT1 corresponding to
coordinates 87,840,300–87,841,199 (human genome version 19 (Hg19)) [277]. This AHR
binding site was investigated in this report by ChIP-qPCR with primers that span coordinates
87,840,403–87,840,544, which were: [forward 5′-GCACGTACCTGTAGGGGTTG-3′ and
reverse 5′-ATGCTCTCTCCCCGGTGATT-3′]. The ChIP-qPCR primers used to amplify the
AHR binding sites in the CYP1B1 gene have been published [330]. ChIP-qPCR data were
expressed as % input in which signals obtained from the ChIP are divided by signals obtained
from an input sample. Statistical differences among groups were determined by the SNK post
hoc test following one-way analysis of variance (ANOVA).
7.2.7. Leucine uptake experiments
Leucine uptake experiments were performed in MCF-7 cells grown to confluence on 24
well plates. The cells were first washed twice with Na-free buffer (130 mM TMACl, 4.7 mM
KCl, 1 mM MgSO4, 1.25 mM CaCl2, 20 mM HEPES; pH 7.4) and incubated with the same for
ten min at room temperature. The uptake was then initiated by incubating the cells for 30 s with
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Na-HEPES buffer (130 mM NaCl, 4.7 mM KCl, 1 mM MgSO4, 1.25 mM CaCl2, 20 mM
HEPES; pH 7.4) with 10 μCi of 3H-l-Leucine (PerkinElmer; Waltham, MA) and 10 μM lLeucine (Sigma–Aldrich). The reaction was stopped with ice cold Na-HEPES buffer after which
the cells were washed twice with the same ice-cold buffer. The cells were then lysed in 500 μl of
1 N NaOH followed by incubation for 20 min at 70° C. The lysed contents of each well was
collected in a 7 ml scintillation tube and mixed with 5 ml Ecoscint A (National Diagnostics;
Atlanta, GA). Leucine uptake experiments were conducted using chemicals obtained from
Sigma–Aldrich. The vials were kept in the dark for 48 hr and the radioactivity was determined in
a Beckman 6500 scintillation counter.
7.2.8. MDA-MB-231 and MCF-7 proliferation experiments
20,000 MDA-MB-231 or 10,000 MCF-7 cells in 1 mL of DMEM + 10% FBS were mixed
directly with siRNA’s (100 nM) that were non-targeting, AHR-targeting or LAT1-targeting and 3
μL of RNAiMax Transfection Reagent. The cells were then plated into 96 well plates at a density
of 2000 MDA-MB-231 or 1000 MCF-7 cells per well. After three days, cell proliferation was
assayed with the Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) in
accordance with the manufacturer’s protocol.
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7.3. RESULTS
7.3.1. TCDD RNA-Seq
RNA-Seq analysis revealed that TCDD-regulated the expression of 137 genes in MCF-7
BCCs at an FDR <5%, with all fold changes greater than or equal to 1.3 compared with vehicle.
Of these 137 TCDD-regulated genes (TRGs), 116 were mapped to known functions by IPA.
Comparison of TRGs with a published TCDD/AHR-ChIP-Seq dataset [277] revealed that 47
genes were shared between the two gene sets (Figure 23). These 47 genes included known
TCDD target genes such as CYP1A1 [331], CYP1B1 [331] and ALDH3A1 [299] (Figure 23).
Bioinformatic analysis revealed that the 47 TCDD target genes were significantly associated
with metabolic pathways including: lipid metabolism, carbohydrate metabolism, nucleic acid
metabolism, vitamin and mineral metabolism and energy production (Table 11). The 47 TCDD
target genes were also associated with cancer processes including: cell death and survival, cell
cycle, cellular growth and proliferation, and molecular transport (Table 11).
7.3.2. TCDD/AHR regulation of LAT1 and leucine uptake
The TCDD-RNA-Seq indicated that LAT1 (also known as SLC7A5) was induced 2.33fold by TCDD (Table 11), while TCDD-ChIP-Seq evidence suggested that AHR could directly
bind to intron 2 of the LAT1 gene [277]. We decided to further investigate extrinsic regulation of
LAT1 by TCDD, considering that prior reports indicate that upregulation of LAT1 could be
important for breast cancer progression [117, 332, 333]. To investigate whether TCDD increases
LAT1 expression through AHR, MCF-7 cells were transfected with short interfering RNA
against AHR (AHRi). Control MCF-7 cells were transfected with non-targeting siRNA (cRNAi).
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Figure 23. Genes common between TCDD RNA-Seq data and TCDD-ChIP-Seq data.
Analysis of reported MCF-7 TCDD-ChIP-Seq data revealed that 47 of the 116 TCDD-RNA-Seq
genes were TCDD-AHR/ARNT bound genes. The specific 47 TCDD-regulated genes and their
associated fold changes are shown in the table.
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Table 11. IPA cellular and molecular functions associated with the 47 TRGs that overlap with
reported TCDD-AHR/ARNT ChIP-seq.
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SiRNA-treated cells were then exposed to either vehicle or TCDD (10 nM) for six hr. Reductions
in AHR mRNA were confirmed in MCF-7 cells transfected with AHRi compared with those
transfected with cRNAi (Figure 24 (A)). As expected, TCDD-stimulated increases (three-fold) in
LAT1 mRNA compared with vehicle in MCF-7 cells transfected with cRNAi (Figure 24 (B)). In
contrast, AHRi significantly reduced the stimulatory effect of TCDD on LAT1 expression (P <
0.01; Figure 24 (B)). These results indicate that LAT1 regulation by TCDD is mediated by AHR.
To investigate whether TCDD increases LAT1 expression by binding to AHR, MCF-7
cells were treated with CH-221391, which is an AHR antagonist that specifically inhibits the
binding of TCDD to AHR [334]. TCDD induction of CYP1A1 transcription is a commonly used
readout of TCDD-induced AHR activity that requires TCDD to bind AHR. To verify that CH221391 is an AHR antagonist in MCF-7 cells, its ability to suppress induction of CYP1A1 by
TCDD was measured by RT-qPCR. The findings revealed that TCDD-induced increases in
CYP1A1 were indeed reduced by CH-221391, indicating that it is an effective AHR antagonist
in MCF-7 cells (Figure 24 (C)). As expected, TCDD-stimulated increases (∼three-fold) in LAT1
mRNA in control MCF-7 cells not treated with CH-221391 (Figure 24 (D)). In contrast, CH221391 significantly (P < 0.01) suppressed the stimulatory effect of TCDD on LAT1 expression
(Figure 24 (D)). These results indicate that regulation of LAT1 by TCDD requires TCDD to bind
AHR.
Western blot experiments were conducted to confirm that TCDD induction of LAT1
mRNA leads to increases in LAT1 protein. Exposure to TCDD stimulated robust increases (∼tenfold) in LAT1 protein in MCF-7 cells transfected with cRNAi (Figure 25 (A) and (B)). Induction
of LAT1 protein by TCDD was completely suppressed in MCF-7 cells transfected with AHRi
(Figure 25 (A) and (B)). As expected, AHR protein levels in MCF-7 cells transfected with AHRi
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Figure 24. AHR mediates TCDD-stimulated increases in LAT1 mRNA. (A and B) MCF-7
cells were transfected with siRNAs that were either non-targeting (cRNAi) or AHR targeting
(AHRi) and then treated with DMSO vehicle (Veh) or TCDD (10 nM) for 6 h. (C and D) MCF-7
cells were treated vehicle or TCDD (10 nM) in the absence (controls) or presence of CH-223191
(10 µM) for 6 h. (A–D) AHR, LAT1, CYP1A1 or GAPDH mRNA were quantified by qRT-PCR
from total RNA. GAPDH mRNA levels were used to normalize samples. * P < 0.05; **P > 0.01.
Data shown are the mean ± S.E. of three independent experiments.
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Figure 25. AHR mediates TCDD-stimulated increases in LAT1 protein. (A–C) MCF-7 cells
were transfected with siRNAs that were either non-targeting (cRNAi) or AHR targeting (AHRi)
and then treated with vehicle (Veh) or TCDD (10 nM) for 16 h. Total cellular protein was then
isolated and subjected to Western blot analysis. The blot was then probed with the indicated
antibodies. Relative levels of AHR or LAT1 protein were expressed as a ratio to GAPDH loading
control. * P < 0.05; **P > 0.01. Data shown are the mean ± S.E. of three independent
experiments.
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were lower than those transfected with cRNAi (Figure 25 (A) and (C)). Leucine uptake
experiments were performed to investigate if the induction of LAT1 protein by TCDD coincided
with increases in leucine uptake by MCF-7 cells. Significant increases in leucine uptake by cells
was observed in response to TCDD exposure compared with vehicle-treated cells (Figure 26).
Taken together, these results indicate that the induction of LAT1 protein by TCDD leads to a
functional increase in leucine uptake by MCF-7 cells.
7.3.3. TCDD-induced AHR/ARNT/p300 recruitment to an AHR binding site in the LAT1
gene
A prior report by Lo and Matthews (2012) identified an AHR binding site in intron 2 of
the LAT1 gene by TCDD-ChIP-seq analysis in MCF-7 cells [277]. In order to characterize the
mechanism of LAT1 induction, we measured AHR recruitment to the AHR response elements
(AHR-REs) in LAT1 intron 2 by ChIP-qPCR analysis. The results showed a significant (P <
0.05) 4-fold increase in AHR binding to the intron 2 site in response to TCDD compared with
vehicle (Figure 27 (A)). In accordance with its known mechanism of action, TCDD-increased
(by 37-fold) AHR binding to AHR-REs that are located upstream from the CYP1B1 transcription
start site (Figure 27 (D)).
By binding to AHR, the ARNT transcription factor promotes AHR recruitment to AHRREs in TCDD target genes [36, 253]. We assessed ARNT binding to the LAT1 intron 2 and
CYP1B1 using ChIP-qPCR analysis and the findings revealed its recruitment to AHR-REs in the
LAT1 and CYP1B1 genes was increased by 12- and 55-fold, respectively in response to TCDD
(Figure 27 (B) and (E)). Prior reports indicate that AHR/ARNT heterodimers recruit the p300
transcription complex to TCDD target genes [37]. The AHR-REs in LAT1 and CYP1B1 genes
exhibited three-fold and ten-fold increases, respectively, in p300 binding in response to TCDD
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Figure 26. TCDD increases leucine uptake. MCF-7 cells were treated with vehicle or 10 nM
TCDD for 6 h, followed by analysis of leucine uptake as detailed in the material and methods. *
P < 0.05. Data shown are the mean ± S.E. of three independent experiments
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Figure 27. TCDD-stimulated
AHR/ARNT/p300 recruitment and histone
H3 acetylation at an AHR binding site in the
LAT1 gene. (A–E) MCF-7 cells were treated
with DMSO or 10 nM TCDD for 45 min. Cells
were then subjected to ChIP with non-specific
IgG (IgG), or AHR, ARNT, p300, acetylated
histone H3 (lysine 9 or 14) targeting
antibodies, followed by qPCR amplification of
the AHR binding site in the LAT1 (A–C) or
CYP1B1 (D and E) genes. Significant
increases in AHR, ARNT, or p300 binding to
AHR binding sites in the LAT1 (A–C) or
CYP1B1 (D and E) gene by TCDD are
indicated by * P < 0.05, or **P < 0.01. (C)
Significant increases in the acetylation of
lysine 9 or 14 in histone H3 at the AHR binding site in the LAT1 gene by TCDD are indicated by
#P < 0.05. Data shown are the mean ± S.E. of three independent experiments.
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compared with vehicle (Figure 27 (B) and (E)).
The p300 complex has inherent histone acetylase activity and is known to increase in
histone H3 acetylation at lysine 9 and lysine 14, both of which are markers of active transcription
[335]. Consistent with its physical recruitment to the LAT1 AHR-RE, we observed increases in
the acetylation of histone H3 at lysine 9 and lysine 14 (by 2.4 and 1.8-fold, respectively) at the
AHR-RE in response to TCDD (Figure 27 (C)). Collectively, these data indicate that extrinsic
regulation of LAT1 by TCDD is mediated via the AHR binding and recruitment of p300 to the
AHR-RE in the LAT1 gene.
7.3.4. Endogenous regulation of LAT1 by AHR promotes MCF-7 and MDA-MB-231
proliferation
Intrinsic regulation of LAT1 by AHR was investigated in MCF-7 and MDA-MB-231
cells because these BCC lines have been reported to exhibit endogenous AHR activity [59, 107109]. Western blot analysis revealed basal AHR and LAT1 protein expression in MCF-7 (Figure
28 (A)) and MDA-MB-231 (Figure 28 (C)) cells transfected with cRNAi. Transfection with
AHRi reduced AHR protein in MCF-7 (Figure 28 (A)) and MDA-MB-231 cells (Figure 28 (C))
to levels that were not detected by standard Western blot analysis. Reducing AHR protein
expression with AHRi also suppressed the levels of LAT1 protein in MCF-7 (by ∼70%) (Figure
28 (A)) and MDA-MB-231 (by ∼60%) (Figure 28 (C)) and the levels of LAT1 mRNA in MCF-7
(by ∼50%) (Figure 28 (B)) or MDA-MB-231 (by ∼40%) (Figure 28 (D)) compared with
controls. These data indicate that endogenous AHR activity regulates LAT1 expression in MCF-7
and MDA-MB-231 cells.
Since LAT1 is known to promote cancer cell proliferation by stimulating the amino acid
uptake [233], we sought to determine if AHR expression and its regulation of LAT1 in MCF-7
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Figure 28. Endogenous regulation of LAT1 by AHR in MCF-7 and MDA-MB-231 cells. (A–
D), MCF-7 (A and B) or MDA-MB-231 (C and D) cells were transfected with control (cRNAi)
or AHR (AHRi) siRNA for 72 or 48 h, respectively. (A and C) Total cellular protein was then
isolated and subjected to Western blot analysis. Blots were then probed with the indicated
antibodies. Relative levels of AHR or LAT1 protein was expressed as a ratio of AHR/GAPDH or
LAT1/GAPDH, respectively. * P < 0.05; **P > 0.01. (B and D) RTqPCR analyses of LAT1
mRNA levels in MCF-7 (B) or MDA-MB-231 (D) cells transfected with cRNAi or AHRi.
GAPDH mRNA levels were used to normalize samples. * P < 0.05. (A–D) Data shown are the
mean ± S.E. of three independent experiments.
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Figure 29. AHR and LAT1 promote MCF-7 and MDA-MB-231 proliferation. (A and B),
MCF-7 (A) or MDA-MB-231 (B) cells were transfected with cRNAi, LAT1i or AHRi for 3 days,
followed by analysis of proliferation (please see methods for details). Significant decreases in
proliferation by LAT1i or AHRi are indicated by * P < 0.05, or **P < 0.01. Data shown are the
mean ± S.E. of nine replicates.
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and MDA-MB-231 are important for proliferation. To this end, MCF-7 and MDA-MD-231 cells
were transfected with cRNAi, AHRi or LAT1-targeting siRNA (LAT1i). After three days,
significant reductions in proliferation was observed in MCF-7 (Figure 29 (A)) and MDA-MB231 (Figure 29 (B)) cells expressing LAT1i or AHRi compared with those transfected with
cRNAi. These findings suggest that AHR regulation of LAT1 and LAT1 expression are important
for the proliferation of MCF-7 and MDA-MB-231 cells.
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7.4. DISCUSSION
The findings of this report provide new insight into extrinsic and intrinsic regulation of
LAT1 by AHR. Reducing AHR with AHRi suppressed extrinsic regulation of LAT1 by TCDD in
MCF-7 cells (Figures 24 and 25) and intrinsic regulation of LAT1 in MCF-7 and MDA-MB-231
cells (Figure 28). These findings indicate that AHR regulates LAT1 expression. ChIP-qPCR
results indicate that extrinsic regulation of LAT1 by TCDD is mediated via the AHR binding site
in the LAT1 gene (Figure 27). Indeed, the binding of AHR/ARNT/p300 and the acetylation of
histone H3 at the AHR site in the LAT1 gene was increased by TCDD (Figure 27). Consistent
with reports showing that AHR promotes MCF-7 and MDA-MB-231 cancer processes [109,
114], our proliferation assays indicate that reducing AHR suppressed their proliferation (Figure
29).
Prior reports have provided important insights into amino acid uptake by other
transporters in MCF-7 and MDA-MB-231 cells. Karunakaran et al. demonstrated that SLC6A14
(also known as ATBo+) is a Na+ dependent, estrogen-induced transporter that mediates the
uptake of all essential amino acids, including leucine, in MCF-7 cells [336]. The SLC6A14
inhibitor α-methyl-dl-tryptophan stimulated apoptosis of MCF-7, but not MDA-MB-231 cells,
which was attributed to selective expression of SLC6A14 in MCF-7, but not MDA-MB-231 cells
[336]. Shennan et al. established that MCF-7, but not MDA-MB-231 cells express LAT2, which
is an isoform of LAT1 that also mediates leucine uptake [337]. Our observation that MCF-7 cells
exhibit high basal leucine uptake activity in the absence of TCDD can be explained by the
transporter activity of SLC6A14 and LAT2 as well as basal LAT1 activity (Figure 26). Since
TCDD induction of SLC6A14 and LAT2 mRNA was not observed in our RNA-Seq data, we

146

conclude that the increase in leucine uptake in the presence of TCDD in MCF-7 cells is mediated
via increased expression of LAT1.
CYP1A1 and CYP1B1 harbor upstream AHR-REs within 1 kb of their transcription start
sites [330, 338, 339]. Reported TCDD-ChIP-seq data indicated that the LAT1 gene lacks
promoter AHR-REs [277], but its expression is regulated by an AHR binding site located in
intron 2 (Figure 27), which is 29 kb from the LAT1 promoter. Although long distance regulation
of gene promoters by AHR-REs is relatively novel for TCDD, it is not uncommon for gene
promoters to be regulated by distal enhancers [340].
AHR stimulation of transcription may rely on endogenous ligands. D’Amato et al.
demonstrated that MDA-MB-231 cells synthesize kynurenine, which is a tryptophan metabolite
and a known endogenous AHR ligand [109]. Production of kynurenine by MDA-MB-231 cells is
mediated by tryptophan 2,3-dioxygenase (TDO2), which is the first and rate-limiting enzyme in
the kynurenine synthesis pathway [109]. Thus, the observed AHR activity that is required for
LAT1 expression in MDA-MB-231 cells could be attributed to kynurenine interacting with AHR.
However, endogenous AHR activity could also reflect its interaction with the other tryptophan
metabolites that also function as AHR agonists such as kynurenic acid or xanthurenic acid [95].
Regulation of LAT1 by unliganded AHR is also a possibility, considering that AHR can be
regulated by cyclic AMP [341, 342].
Previous reports have provided important evidence that breast cancer progression may
require LAT1. For instance, LAT1 expression is upregulated in human breast tumors compared
with normal breast tissue [332]. Shennan et al. demonstrated that 2-aminobicyclo-(2,2,1)heptane-2-carboxylic acid (BCH), which inhibits L type transporters, suppressed the proliferation
of MCF-7, MDA-MB-231 and ZR-75-1 BCCs [117]. Our findings now establish that specifically
147

knocking down the expression of LAT1 with siRNA inhibits proliferation of MCF-7 and MDAMB-231 cells (Figure 29).
In addition to breast cancer cells, normal cells that require high levels of amino acid
uptake for their proliferation and differentiation have been reported to express LAT1 and AHR.
In this regard, leucine uptake by activated T cells is mediated through LAT1 and LAT1 null T
cells exhibit defects in proliferation and effector activity [343-345]. As noted in the introduction,
AHR promotes the differentiation of Tregs and Th17 cells in response to TCDD or FICZ,
respectively [73, 74, 77]. Given these prior reports, it is possible that in addition to
carcinogenesis, the induction of LAT1 by AHR may promote the proliferation and differentiation
of Tregs or Th17 cells depending on which AHR ligand is present.
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CHAPTER VIII: DISCUSSION AND FUTURE DIRECTIONS
8.1. DISCUSSION.
At the end of my research project, I still find AHR signaling to be as fascinating now as it
was to me when I first began studying it four years ago. This is due in part to the vastness of
AHR biology, which seems to reveal itself slowly and veer into new directions with each decade.
In toxicology, AHR is without a doubt the most highly studied receptor, given the breadth of
compounds which work through AHR to exert their effects. While the AHR has been extensively
studied in response to environmental pollutants/toxicants, there is still much to be learned about
endogenous AHR cellular signaling. To date, over 400 exogenous ligands for the AHR have been
found [346]. AHR is an evolutionarily conserved protein [347], and over the past decade great
strides have been made in understanding endogenous AHR function as well as the
characterization of endogenous AHR ligands [44, 59, 75, 95, 107-109]. While AHR research has
shifted from toxicology-based to a more cancer-based emphasis, it is clear there is still much to
learn regarding AHR functioning in both normal and cancerous tissues.
The objectives for our research were simple, yet with a broad spectrum: to reveal new
tumor promoting roles for the AHR in breast cancer. We have done that, and continue to
approach this objective from many new angles, as I will detail in the next sections. First, we
revealed that adipokine-induced increases in MCF-7 BCC proliferation required AHR,
considering that its knockdown suppressed MCF-7 proliferation in response to adipo-CM or
IGF-2 compared with controls (Figure 16). In addition to characterizing new roles for AHR, our
work also identified that IGF-2 is an important adipocyte-secreted factor that promotes MCF-7
and T-47D proliferation. Our finding that IGF-2-mediated cancer effects are mediated in part
through AHR suggests that combining AHR antagonists with IGF1-R blocking antibodies [348]
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may increase the efficiency of IGF1-R blocking antibody therapy in women with breast cancer.
This combination could be particularly effective in obese women with breast cancer, considering
that many obese women have hyperinsulinemia and the fact that adipose tissue secretes IGF-1
and IGF-2 [111-113]. Measuring gene expression with cancer profiling gene arrays revealed that
TCDD, which potentially suppresses endogenous AHR signaling by downregulating AHR
protein, induced decreases in the expression of CCND1 in IGF-2-treated MCF-7 BCCs (Table
7). This novel result opened up a new line of study, investigating whether IGF-2 upregulation of
CCND1 required endogenous AHR. We addressed this question in my second publication as
detailed in the next paragraph.
In our next study, we extended upon our first report showing that AHR responds to and
mediates the effects of adipokines/IGF-2 and asked whether the adipokine/IGF target CCND1
was in fact a primary AHR gene target. We discovered that IGF-2 signaling increased both AHR
mRNA and AHR protein levels, as well as the recruitment of AHR to AP-1 and TCF response
elements within the CCND1 promoter (Figures 14 and 15). This recruitment was undoubtedly
very important, as silencing AHR with AHR-targeting siRNA significantly blunted IGF-2stimulated increases in CCND1 mRNA and protein when compared to control cells (Figure 16).
Based on the findings from Barhoover et al. [105], we hypothesized that increases in AHR would
promote its interaction with the CCND1 and CDK4 complex, and that AHR/CCND1/CDK4
complexes would in turn suppress Rb activity by phosphorylating Rb, which would promote cell
cycle advancement (Figure 17 (B)). The observation that AHR-null cells are less responsive to
the proliferative effects of IGF-2 supports the requirement of AHR for the proper
phosphorylation of Rb in BCCs (Figure 17 (A)) [105]. Our findings in this study complemented
those found by Barhoover et al [105], leading to two unique but ultimately linked mechanisms by
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which endogenous AHR functions to promote cell cycle progression in response to growth
factors like IGF-2.
Considering our finding that reducing AHR decreased the expression of CCND1 (Figure
16), we hypothesized that AHR regulates endogenous gene expression in MCF-7 BCCs. To
address this hypothesis, we performed RNA-seq analysis to establish genome-wide changes in
gene expression in response to AHR knockdown in MCF-7 BCCs. RNA-seq revealed that AHR
knockdown altered the expression of over 600 genes in MCF-7 cells. Ingenuity Pathway
Analysis revealed that AHR-regulated genes were significantly associated with toxicant and
tumor necrosis factor (TNF) pathways (Table 10). We then treated MCF-7 BCCs with TNF and
established that TNF-stimulated increases in MnSOD mRNA and protein required AHR and
RELA, and that this coincided with AHR and RELA recruitment to a transcriptionally active NFκB response element in the SOD2 gene (Figure 22). AHR-null cells were more sensitive to TNFinduced cytotoxicity than controls (Figure 22 (D)). Considering that MnSOD protects cancer
cells from TNF-induced cell death by reducing ROS production [228, 314], we hypothesize that
the reduced levels of MnSOD in AHR-null MCF-7 BCCs increases ROS levels in response to
TNF, causing cell death. Our finding extends prior reports showing that AHR and NF-KB
interact to modulate signaling induced by cytokines. For instance, IL-1 has been shown to
promote the binding of AHR and RELA to the IL-6 gene promoter [309], and this stimulates the
expression of IL-6 [309]. AHR also interacts with RELB to regulate IL-8 expression [311, 312].
Collectively, our work established that IGF-2 and TNF, which are major cancer pathways,
regulate gene expression through AHR in MCF-7 BCCs.
To further characterize AHR regulation of gene expression, we conducted RNA-seq to
identify TCDD/AHR regulated genes in MCF-7 BCCs. To this end, MCF-7 BCCs were treated
151

with either DMSO vehicle or 10 nM TCDD for six hr. We identified that TCDD regulated the
expression of 118 genes (Figure 23). TCDD-regulated mRNAs were overlapped with a reported
TCDD-ChIP-seq dataset to identify primary TCDD/AHR gene targets [277]. This analysis
identified that SLC7A5 was a primary TCDD/AHR target gene. Considering that SLC7A5 is
reportedly overexpressed in breast cancer compared with normal tissue [233], we investigated its
regulation by TCDD/AHR in further detail. ChIP analysis revealed that TCDD induced
recruitment of a transcriptional complex to intron 2 of the LAT1 gene and that this complex
consisted of AHR, ARNT, and p300, and finally that their binding correlated with increases in
histone H3 acetylation (Figure 27). Further characterization of AHR regulation of LAT1
expression established that endogenous AHR activity promoted the expression of LAT1 in MCF7 and MDA-MB-231 BCCs (Figure 28). We postulate that endogenous AHR ligands produced
by MCF-7 and MDA-MB-231 BCCs activate AHR and that this, in turn, stimulates LAT1
expression. Potential endogenous AHR ligands that could be involved in the regulation of LAT1
include the breakdown products of tryptophan metabolism: kynurenine, kynurenic acid, and
xanthurenic acid [75, 95]. Given prior reports from our lab and others suggesting that AHR is
crucial for BCC proliferation [107, 108, 111, 114], it was expected that reductions in AHR or
LAT1 would reduce the proliferation of MCF-7 or MDA-MB-231 BCCs. Supporting this,
siRNA-mediated knockdown of AHR or LAT1 confirmed that both genes are required for the
proliferation of MCF-7 and MDA-MB-231 BCCs (Figure 29). Even though MCF-7 also express
LAT2 and SLC6A14 [336, 337], it is important to note that these two leucine transporters cannot
compensate for the loss of LAT1, as knockdown of LAT1 reduced MCF-7 proliferation (Figure
29). Our work supports the findings of prior reports showing that the LAT system inhibitor, 2amino-bicyclo[2.2.1]heptane-2-carboxylic acid (BCH), reduced the proliferation of MCF-7, ZR-
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75-1 and MDA-MB-231 BCC proliferation [117], providing further evidence for the importance
of leucine transport in breast cancer.
In short, we have uncovered several novel roles for AHR in breast cancer. AHR is
required for the proliferative effects of adipokines on breast tumor cells (Chapter IV). IGF-2, a
dominant adipokine, recruits AHR to the CCND1 promoter to increase CCND1 mRNA and
protein, and silencing AHR blocked this induction (Chapter V). Finally, RNA sequencing studies
revealed AHR is needed for maximal induction of SOD2 by TNF in MCF-7 BCCs (Chapter VI),
and that AHR regulates the expression of the important amino acid transporter LAT1 in MCF-7
and MDA-MB-231 BCCs (Chapter VII).
8.2. PRELIMINARY DATA.
In addition to investigating the mechanism how TCDD/AHR-induced increases in LAT1
expression, I also have addressed if estrogen (E2) and adipo-CM also regulate LAT1 expression.
In order to reduce confounding estrogenic effects from serum, or phenol-red, experiments were
conducted in serum-free, phenol-red free cell culture medium. Stimulating MCF-7 and T-47D
BCCs with estrogen increased LAT1 mRNA and protein (Figure 30 A and B). We questioned
whether E2 induced ERα binding to the AHR binding site in the LAT1 gene. ChIP analysis
revealed that E2 increased the binding of ERα to the AHR binding site in intron 2 of the LAT1
promoter (Figure 30 C). Given our lab’s focus on obesity-driven increases in breast cancer, we
questioned whether adipo-CM could exert the same effect on LAT1. MCF-7 cells were treated
with either unconditioned media (con-CM), fibroblast-conditioned media (fibro-CM), or
adipocyte-conditioned media (adipo-CM) which was devoid of FBS and phenol-red for 24 h.
Adipo-CM increased the levels of LAT1 protein relative to other treatment conditions. As
described in our report [111], adipo-CM contains a cocktail of adipokines including leptin and
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Figure 30. Estrogen treatment increases LAT1 expression and the binding of ERα to the
AHR binding site in the LAT1 gene in MCF-7 cells. (A & B) MCF-7 cells maintained in E2free conditions for 48 h were then treated with vehicle or 10 nM estradiol (E2) for 24 h. LAT1
mRNA (A) and protein (B) levels were then determined. (C) MCF-7 cells were maintained in
E2-free conditions for 48 h before treatment with vehicle or E2 for 1 h. ChIP was performed with
a non-specific IgG or an ERα specific antibody. Recruitment expressed as % input as determined
through qPCR. “*” denotes statistical significance reached (P < 0.05) as determined by Student’s
T-test (A & B) or one-way ANOVA (C).
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Figure 31. Adipo-CM treatment increases LAT1 expression via ERα and AHR recruitment
to AHR response elements in the LAT1 promoter in MCF-7 cells. (A) MCF-7 cells were
maintained in E2-free conditions for 48 h prior to treatment with con-CM, fibro-CM, or adipoCM for 24 h. Total protein was extracted and LAT1 protein levels were determined by western
blot. (B) MCF-7 cells were maintained in E2-free conditions for 48 h before treatment with conCM, fibro-CM, or adipo-CM for 1 h. ChIP assays were conducted with anti-ERα or anti-AHR
antibodies. Recruitment expressed as % input as determined through qPCR.
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Figure 32. Proposed mechanism by which E2 and adipo-CM increase LAT1 expression. (A)
E2, leptin and adiponectin upon binding their cognate receptors induce signaling that increases
ERK activation. (B) Upon its activation, ERK phosphorylates and activates ERα, facilitating
interactions between AHR and SRC-3 and their recruitment to an AHR binding site in the LAT1
gene. (C) Increased LAT1 transcription drives the accumulation of LAT1 and the transport of
leucine. (D) Leucine activates mTOR signaling and increases proliferation. Adipo-CM =
adipocyte conditioned media, E2 = 17-β-Estradiol, ERK = extracellular regulated kinase, AHR =
aryl hydrocarbon receptor, ERα = estrogen receptor alpha, SRC-3 = steroid receptor coactivator
3, LAT1 = l-type amino acid transporter 1, Gln = glutamine, Leu = leucine, mTORC1 =
mammalian target of rapamycin complex 1.
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adiponectin. These results suggest the high levels of leptin and low levels of adiponectin secreted
by adipocytes in obesity could promote the expression of LAT1 in breast tumors in obese
patients (Figure 31 A). ChIP analysis was conducted to investigate if adipo-CM promoted the
binding of AHR and ERα to the AHR binding site in the LAT1 gene, and the findings revealed
increased binding of both transcription factors (Figure 31 B). Collectively, these data suggest
that adipocyte-secreted factors in combination with environmental pollutants like TCDD may
promote the expression of LAT1 in BCCs via AHR and ERα. Such regulation would be expected
to increase BCC proliferation, considering that increases in LAT1 would promote the activity of
the mTORC1 pathway (Figure 32). The following sections will outline the rationale and
proposed experiments to study this new finding.
8.3. RATIONALE FOR NEW EXPERIMENTS.
As shown in our model shown in Figure 32, we hypothesize that estrogen and adipo-CM
will increase the expression of LAT1 by stimulating the binding of AHR, ERα and SRC-3 to the
AHR binding site of the LAT1 gene. The rational for this hypothesis stems from prior reports
showing that obese women have higher levels of estrogen due to excess adipose tissue than lean
women [161]. Upon estrogen binding, ERα binds to and recruits the transcriptional co-activator
SRC-3 to ER target genes that stimulate cancer, including CCND1 and cMYC [349, 350]. The
binding of ERα to SRC-3 is highly relevant to breast cancer, considering that transgenic
overexpression of SRC-3 is sufficient to induce breast cancer in mice [351]. In human breast
cancer, the SRC-3 gene is often amplified, and one report noted SRC-3 expression was elevated
in over 60% of breast cancer cases [352]. As mentioned, SRC-3 is an ERα transcriptional coactivator and amplification of SRC-3 is typically seen in ER-expressing breast tumors. In this
regard, one study noted SRC-3 was critical for MCF-7 BCC growth in vitro and in vivo [353].
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High SRC-3 expression is linked to chemotherapeutic resistance to tamoxifen in breast cancer
patients [354]. SLC7A5 (LAT1) expression has also been linked to tamoxifen resistance [237,
238]. Phosphorylation of both SRC-3 and ERα by ERK increase their transcriptional activity
[355, 356], and E2 and certain adipokines have been shown to increase ERK signaling [357359]. Our preliminary data demonstrates that E2 and adipo-CM increase the expression of LAT1,
and we provide the first evidence that this could be mediated through ERα and AHR recruitment
to AHR-RE in intron 2 of the LAT1 gene (Figures 28 and 29). Given the reports linking both
LAT1 and SRC-3 to tamoxifen resistance, we hypothesize that E2 and adipo-CM stimulate
increases in LAT1 expression through formation of a transcriptional complex including ERα,
AHR, and SRC-3 at AHR binding site in the LAT1 gene leading to upregulation of LAT1
expression in breast tumors and activation of mTORC1 (Figure 32). The following sections will
detail future experiments that will be done to test our hypothesis.
8.4. ERα, AHR, AND SRC-3 KNOCKDOWN TO TEST THEIR ROLE IN THE
REGULATION OF LAT1
To investigate whether AHR, ERα, and SRC-3 are important for stimulus-induced LAT1
expression, non-malignant MCF-10A cells, ERα positive (MCF-7, T-47D, or ZR-75-1) or ERα
negative (MDA-MB-231) BCCs would be transfected with non-targeting (control), AHR, SRC3, ERα targeting siRNA’s using methods that we have published [44, 114], and detailed in
Chapter III. After 24 h, siRNA’s would be removed and cells will be serum-starved overnight in
phenol red-free DMEM devoid of FBS prior to treatment with vehicle, E2 (10 nM), con-CM,
fibro-CM, or adipo-CM for time course studies. Western blot and real time qPCR analysis of
ERα, AHR, and SRC-3 would be conducted to verify their knockdown by their respective
siRNA’s compared with non-targeting siRNA. Protein and mRNA levels of LAT1 would be
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measured by western blot and real time qPCR, respectively, to investigate our hypothesis that its
regulation is dependent on ERα, AHR, and SRC-3. I expect ERα, AHR, and SRC-3 knockdown
will compromise induction of LAT1 expression upon treatment with E2 or adipo-CM, given our
preliminary data showing ERα and AHR recruitment to the AHR binding site in the LAT1 gene
(Figures 30 & 31), and the extensive literature showing SRC-3 to be an important ER-coactivator [349, 362-364].
8.5. CHIP ANALYSIS TO EVALUATE THE BINDING OF ERα, AHR, AND SRC-3 TO
THE AHR SITE IN THE LAT1 GENE.
The binding of ERα, AHR and SRC-3 to the AHR binding site in the LAT1 gene would
need to be investigated using ChIP-qPCR assays, as described in Chapter III. Non-cancerous
MCF-10A cells, ERα positive BCCs (MCF-7, T-47D or ZR-75-1) or ERα negative BCCs
(MDA-MB-231) would be seeded into 60mm plates for 24 h prior to overnight serum-starvation
in phenol-red free DMEM devoid of FBS then stimulated with vehicle, E2 (10 nM), fibro-CM, or
adipo-CM for time course studies. ChIP-qPCR analysis using methods detailed in our recent
publications [44, 114] would then be performed to assess the binding of ERα, AHR, and SRC-3
at the AHR binding site in intron 2 of the LAT1 gene. The acetylation of histone H3 at lysine 9
and lysine 14 are markers of active transcription, and these histone H3 modifications in intron 2
of the LAT1 gene would also be investigated by ChIP-qPCR. Non-specific IgG would be used to
control for antibody binding specificity, as we have used in our prior reports [44, 114]. The
comparative CT method will be used to calculate transcription factor binding, with input ChIP
DNA used to normalize samples as detailed in our prior reports [44, 114] and Chapter III. I
expect these experiments would reveal ERα, AHR and SRC-3 form an active transcriptional
complex at the AHR binding site of LAT1 to regulate its expression.
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8.6. ANALYSIS OF TRANSCRIPTIONAL ACTIVITY OF AHR BINDING SITE IN
INTRON 2 OF LAT1 GENE.
These experiments would establish the transcriptional activity of the AHR-REs in intron
2 of the LAT1 gene in response to E2 or adipo-CM stimulus, a very important question to
address. The region of the LAT1 gene that harbors intron 2 and accompanying AHR-REs would
be subcloned into promoter reporter luciferase constructs following methods we have previously
published [272]. Non-cancerous MCF-10A cells, ERα positive BCCs (MCF-7, T-47D, ZR-75-1)
or ERα negative BCCs (MDA-MB-231) would be seeded into 96 well plates at a density of
5,000 cells per well for 24 h prior to transfection with 100 ng of an “empty” luciferase reporter
vector (Dual Light Reporter Gene Assay System; Life Technologies) or the luciferase reporter
vector which will express the 1 KB region containing intron 2 of the LAT1 gene. After 24 h, cells
would be treated with vehicle, E2 (10 nM), con-CM, fibro-CM, or adipo-CM for time course
studies and reporter activity would be measured using a luminometer. To verify that increases in
intron 2 of the LAT1 gene is attributed to AHR-REs, these specific sites in intron 2 of the LAT1
gene could be mutated using standard procedures (QuikChange II XL Site-Directed Mutagenesis
Kits, Agilent Technologies). Given that we found there are three putative AHR-REs in the LAT1
gene, these AHR-REs may differ in activity. To address this, several different LAT1 intron 2
constructs could be made that either contain a mutation in one of the AHR-REs, two of the AHRREs, or a construct in which all three of AHR-REs have been mutated to assess activity of the
different sites. I expect that AHR is able to bind to all of these regions, and therefore, constructs
containing the three mutated AHR-REs would inhibit transcriptional activity at the AHR binding
site most effectively.
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8.7. SILENCING AHR, ERα, OR SRC-3 WITH TAMOXIFEN TREATMENT:
INCREASED TUMOR CELL DEATH?
Given reports that have linked LAT-1 and SRC-3 expression to tamoxifen resistance [237,
238, 354], and our recent report characterizing AHR regulation of LAT-1 [44], we would assay
whether silencing ERα, AHR, or SRC-3 sensitizes ERα-expressing tumor cells to tamoxifen
treatment. To this end, we would reverse transfect 200,000 ERα positive (MCF-7, T-47D, or ZR75-1) BCCs in the presence of con-siRNA, ERα-siRNA, AHR-siRNA, or SRC-3-siRNA for 36 h
prior to treatment with tamoxifen (0.001, 0.01, 0.1, or 1 µM). Lower concentrations which have
been shown to have minimal effect or which only induce cell-cycle arrest will be used, instead of
higher concentrations (above 5 µM) which have been shown to induce apoptosis in MCF-7
BCCs [360]. Cell viability would then be determined utilizing the Aqueous One Solution Cell
Proliferation Assay (Promega, Madison, WI), which we used to assess cell number in our recent
report [44], as well as manual cell counting using the trypan blue exclusion method to identify
dead cells [240]. If viability is reduced, parallel western blot experiments would be performed
looking at hallmarks of apoptosis, including cleavage of caspases as well as cleavage of poly
ADP ribose polymerase (PARP) [361], upon treatment. Considering that obesity induces breast
tumors in post-menopausal women [112, 113], and tamoxifen is especially indicated for use in
ERα-expressing tumors in post-menopausal women [360], experiments silencing AHR, ERα, or
SRC-3 to see if loss of these important transcriptional regulators confers sensitivity to tamoxifen
treatment will be especially informative.
8.8. ANTICIPATED AND ALTERNATIVE OUTCOMES FOR PROPOSED
EXPERIMENTS.
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Given our preliminary data showing E2 and adipo-CM can stimulate a marked increase in
LAT1 expression in MCF-7 BCCs (Figure 30 A and B, Figure 31 A), as well as increased
recruitment of ERα and AHR to AHR-RE in intron 2 of LAT1 in response to E2 or adipo-CM
stimulus (Figure 30 C, Figure 31 B), I expect that knockdown of ERα and AHR will abrogate E2
and adipo-CM regulation of LAT1 expression. I also expect SRC-3 knockdown to compromise
stimulus-driven increases in LAT1, due to the extensive literature showing SRC-3 is a
transcriptional co-activator of ERα signaling [349, 362-364]. Our prior report has characterized
the AHR binding site in intron 2 of LAT1 to be important for TCDD-stimulated increases in
LAT1 [44]. Experiments looking at transcriptional activity of intron 2 of LAT1 upon stimulus
would provide additional insights as to the role of this 1 KB fragment in E2 or adipo-CMstimulated increases in LAT1. Site-directed mutagenesis experiments would prove important in
determining if one, two, or all three of the putative AHR binding sites in this fragment are
important for conferring transcriptional activity upon stimulus. Finally, I predict silencing AHR,
ERα, or SRC-3 will allow tamoxifen to induce apoptosis in ER-expressing BCCs at lower
concentrations due to reductions in LAT1 expression, as LAT1 levels have been linked to
tamoxifen resistance in breast tumors [237, 238].
Alternative outcomes exist for these experiments. An important alternative outcome is
that silencing SRC-3 may prove insignificant to blunt E2 and adipo-CM-stimulated induction of
LAT1. If this is the case, looking at other ERα co-activators which ERα-signaling has been
shown to utilize to regulate gene expression, including other members of the p160 family like
SRC-1 [365], would provide additional insight. SRC-1 has been shown to interact both with ERα
and AHR [37, 365], where SRC-3 has only been shown to interact with ERα. The proposed ERαAHR crosstalk mechanism for regulating LAT1 in response to E2 and adipo-CM may recruit
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SRC-1 to AHR-RE to regulate LAT1 as part of the transcriptional complex in place of SRC-3.
Similarly, p300 is a known ERα and AHR co-activator [366]. We have already shown p300
recruitment to the AHR binding site upon TCDD stimulus [44]. Thus, p300 binding at the AHR
site in response to E2 and adipo-CM stimulus may be a critical player in the observed increases
in LAT1 we have seen (Figures 30 & 31). Once the co-activator(s) have been determined, the
alternative co-activator(s) could then be silenced using targeting siRNAs to reduce their
expression and determine first, whether LAT1 expression is compromised upon their silencing,
and second, whether sensitivity to tamoxifen occurs with their loss.
I do not anticipate any pitfalls in completing these experiments, as we have used all of the
proposed methods (western blotting, real time qPCR, ChIP, etc) numerous times in previously
published reports to generate data [44, 59, 111, 114, 272]. Overall, I expect these future
experiments to reveal that E2 and mitogenic factors present in adipo-CM (i.e. leptin) increase
LAT1 expression through recruitment of ERα, AHR, and SRC-3 to the characterized AHR
binding site in intron 2 of the LAT1 gene. To build on our adipo-CM findings, determining which
factor or cocktail of factors critical for the observed increases in LAT1 upon adipo-CM treatment
could then be assessed. I feel that targeting members of this transcriptional complex, such as the
use of AHR antagonists, as part of a combinatorial treatment regimen could be beneficial in
treatment of breast cancer in obese patients, as well as sensitizing ERα-expressing breast tumors
to tamoxifen treatment.
8.9. CONCLUSION
My thesis research over the past four years has led to a better understanding of the
complex roles that AHR plays in breast cancer. By uncovering some novel tumor promoting
roles for AHR, it begs the question whether more emphasis should be given to AHR modulating
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drugs for use in cancer patients. While targeting the IGF-1 and PI3K/AKT/mTOR pathways have
received great attention over the years, recent strides in AHR research suggests that targeting
AHR warrants continued investigation. In this regard, AHR and its roles in tumor initiation,
invasion, and metastasis are being explored in many cancer types in addition to breast cancer,
including prostatic, ovarian, colorectal, melanoma, and gliomas. Targeting AHR as a
chemotherapeutic could, therefore, have broad-spectrum effects on the treatment outcome of a
variety of cancers in future patients.
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APPENDIX B: ABBREVIATIONS
3-MC…3-methylcholanthrene
4EBP…4E binding protein
5-LOX… arachidonate 5-lipoxygenase
5,6-DiHETEs…5,6-dihydroxyeicosatetraenoic acid isomers
ABCG2…ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 (Junior Blood Group)
ACPR30…adiponectin
ADG…AHR dependent gene
Adipo-CM…adipocyte conditioned media
AdipoR1…adiponectin receptor 1
AdipoR2…adiponectin receptor 2
ADORA…adenosine receptor
AHH…aryl hydrocarbon hydroxylase
AHR…aryl hydrocarbon receptor
AHR -/-…AHR-null mice
AHRi… short inferfering RNA targeting the AHR gene
AHRR…aryl hydrocarbon receptor repressor
AHR-RE… aryl hydrocarbon receptor response element
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AHR-siRNA…short inferfering RNA targeting the AHR gene
AIP…AHR interacting protein
AKT…protein kinase B
ALDH1A3…Aldehyde Dehydrogenase 1 Family, Member A3
ALDH3A1… Aldehyde Dehydrogenase 3 Family, Member A1
ALOX5… Arachidonate 5-Lipoxygenase
AMPK…adenosine monophosphate dependent kinase
ANOVA…analysis of variance
AP-1…activator protein-1
AP-1-RE… activator protein-1 response element
AR…androgen receptor
ARE…androgen response element
ARNT…aryl hydrocarbon nuclear translocator
ATP… adenosine triphosphate
B(a)P… benzo(α)pyrene
BCC…breast cancer cell
BCH…2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid
bFGF…basic fibroblast growth factor
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bHLH…basic helix loop helix
BME…β-mercaptoethanol
BRG-1…brahma related gene-1
bZIP… Basic Leucine Zipper Domain
CBP…CREB binding protein
CCND1…cyclin D1
CD98… 4F2 cell-surface antigen heavy chain
CDK…cyclin dependent kinase
CDK4… cyclin dependent kinase 4
CDKN1A… Cyclin-Dependent Kinase Inhibitor 1A
ChIP…chromatin immunoprecipitation
ChIP-Seq… chromatin immunoprecipitation sequencing
Co-IP…co-immunoprecipitation
Con-CM…unconditioned/control media
Con-siRNA…non-specific control short interfering RNA
CREB3L… cAMP-responsive element-binding protein 3-like protein
cRNAi… non-specific control short interfering RNA
CSC…cancer stem cell
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CSP…chondroitin sulfate proteoglycan
CUL4B…cullin 4B
CYP1A1…cytochrome P450 1A1
CYP1B1…cytochrome P450 1B1
DDB1…damaged DNA binding protein-1
DIM…3,3-diidolylmethane
DMBA…7,12-dimethylbenz[a]anthracene
DMEM… Dulbecco's Modified Eagle Medium
DMSO…dimethyl sulphoxide
DRE… dioxin response element
E2… 17β-estradiol
E2F4…E2F transcription factor 4
EDTA… ethylenediaminetetraacetic acid
EGF…epidermal growth factor
eIF…eukaryotic initiation factor
EMT…epithelial to mesenchymal transition
ER…estrogen receptor
ERRBB2… Erb-B2 Receptor Tyrosine Kinase 2
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ERK…extracellular regulated kinase
FBS…fetal bovine serum
FDR…false discovery rate
Fibro-CM…fibroblast conditioned media
FICZ…6-formylindolo [3,2-b] carbazole
FSH…follicle stimulating hormone
GAPDH… glyceraldehyde 3-phosphate dehydrogenase
GEO…gene expression omnibus
GPX…glutathione peroxidase
GR…glutathione reductase
GSH…reduced glutathione
GSSG…oxidized glutathione
GST…glutathione-S-transferase
H2O2…hydrogen peroxide
HAH…halogenated aromatic hydrocarbon
Hepa-1…mouse derived liver cell line
HER2…epidermal growth factor receptor 2
HMGCS2…3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (Mitochondrial)
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HRP…horseradish peroxidase
HSP90…heat shock protein-90
I3C…indole-3-carbinol
IBMX… 3-isobutyl-1-methylxanthine
ICZ…indolo [3,2-b] carbazole
IGF-1…insulin-like growth factor 1
IGF1-R…insulin-like growth factor 1 receptor
IGF1-R/IR…hybrid IGF/IR receptor
IGF-2…insulin-like growth factor 2
IGF-2R…insulin-like growth factor 2 receptor
IgG…immunoglobulin G
IL-1…interleukin 1
IL-1β…interleukin 1-beta
IL-6…interleukin 6
IL-8…interleukin 8
INBRE… IDeA Network of Biomedical Research Excellence
IPA…ingenuity pathway analysis
IR…insulin receptor
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IR-A…type A insulin receptor
JAK…janus kinase
JUND…Jun D proto-oncogene
Kyn…kynurenine
LAT1…L-type amino acid transporter-1
LEPR…leptin receptor
LEPR-b…dominant isoform of leptin receptor
LH…luteinizing hormone
LOX1…lipoxygenase 1
LPS…lipopolysaccharide
MAPK…mitogen activated protein kinase
MCL…mantle cell lymphoma
MEF…mouse embryonic fibroblast
MGP… Matrix Gla Protein
MMP…matrix metalloproteinase
MnSOD…manganese superoxide dismutase
MPE…malignant pleural effusion
MRK… dominant-negative IGF1-R mice
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mRNA…messenger ribonucleic acid
mTOR…mammalian target of rapamycin
MUC1…mucin 1
MYB… Avian Myeloblastosis Viral Oncogene Homolog
NANOG…nanog homeobox
NADPH… nicotinamide adenine dinucleotide phosphate
NCBI… National Center for Biotechnology Information
NCOA-1…nuclear receptor co-activator 1
NF-κB…nuclear factor kappa-light-chain-enhancer of activated B cells
NF-κB-RE… NF-κB response element
NRF2… nuclear factor erythroid 2-related factor
NRP…neuropilin
O2.-...superoxide anion radical
OAS1…2'-5'-Oligoadenylate Synthetase 1
OCT4…octamer-binding transcription factor 4
OxLDL…oxidized low-density lipoprotein
p70S6K…ribosomal S6 kinase
PAH… polycyclic aromatic hydrocarbon
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PBS…phosphate buffered saline
PDFG…platelet derived growth factor
PGR…progesterone receptor
PhRMA… the Pharmaceutical Research and Manufacturers of America
PI3K… phosphatidylinositol-3-kinase
PKD1L1… Polycystic Kidney Disease 1 Like 1
PLA2G2… phospholipase A2 group IIA
PMA… phorbol 12-myristate 13-acetate
PPP…picropodophyllin
PVDF… polyvinylidene difluoride
PYDC1… pyrin domain containing 1
qPCR…quantitative polymerase chain reaction
Rb…retinoblastoma protein
RBX-1… ring box-1
RELA…p65 subunit of NF-κB
RELB…p50 subunit of NF-κB
RNA…ribonucleic acid
RNA-Seq…RNA sequencing
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ROS…reactive oxygen species
SDS…sodium dodeacyl sulfate
SERPIN3A…serpin 3a
SERPIN5A…serpin 5a
siRNA…short-interfering ribonucleic acid
SLC7A5… solute carrier family 7 (amino acid transporter light chain, L system) member 5
SNK…Student Newman-Keuls test
SOD1… superoxide dismutase 1
SOD2…superoxide dismutase 2
SOD3… superoxide dismutase 3
SOX2…SRY (sex determining region Y)-box 2
SRC…steroid receptor co-activator
STAT…signal transducer and activator of transcription
SU5416… [3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indole-2-one]
SWI/SNF… SWItch/Sucrose Non-Fermentable
TCDD…2,3,7,8-tetrachlorodibenzo-p-dioxin
TCF…T-cell factor
TCF/LEF…T-cell factor/lymphoid enhancing factor
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TCF-RE…TCF response element
TDO2…tryptophan dioxygenase 2
TGFα…transforming growth factor alpha
Th17…T-helper 17 cells
TNBC…triple-negative breast bancer
TNF…tumor necrosis factor α
TP53…p53 tumor suppressor gene
Tregs…T regulatory cells
TRGs…TCDD regulated genes
TSS…transcriptional start site
UGTAs… UDP-glucuronosyltransferase genes
VEGF…vascular endothelial growth factor
VEGFR…VEGF receptor
XAP2… hepatitis B virus X-associated protein 2
XRE…xenobiotic response element
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